BRCA1 NNP O
is VBZ O
secreted VBN O
and CC O
exhibits JJ O
properties NNS O
of IN O
a DT O
granin NN O
. . O

Germline NNP O
mutations NNS O
in IN O
BRCA1 NNP O
are VBP O
responsible JJ O
for IN O
most JJS O
cases NNS O
of IN O
inherited JJ B-Disease
breast NN I-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
. . O

However RB O
, , O
the DT O
function NN O
of IN O
the DT O
BRCA1 NNP O
protein NN O
has VBZ O
remained VBN O
elusive JJ O
. . O

We PRP O
now RB O
show VBP O
that IN O
BRCA1 NNP O
encodes VBZ O
a DT O
190 CD O
- : O
kD NN O
protein NN O
with IN O
sequence NN O
homology NN O
and CC O
biochemical JJ O
analogy NN O
to TO O
the DT O
granin NN O
protein NN O
family NN O
. . O

Interestingly RB O
, , O
BRCA2 NNP O
also RB O
includes VBZ O
a DT O
motif NN O
similar JJ O
to TO O
the DT O
granin NN O
consensus NN O
at IN O
the DT O
C NNP O
terminus NN O
of IN O
the DT O
protein NN O
. . O

Both DT O
BRCA1 NNP O
and CC O
the DT O
granins NNS O
localize VBP O
to TO O
secretory JJ O
vesicles NNS O
, , O
are VBP O
secreted VBN O
by IN O
a DT O
regulated JJ O
pathway NN O
, , O
are VBP O
post VBN O
- : O
translationally RB O
glycosylated VBN O
and CC O
are VBP O
responsive JJ O
to TO O
hormones NNS O
. . O

As IN O
a DT O
regulated JJ O
secretory NN O
protein NN O
, , O
BRCA1 NNP O
appears VBZ O
to TO O
function VB O
by IN O
a DT O
mechanism NN O
not RB O
previously RB O
described VBN O
for IN O
tumour NN B-Disease
suppressor NN O
gene NN O
products NNS O
. . O
. . O

Ovarian JJ B-Disease
cancer NN I-Disease
risk NN O
in IN O
BRCA1 NNP O
carriers NNS O
is VBZ O
modified VBN O
by IN O
the DT O
HRAS1 NNP O
variable JJ O
number NN O
of IN O
tandem JJ O
repeat NN O
( ( O
VNTR NNP O
) ) O
locus NN O
. . O

Women NNS O
who WP O
carry VBP O
a DT O
mutation NN O
in IN O
the DT O
BRCA1 NNP O
gene NN O
( ( O
on IN O
chromosome NN O
17q21 CD O
) ) O
, , O
have VBP O
an DT O
80 CD O
% NN O
risk NN O
of IN O
breast NN B-Disease
cancer NN I-Disease
and CC O
a DT O
40 CD O
% NN O
risk NN O
of IN O
ovarian JJ B-Disease
cancer NN I-Disease
by IN O
the DT O
age NN O
of IN O
70 CD O
( ( O
ref NN O
. . O
1 CD O
) ) O
. . O

The DT O
variable JJ O
penetrance NN O
of IN O
BRCA1 NNP O
suggests VBZ O
that IN O
other JJ O
genetic JJ O
and CC O
non JJ O
- : O
genetic JJ O
factors NNS O
play VBP O
a DT O
role NN O
in IN O
tumourigenesis NN O
in IN O
these DT O
individuals NNS O
. . O

The DT O
HRAS1 NNP O
variable JJ O
number NN O
of IN O
tandem JJ O
repeats NNS O
( ( O
VNTR NNP O
) ) O
polymorphism NN O
, , O
located VBN O
1 CD O
kilobase NN O
( ( O
kb NN O
) ) O
downstream NN O
of IN O
the DT O
HRAS1 NNP O
proto NN O
- : O
oncogene NN O
( ( O
chromosome JJ O
11p15 CD O
. . O
5 CD O
) ) O
is VBZ O
one CD O
possible JJ O
genetic JJ O
modifier NN O
of IN O
cancer NN B-Disease
penetrance NN O
. . O

Individuals NNS O
who WP O
have VBP O
rare JJ O
alleles NNS O
of IN O
the DT O
VNTR NNP O
have VBP O
an DT O
increased VBN O
risk NN O
of IN O
certain JJ O
types NNS O
of IN O
cancers NNS B-Disease
, , O
including VBG O
breast NN B-Disease
cancer NN I-Disease
( ( O
2 CD O
- : O
4 CD O
) ) O
. . O

To TO O
investigate VB O
whether IN O
the DT O
presence NN O
of IN O
rare JJ O
HRAS1 NNP O
alleles VBZ O
increases NNS O
susceptibility NN O
to TO O
hereditary VB B-Disease
breast NN I-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
, , O
we PRP O
have VBP O
typed VBN O
a DT O
panel NN O
of IN O
307 CD O
female JJ O
BRCA1 NNP O
carriers NNS O
at IN O
this DT O
locus NN O
using VBG O
a DT O
PCR NNP O
- : O
based VBN O
technique NN O
. . O

The DT O
risk NN O
for IN O
ovarian JJ B-Disease
cancer NN I-Disease
was VBD O
2 CD O
. . O

11 CD O
times NNS O
greater JJR O
for IN O
BRCA1 NNP O
carriers NNS O
harbouring VBG O
one CD O
or CC O
two CD O
rare JJ O
HRAS1 NNP O
alleles NNS O
, , O
compared VBN O
to TO O
carriers NNS O
with IN O
only JJ O
common JJ O
alleles NNS O
( ( O
P NNP O
= VBZ O
0 CD O
. . O
15 CD O
) ) O
. . O

The DT O
magnitude NN O
of IN O
the DT O
relative JJ O
risk NN O
associated VBN O
with IN O
a DT O
rare JJ O
HRAS1 NNP O
allele NN O
was VBD O
not RB O
altered VBN O
by IN O
adjusting VBG O
for IN O
the DT O
other JJ O
known VBN O
risk NN O
factors NNS O
for IN O
hereditary JJ B-Disease
ovarian JJ I-Disease
cancer NN I-Disease
( ( O
5 CD O
) ) O
. . O

Susceptibility NN O
to TO O
breast VB B-Disease
cancer NN I-Disease
did VBD O
not RB O
appear VB O
to TO O
be VB O
affected VBN O
by IN O
the DT O
presence NN O
of IN O
rare JJ O
HRAS1 NNP O
alleles NNS O
. . O

This DT O
study NN O
is VBZ O
the DT O
first JJ O
to TO O
show VB O
the DT O
effect NN O
of IN O
a DT O
modifying VBG O
gene NN O
on IN O
the DT O
penetrance NN O
of IN O
an DT O
inherited JJ B-Disease
cancer NN I-Disease
syndrome NN I-Disease

A DT O
novel NN O
homeodomain NN O
- : O
encoding VBG O
gene NN O
is VBZ O
associated VBN O
with IN O
a DT O
large JJ O
CpG NNP O
island NN O
interrupted VBN O
by IN O
the DT O
myotonic JJ B-Disease
dystrophy NN I-Disease
unstable JJ O
( ( O
CTG NNP O
) ) O
n RB O
repeat NN O
. . O

Myotonic JJ B-Disease
dystrophy NN I-Disease
( ( O
DM NNP B-Disease
) ) O
is VBZ O
associated VBN O
with IN O
a DT O
( ( O
CTG NNP O
) ) O
n FW O
trinucleotide JJ O
repeat NN O
expansion NN O
in IN O
the DT O
3 CD O
- : O
untranslated JJ O
region NN O
of IN O
a DT O
protein NN O
kinase SYM O
- : O
encoding VBG O
gene NN O
, , O
DMPK NNP O
, , O
which WDT O
maps VBZ O
to TO O
chromosome VB O
19q13 CD O
. . O

3 CD O
. . O

Characterisation NN O
of IN O
the DT O
expression NN O
of IN O
this DT O
gene NN O
in IN O
patient JJ O
tissues NNS O
has VBZ O
thus RB O
far RB O
generated JJ O
conflicting VBG O
data NNS O
on IN O
alterations NNS O
in IN O
the DT O
steady JJ O
state NN O
levels NNS O
of IN O
DMPK NNP O
mRNA NN O
, , O
and CC O
on IN O
the DT O
final JJ O
DMPK NNP O
protein NN O
levels NNS O
in IN O
the DT O
presence NN O
of IN O
the DT O
expansion NN O
. . O

The DT O
DM NNP B-Disease
region NN O
of IN O
chromosome NN O
19 CD O
is VBZ O
gene NN O
rich JJ O
, , O
and CC O
it PRP O
is VBZ O
possible JJ O
that IN O
the DT O
repeat NN O
expansion NN O
may MD O
lead VB O
to TO O
dysfunction NN O
of IN O
a DT O
number NN O
of IN O
transcription NN O
units NNS O
in IN O
the DT O
vicinity NN O
, , O
perhaps RB O
as IN O
a DT O
consequence NN O
of IN O
chromatin JJ O
disruption NN O
. . O

We PRP O
have VBP O
searched VBN O
for IN O
genes NNS O
associated VBN O
with IN O
a DT O
CpG NNP O
island NN O
at IN O
the DT O
3 CD O
end NN O
of IN O
DMPK NNP O
. . O

Sequencing VBG O
of IN O
this DT O
region NN O
shows VBZ O
that IN O
the DT O
island NN O
extends VBZ O
over IN O
3 CD O
. . O

5 CD O
kb NN O
and CC O
is VBZ O
interrupted VBN O
by IN O
the DT O
( ( O
CTG NNP O
) ) O
n RB O
repeat NN O
. . O

Comparison NNP O
of IN O
genomic JJ O
sequences NNS O
downstream NN O
( ( O
centromeric JJ O
) ) O
of IN O
the DT O
repeat NN O
in IN O
human JJ O
and CC O
mouse NN O
identified JJ O
regions NNS O
of IN O
significant JJ O
homology NN O
. . O

These DT O
correspond NN O
to TO O
exons NNS O
of IN O
a DT O
gene NN O
predicted VBN O
to TO O
encode VB O
a DT O
homeodomain NN O
protein NN O
. . O

RT NNP O
- : O
PCR NN O
analysis NN O
shows VBZ O
that IN O
this DT O
gene NN O
, , O
which WDT O
we PRP O
have VBP O
called VBN O
DM NNP B-Disease
locus SYM O
- : O
associated VBN O
homeodomain NN O
protein NN O
( ( O
DMAHP NNP O
) ) O
, , O
is VBZ O
expressed VBN O
in IN O
a DT O
number NN O
of IN O
human JJ O
tissues NNS O
, , O
including VBG O
skeletal JJ O
muscle NN O
, , O
heart NN O
and CC O
brain NN O
. . O

Germline NNP O
mutations NNS O
in IN O
the DT O
RB1 NNP O
gene NN O
in IN O
patients NNS O
with IN O
hereditary JJ B-Disease
retinoblastoma NN I-Disease
. . O

We PRP O
have VBP O
analyzed VBN O
the DT O
27 CD O
exons NNS O
and CC O
the DT O
promoter NN O
region NN O
of IN O
the DT O
RB1 NNP O
gene NN O
in IN O
familial JJ B-Disease
or CC I-Disease
sporadic JJ I-Disease
bilateral JJ I-Disease
retinoblastoma NN I-Disease
by IN O
using VBG O
single JJ O
- : O
strand NN O
conformation NN O
polymorphism NN O
analysis NN O
. . O

For IN O
improvement NN O
over IN O
previous JJ O
studies NNS O
, , O
a DT O
new JJ O
set NN O
of IN O
primers NNS O
has VBZ O
been VBN O
designed VBN O
, , O
which WDT O
allow VBP O
for IN O
amplification NN O
of IN O
the DT O
coding NN O
and CC O
splicing NN O
sequences NNS O
only RB O
. . O

The DT O
positioning NN O
of IN O
the DT O
polymerase NN O
chain NN O
reaction NN O
( ( O
PCR NNP O
) ) O
primers NNS O
was VBD O
such JJ O
that IN O
the DT O
resulting VBG O
PCR NNP O
products NNS O
were VBD O
of IN O
different JJ O
sizes NNS O
, , O
which WDT O
enabled VBD O
us PRP O
to TO O
analyze VB O
two CD O
different JJ O
exons NNS O
simultaneously RB O
and CC O
still RB O
distinguish VB O
between IN O
the DT O
banding NN O
profiles NNS O
for IN O
both DT O
( ( O
biplex JJ O
analysis NN O
) ) O
. . O

By IN O
using VBG O
this DT O
approach NN O
, , O
we PRP O
were VBD O
able JJ O
to TO O
identify VB O
mutation NN O
in IN O
22 CD O
new JJ O
patients NNS O
, , O
but CC O
the DT O
overall JJ O
efficiency NN O
of IN O
the DT O
procedure NN O
when WRB O
we PRP O
used VBD O
a DT O
single JJ O
- : O
pass NN O
regimen NN O
was VBD O
only RB O
48 CD O
% NN O
. . O

The DT O
mutations NNS O
were VBD O
small JJ O
insertions NNS O
and CC O
deletions NNS O
and CC O
point NN O
mutations NNS O
in IN O
roughly RB O
equal JJ O
proportions NNS O
. . O
. . O

Type NNP B-Disease
II NNP I-Disease
human JJ I-Disease
complement NN I-Disease
C2 NNP I-Disease
deficiency NN I-Disease
. . O

Allele NNP O
- : O
specific JJ O
amino NN O
acid JJ O
substitutions NNS O
( ( O
Ser189 NNP O
- : O
- : O
> NN O
Phe NNP O
; : O
Gly444 NNP O
- : O
- : O
> NN O
Arg NNP O
) ) O
cause NN O
impaired JJ O
C2 NNP O
secretion NN O
. . O

Type NNP B-Disease
II NNP I-Disease
complement NN I-Disease
protein NN I-Disease
C2 NNP I-Disease
deficiency NN I-Disease
is VBZ O
characterized VBN O
by IN O
a DT O
selective JJ O
block NN O
in IN O
C2 NNP O
secretion NN O
. . O

The DT O
Type NNP O
II NNP O
C2 NNP O
null JJ O
allele NN O
( ( O
C2Q0 NNP O
) ) O
is VBZ O
linked VBN O
to TO O
two CD O
major JJ O
histocompatibility NN O
haplotypes NNS O
( ( O
MHC NNP O
) ) O
that WDT O
differ VBP O
from IN O
the DT O
MHC NNP O
of IN O
the DT O
more RBR O
common JJ O
Type NNP B-Disease
I PRP I-Disease
C2 NNP I-Disease
deficiency NN I-Disease
. . O

To TO O
determine VB O
the DT O
molecular JJ O
basis NN O
of IN O
Type NNP B-Disease
II NNP I-Disease
deficiency VBZ I-Disease
the DT O
two CD O
Type NNP O
II NNP O
C2Q0 NNP O
genes NNS O
were VBD O
isolated VBN O
and CC O
transfected VBN O
separately RB O
into IN O
L NNP O
- : O
cells NNS O
. . O

Subsequent JJ O
molecular JJ O
biology NN O
, , O
biosynthetic JJ O
, , O
and CC O
immunofluorescence NN O
studies NNS O
demonstrated VBD O
that IN O
C2 NNP O
secretion NN O
is VBZ O
impaired VBN O
in IN O
Type NNP B-Disease
II NNP I-Disease
C2 NNP I-Disease
deficiency NN I-Disease
because IN O
of IN O
different JJ O
missense NN O
mutations NNS O
at IN O
highly RB O
conserved VBN O
residues NNS O
in IN O
each DT O
of IN O
the DT O
C2Q0 NNP O
alleles NNS O
. . O

One CD O
is VBZ O
in IN O
exon JJ O
5 CD O
( ( O
nucleotide JJ O
C566 NNP O
- : O
- : O
> NN O
T NNP O
; : O
Ser189 NNP O
- : O
- : O
> NN O
Phe NNP O
) ) O
of IN O
the DT O
C2Q0 NNP O
gene NN O
linked VBD O
to TO O
the DT O
MHC NNP O
haplotype NN O
A11 NNP O
, , O
B35 NNP O
, , O
DRw1 NNP O
, , O
BFS NNP O
, , O
C4A0B1 NNP O
. . O

The DT O
other JJ O
is VBZ O
in IN O
exon JJ O
11 CD O
( ( O
G1930 NNP O
- : O
- : O
> VB O
A DT O
; : O
Gly444 NNP O
- : O
- : O
> NN O
Arg NNP O
) ) O
of IN O
the DT O
C2Q0 NNP O
gene NN O
linked VBD O
to TO O
the DT O
MHC NNP O
haplotype NN O
A2 NNP O
, , O
B5 NNP O
, , O
DRw4 NNP O
, , O
BFS NNP O
, , O
C4A3B1 NNP O
. . O

Each DT O
mutant JJ O
C2 NNP O
gene NN O
product NN O
is VBZ O
retained VBN O
early RB O
in IN O
the DT O
secretory JJ O
pathway NN O
. . O

These DT O
mutants NNS O
provide VBP O
models NNS O
for IN O
elucidating VBG O
the DT O
C2 NNP O
secretory NN O
pathway NN O
. . O
. . O

Defective JJ O
dimerization NN O
of IN O
von JJ B-Disease
Willebrand NNP I-Disease
factor NN O
subunits NNS O
due JJ O
to TO O
a DT O
Cys NNP O
- : O
> NN O
Arg NNP O
mutation NN O
in IN O
type NN B-Disease
IID NNP I-Disease
von NNP I-Disease
Willebrand NNP I-Disease
disease NN I-Disease
. . O

The DT O
same JJ O
heterozygous JJ O
T NNP O
- : O
> NN O
C NNP O
transition NN O
at IN O
nt JJ O
8567 CD O
of IN O
the DT O
von NN B-Disease
Willebrand NNP I-Disease
factor NN O
( ( O
vWF NN O
) ) O
transcript NN O
was VBD O
found VBN O
in IN O
two CD O
unrelated JJ O
patients NNS O
with IN O
type JJ B-Disease
IID NNP I-Disease
von NNP I-Disease
Willebrand NNP I-Disease
disease NN I-Disease
, , O
with IN O
no DT O
other JJ O
apparent JJ O
abnormality NN O
. . O

In IN O
one CD O
family NN O
, , O
both DT O
alleles NNS O
were VBD O
normal JJ O
in IN O
the DT O
parents NNS O
and CC O
one CD O
sister NN O
; : O
thus RB O
, , O
the DT O
mutation NN O
originated VBD O
de FW O
novo FW O
in IN O
the DT O
proposita NN O
. . O

The DT O
second JJ O
patient NN O
also RB O
had VBD O
asymptomatic JJ O
parents NNS O
who WP O
, , O
however RB O
, , O
were VBD O
not RB O
available JJ O
for IN O
study NN O
. . O

The DT O
structural JJ O
consequences NNS O
of IN O
the DT O
identified JJ O
mutation NN O
, , O
resulting VBG O
in IN O
the DT O
CyS2010 NNP O
- : O
> NN O
Arg NNP O
substitution NN O
, , O
were VBD O
evaluated VBN O
by IN O
expression NN O
of IN O
the DT O
vWF NN O
carboxyl SYM O
- : O
terminal JJ O
domain NN O
containing VBG O
residues NNS O
1366 CD O
- : O
2050 CD O
. . O

Insect NNP O
cells NNS O
infected VBN O
with IN O
recombinant JJ O
baculovirus NN O
expressing VBG O
normal JJ O
vWF JJ O
sequence NN O
secreted VBD O
a DT O
disulfide NN O
linked VBN O
dimeric JJ O
molecule NN O
with IN O
an DT O
apparent JJ O
molecular JJ O
mass NN O
of IN O
150 CD O
kDa NNS O
before IN O
reduction NN O
, , O
yielding VBG O
a DT O
single JJ O
band NN O
of IN O
80 CD O
kDa NNS O
after IN O
disulfide JJ O
bond NN O
reduction NN O
. . O

In IN O
contrast NN O
, , O
cells NNS O
expressing VBG O
the DT O
mutant JJ O
fragment NN O
secreted VBD O
a DT O
monomeric JJ O
molecule NN O
of IN O
apparent JJ O
molecular JJ O
mass NN O
of IN O
80 CD O
kDa NNS O
, , O
which WDT O
remained VBD O
unchanged JJ O
after IN O
reduction NN O
. . O

We PRP O
conclude VBP O
that DT O
CyS2010 NNP O
is VBZ O
essential JJ O
for IN O
normal JJ O
dimerization NN O
of IN O
vWF NN O
subunits NNS O
through IN O
disulfide JJ O
bonding NN O
of IN O
carboxyl NN O
- : O
terminal NN O
domains NNS O
and CC O
that IN O
a DT O
heterozygous JJ O
mutation NN O
in IN O
the DT O
corresponding JJ O
codon NN O
is VBZ O
responsible JJ O
for IN O
defective JJ O
multimer NN O
formation NN O
in IN O
type NN B-Disease
IID NNP I-Disease
von NNP I-Disease
Willebrand NNP I-Disease
disease NN I-Disease
. . O
. . O

Wiskott NNP B-Disease
- : I-Disease
Aldrich NNP I-Disease
syndrome VBD I-Disease
protein NN O
, , O
a DT O
novel JJ O
effector NN O
for IN O
the DT O
GTPase NNP O
CDC42Hs NNP O
, , O
is VBZ O
implicated VBN O
in IN O
actin JJ O
polymerization NN O
. . O

The DT O
Rho NNP O
family NN O
of IN O
GTPases NNP O
control NN O
diverse JJ O
biological JJ O
processes NNS O
, , O
including VBG O
cell NN O
morphology NN O
and CC O
mitogenesis NN O
. . O

We PRP O
have VBP O
identified VBN O
WASP NNP O
, , O
the DT O
protein NN O
that WDT O
is VBZ O
defective JJ O
in IN O
Wiskott NNP B-Disease
- : I-Disease
Aldrich NNP I-Disease
syndrome NN I-Disease
( ( O
WAS NNP B-Disease
) ) O
, , O
as IN O
a DT O
novel JJ O
effector NN O
for IN O
CDC42Hs NNP O
, , O
but CC O
not RB O
for IN O
the DT O
other JJ O
Rho NNP O
family NN O
members NNS O
, , O
Rac NNP O
and CC O
Rho NNP O
. . O

This DT O
interaction NN O
is VBZ O
dependent JJ O
on IN O
the DT O
presence NN O
of IN O
the DT O
G NNP O
protein SYM O
- : O
binding NN O
domain NN O
. . O

Cellular JJ O
expression NN O
of IN O
epitope NN O
- : O
tagged VBN O
WASP NNP O
produces VBZ O
clusters NNS O
of IN O
WASP NNP O
that WDT O
are VBP O
highly RB O
enriched VBN O
in IN O
polymerized JJ O
actin NN O
. . O

This DT O
clustering NN O
is VBZ O
not RB O
observed VBN O
with IN O
a DT O
C NNP O
- : O
terminally RB O
deleted VBN O
WASP NNP O
and CC O
is VBZ O
inhibited VBN O
by IN O
coexpression NN O
with IN O
dominant JJ O
negative JJ O
CDC42Hs NNP O
- : O
N17 NN O
, , O
but CC O
not RB O
with IN O
dominant JJ O
negative JJ O
forms NNS O
of IN O
Rac NNP O
or CC O
Rho NNP O
. . O

Thus RB O
, , O
WASP NNP O
provides VBZ O
a DT O
novel JJ O
link NN O
between IN O
CDC42Hs NNP O
and CC O
the DT O
actin JJ O
cytoskeleton NN O
, , O
which WDT O
suggests VBZ O
a DT O
molecular JJ O
mechanism NN O
for IN O
many JJ O
of IN O
the DT O
cellular JJ O
abnormalities NNS O
in IN O
WAS NNP B-Disease
. . O

The DT O
WASP NNP O
sequence NN O
contains VBZ O
two CD O
novel NN O
domains NNS O
that WDT O
are VBP O
homologous JJ O
to TO O
other JJ O
proteins NNS O
involved VBN O
in IN O
action NN O
organization NN O
. . O
. . O

X LS B-Disease
- : I-Disease
linked VBN I-Disease
adrenoleukodystrophy NN I-Disease
is VBZ O
a DT O
frequent JJ O
cause NN O
of IN O
idiopathic JJ O
Addison NNP B-Disease
' POS I-Disease
s JJ I-Disease
disease NN I-Disease
in IN O
young JJ O
adult NN O
male JJ O
patients NNS O
. . O

X LS B-Disease
- : I-Disease
Linked VBN I-Disease
adrenoleukodystrophy NN I-Disease
( ( O
ALD NNP B-Disease
) ) O
is VBZ O
a DT O
genetic JJ B-Disease
disease NN I-Disease
associated VBN O
with IN O
demyelination NN B-Disease
of IN I-Disease
the DT I-Disease
central JJ I-Disease
nervous JJ I-Disease
system NN I-Disease
, , O
adrenal JJ B-Disease
insufficiency NN I-Disease
, , O
and CC O
accumulation NN O
of IN O
very RB O
long RB O
chain NN O
fatty JJ O
acids NNS O
in IN O
tissue NN O
and CC O
body NN O
fluids NNS O
. . O

ALD NNP B-Disease
is VBZ O
due JJ O
to TO O
mutation NN O
of IN O
a DT O
gene NN O
located VBN O
in IN O
Xq28 NNP O
that WDT O
encodes VBZ O
a DT O
peroxisomal JJ O
transporter NN O
protein NN O
of IN O
unknown JJ O
function NN O
. . O

The DT O
most RBS O
common JJ O
phenotype NN O
of IN O
ALD NNP B-Disease
is VBZ O
the DT O
cerebral JJ O
form NN O
( ( O
45 CD O
% NN O
) ) O
that WDT O
develops VBZ O
in IN O
boys NNS O
between IN O
5 CD O
- : O
12 CD O
yr NN O
. . O

Adrenomyeloneuropathy NNP B-Disease
( ( O
AMN NNP B-Disease
) ) O
involves VBZ O
the DT O
spinal JJ O
cord NN O
and CC O
peripheral JJ O
nerves NNS O
in IN O
young JJ O
adults NNS O
( ( O
35 CD O
% NN O
) ) O
. . O

Adrenal JJ B-Disease
insufficiency NN I-Disease
( ( O
Addisons NNP B-Disease
disease NN I-Disease
) ) O
is VBZ O
frequently RB O
associated VBN O
with IN O
AMN NNP B-Disease
or CC O
cerebral JJ B-Disease
ALD NNP I-Disease
and CC O
may MD O
remain VB O
the DT O
only JJ O
clinical JJ O
expression NN O
of IN O
ALD NNP B-Disease
( ( O
8 CD O
% NN O
of IN O
cases NNS O
) ) O
. . O

The DT O
prevalence NN O
of IN O
ALD NNP B-Disease
among IN O
adults NNS O
with IN O
Addisons NNP B-Disease
disease NN I-Disease
remains VBZ O
unknown JJ O
. . O

To TO O
evaluate VB O
this DT O
prevalence NN O
, , O
we PRP O
performed VBD O
biochemical JJ O
analysis NN O
of IN O
very RB O
long RB O
chain NN O
fatty JJ O
acids NNS O
in IN O
14 CD O
male NN O
patients NNS O
( ( O
age NN O
ranging VBG O
from IN O
12 CD O
- : O
45 CD O
yr NN O
at IN O
diagnosis NN O
) ) O
previously RB O
diagnosed VBN O
as IN O
having VBG O
primary JJ O
idiopathic JJ O
adrenocortical JJ B-Disease
insufficiency NN I-Disease
. . O

In IN O
5 CD O
of IN O
14 CD O
patients NNS O
( ( O
35 CD O
% NN O
) ) O
, , O
elevated VBD O
plasma JJ O
concentrations NNS O
of IN O
very RB O
long RB O
chain NN O
fatty JJ O
acids NNS O
were VBD O
detected VBN O
. . O

None NN O
of IN O
these DT O
patients NNS O
had VBD O
adrenocortical JJ O
antibodies NNS O
. . O

By IN O
electrophysiological JJ O
tests NNS O
and CC O
magnetic JJ O
resonance NN O
imaging VBG O
it PRP O
was VBD O
determined VBN O
that IN O
two CD O
patients NNS O
had VBD O
cerebral JJ B-Disease
ALD NNP I-Disease
, , O
one CD O
had VBD O
adrenomyeloneuropathy VBN B-Disease
with IN O
cerebral JJ O
involvement NN O
, , O
and CC O
two CD O
had VBD O
preclinical JJ O
AMN NNP B-Disease
. . O

Our PRP$ O
data NNS O
support NN O
the DT O
hypothesis NN O
that IN O
ALD NNP B-Disease
is VBZ O
a DT O
frequent JJ O
cause NN O
of IN O
idiopathic JJ O
Addisons NNP B-Disease
disease NN I-Disease
in IN O
children NNS O
and CC O
adults NNS O
. . O
. . O

Tumor NNP B-Disease
suppression NN O
and CC O
apoptosis NN O
of IN O
human JJ O
prostate NN B-Disease
carcinoma NN I-Disease
mediated VBN O
by IN O
a DT O
genetic JJ O
locus NN O
within IN O
human JJ O
chromosome NN O
10pter CD O
- : O
q11 NN O
. . O

Prostate NNP B-Disease
cancer NN I-Disease
is VBZ O
the DT O
second JJ O
leading JJ O
cause NN O
of IN O
male JJ O
cancer NN B-Disease
deaths NNS O
in IN O
the DT O
United NNP O
States NNPS O
. . O

Yet RB O
, , O
despite IN O
a DT O
large JJ O
international JJ O
effort NN O
, , O
little JJ O
is VBZ O
known VBN O
about IN O
the DT O
molecular JJ O
mechanisms NNS O
that WDT O
underlie VBP O
this DT O
devastating JJ O
disease NN O
. . O

Prostate NNP O
secretory NN O
epithelial JJ O
cells NNS O
and CC O
androgen NN O
- : O
dependent JJ O
prostate NN B-Disease
carcinomas NN I-Disease
undergo JJ O
apoptosis NN O
in IN O
response NN O
to TO O
androgen VB O
deprivation NN O
and CC O
, , O
furthermore RB O
, , O
most JJS O
prostate JJ B-Disease
carcinomas NN I-Disease
become VBN O
androgen JJ O
independent JJ O
and CC O
refractory NN O
to TO O
further RBR O
therapeutic JJ O
manipulations NNS O
during IN O
disease NN O
progression NN O
. . O

Definition NN O
of IN O
the DT O
genetic JJ O
events NNS O
that WDT O
trigger VBP O
apoptosis NN O
in IN O
the DT O
prostate NN O
could MD O
provide VB O
important JJ O
insights NNS O
into IN O
critical JJ O
pathways NNS O
in IN O
normal JJ O
development NN O
as RB O
well RB O
as IN O
elucidate NN O
the DT O
perturbations NNS O
of IN O
those DT O
key JJ O
pathways NNS O
in IN O
neoplastic JJ O
transformation NN O
. . O

We PRP O
report VBP O
the DT O
functional JJ O
definition NN O
of IN O
a DT O
novel JJ O
genetic JJ O
locus NN O
within IN O
human JJ O
chromosome NN O
10pter CD O
- : O
q11 NN O
that WDT O
mediates VBZ O
both DT O
in IN O
vivo NN O
tumor NN O
suppression NN O
and CC O
in IN O
vitro JJ O
apoptosis NN O
of IN O
prostatic JJ B-Disease
adenocarcinoma NN I-Disease
cells NNS O
. . O

A DT O
defined JJ O
fragment NN O
of IN O
human JJ O
chromosome NN O
10 CD O
was VBD O
transferred VBN O
via IN O
microcell NN O
fusion NN O
into IN O
a DT O
prostate JJ B-Disease
adenocarcinoma NN I-Disease
cell NN O
line NN O
. . O

Microcell NNP O
hybrids NNS O
containing VBG O
only RB O
the DT O
region NN O
10pter CD O
- : O
q11 NN O
were VBD O
suppressed VBN O
for IN O
tumorigenicity NN O
following VBG O
injection NN O
of IN O
microcell NN O
hybrids NNS O
into IN O
nude JJ O
mice NN O
. . O

Furthermore RB O
, , O
the DT O
complemented JJ O
hybrids NNS O
undergo NN O
programmed VBD O
cell NN O
death NN O
in IN O
vitro NN O
via IN O
a DT O
mechanism NN O
that WDT O
does VBZ O
not RB O
require VB O
nuclear JJ O
localization NN O
of IN O
p53 NN O
. . O

These DT O
data NNS O
functionally RB O
define VBP O
a DT O
novel JJ O
genetic JJ O
locus NN O
, , O
designated VBN O
PAC1 NNP O
, , O
for IN O
prostate NN O
adenocarcinoma NN O
1 CD O
, , O
involved VBN O
in IN O
tumor NN O
suppression NN O
of IN O
human JJ O
prostate NN B-Disease
carcinoma NN I-Disease
and CC O
furthermore RB O
strongly RB O
suggest VBP O
that IN O
the DT O
cell NN O
death NN O
pathway NN O
can MD O
be VB O
functionally RB O
restored VBN O
in IN O
prostatic JJ B-Disease
adenocarcinoma NN I-Disease
. . O
. . O

Low JJ O
incidence NN O
of IN O
BRCA2 NNP O
mutations NNS O
in IN O
breast NN B-Disease
carcinoma NN I-Disease
and CC O
other JJ O
cancers NNS B-Disease
. . O

Inherited VBN O
mutant JJ O
alleles NNS O
of IN O
familial JJ O
tumour NN B-Disease
suppressor NN O
genes NNS O
predispose VBP O
individuals NNS O
to TO O
particular JJ O
types NNS O
of IN O
cancer NN B-Disease
. . O

In IN O
addition NN O
to TO O
an DT O
involvement NN O
in IN O
inherited JJ O
susceptibility NN O
to TO O
cancer NN B-Disease
, , O
these DT O
tumour NNS B-Disease
suppressor NN O
genes NNS O
are VBP O
targets NNS O
for IN O
somatic JJ O
mutations NNS O
in IN O
sporadic JJ B-Disease
cancers NNS I-Disease
of IN O
the DT O
same JJ O
type NN O
found VBD O
in IN O
the DT O
familial JJ O
forms NNS O
. . O

An DT O
exception NN O
is VBZ O
BRCA1 NNP O
, , O
which WDT O
contributes VBZ O
to TO O
a DT O
significant JJ O
fraction NN O
of IN O
familial JJ B-Disease
breast NN I-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
, , O
but CC O
undergoes JJ O
mutation NN O
at IN O
very RB O
low JJ O
rates NNS O
in IN O
sporadic JJ B-Disease
breast NN I-Disease
and CC I-Disease
ovarian JJ I-Disease
cancers NNS I-Disease
. . O

This DT O
finding NN O
suggests VBZ O
that IN O
other JJ O
genes NNS O
may MD O
be VB O
the DT O
principal JJ O
targets NNS O
for IN O
somatic JJ O
mutation NN O
in IN O
breast NN B-Disease
carcinoma NN I-Disease
. . O

A DT O
second JJ O
, , O
recently RB O
identified VBN O
familial JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
gene NN O
, , O
BRCA2 NNP O
( ( O
refs VB O
5 CD O
- : O
8 CD O
) ) O
, , O
accounts NNS O
for IN O
a DT O
proportion NN O
of IN O
breast NN B-Disease
cancer NN I-Disease
roughly RB O
equal JJ O
to TO O
BRCA1 NNP O
. . O

Like IN O
BRCA1 NNP O
, , O
BRCA2 NNP O
behaves VBZ O
as IN O
a DT O
dominantly RB O
inherited VBN O
tumour NN B-Disease
suppressor NN O
gene NN O
. . O

Individuals NNS O
who WP O
inherit VBP O
one CD O
mutant NN O
allele NN O
are VBP O
at IN O
increased VBN O
risk NN O
for IN O
breast NN B-Disease
cancer NN I-Disease
, , O
and CC O
the DT O
tumours NN B-Disease
they PRP O
develop VBP O
lose VB O
the DT O
wild JJ O
- : O
type NN O
allele NN O
by IN O
heterozygous JJ O
deletion NN O
. . O

The DT O
BRCA2 NNP O
coding NN O
sequence NN O
is VBZ O
huge JJ O
, , O
composed VBN O
of IN O
26 CD O
exons NNS O
that IN O
span VBP O
10 CD O
, , O
443 CD O
bp NN O
. . O

Here RB O
we PRP O
investigate VBP O
the DT O
rate NN O
of IN O
BRCA2 NNP O
mutation NN O
in IN O
sporadic JJ B-Disease
breast NN I-Disease
cancers NNS I-Disease
and CC O
in IN O
a DT O
set NN O
of IN O
cell NN O
lines NNS O
that WDT O
represent VBP O
twelve VB O
other JJ O
tumour JJ B-Disease
types NNS O
. . O

Surprisingly RB O
, , O
mutations NNS O
in IN O
BRCA2 NNP O
are VBP O
infrequent JJ O
in IN O
cancers NNS B-Disease
including VBG O
breast NN B-Disease
carcinoma NN I-Disease
. . O

However RB O
, , O
a DT O
probable JJ O
germline NN O
mutation NN O
in IN O
a DT O
pancreatic JJ B-Disease
tumour NN I-Disease
cell NN O
line NN O
suggests VBZ O
a DT O
role NN O
for IN O
BRCA2 NNP O
in IN O
susceptibility NN O
to TO O
pancreatic JJ B-Disease
cancer NN I-Disease
. . O
. . O

Founding VBG O
BRCA1 NNP O
mutations NNS O
in IN O
hereditary JJ B-Disease
breast NN I-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
in IN O
southern JJ O
Sweden NNP O
. . O

Nine NNP O
different JJ O
germ NNS O
- : O
line NN O
mutations NNS O
in IN O
the DT O
BRCA1 NNP O
breast NN B-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
susceptibility NN O
gene NN O
were VBD O
identified VBN O
in IN O
15 CD O
of IN O
47 CD O
kindreds NNS O
from IN O
southern JJ O
Sweden NNP O
, , O
by IN O
use NN O
of IN O
SSCP NNP O
and CC O
heteroduplex JJ O
analysis NN O
of IN O
all DT O
exons NNS O
and CC O
flanking VBG O
intron JJ O
region NN O
and CC O
by IN O
a DT O
protein NN O
- : O
truncation NN O
test NN O
for IN O
exon NN O
11 CD O
, , O
followed VBN O
by IN O
direct JJ O
sequencing NN O
. . O

All DT O
but CC O
one CD O
of IN O
the DT O
mutations NNS O
are VBP O
predicted VBN O
to TO O
give VB O
rise NN O
to TO O
premature VB O
translation NN O
termination NN O
and CC O
include VBP O
seven CD O
frameshift JJ O
insertions NNS O
or CC O
deletions NNS O
, , O
a DT O
nonsense JJ O
mutation NN O
, , O
and CC O
a DT O
splice NN O
acceptor NN O
site NN O
mutation NN O
. . O

The DT O
remaining VBG O
mutation NN O
is VBZ O
a DT O
missense JJ O
mutation NN O
( ( O
Cys61Gly NNP O
) ) O
in IN O
the DT O
zinc NN O
- : O
binding NN O
motif NN O
. . O

Four CD O
novel JJ O
Swedish NNP O
founding NN O
mutations NNS O
were VBD O
identified VBN O
the DT O
nucleotide JJ O
2595 CD O
deletion NN O
A DT O
was VBD O
found VBN O
in IN O
five CD O
families NNS O
, , O
the DT O
C NNP O
1806 CD O
T NNP O
nonsense JJ O
mutation NN O
in IN O
three CD O
families NNS O
, , O
the DT O
3166 CD O
insertion NN O
TGAGA NNP O
in IN O
three CD O
families NNS O
, , O
and CC O
the DT O
nucleotide JJ O
1201 CD O
deletion NN O
11 CD O
in IN O
two CD O
families NNS O
. . O

Analysis NN O
of IN O
the DT O
intragenic JJ O
polymorphism NN O
D17S855 NNP O
supports VBZ O
common JJ O
origins NNS O
of IN O
the DT O
mutations NNS O
. . O

Eleven NNP O
of IN O
the DT O
15 CD O
kindreds NNS O
manifesting VBG O
BRCA1 NNP O
mutations NNS O
were VBD O
breast SYM B-Disease
- : I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
families NNS O
, , O
several JJ O
of IN O
them PRP O
with IN O
a DT O
predominant JJ O
ovarian JJ B-Disease
cancer NN I-Disease
phenotype NN O
. . O

The DT O
set NN O
of IN O
32 CD O
families NNS O
in IN O
which WDT O
no DT O
BRCA1 NNP O
alterations NNS O
were VBD O
detected VBN O
included JJ O
1 CD O
breast NN B-Disease
- : I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
kindred VBD O
manifesting VBG O
clear JJ O
linkage NN O
to TO O
the DT O
BRCA1 NNP O
region NN O
and CC O
loss NN O
of IN O
the DT O
wild JJ O
- : O
type NN O
chromosome NN O
in IN O
associated JJ O
tumors NNS B-Disease
. . O

Other JJ O
tumor NN B-Disease
types NNS O
found VBN O
in IN O
BRCA1 NNP O
mutation NN O
/ NNP O
haplotype NN O
carriers NNS O
included VBD O
prostatic JJ B-Disease
, , I-Disease
pancreas NNS I-Disease
, , I-Disease
skin NN I-Disease
, , I-Disease
and CC I-Disease
lung NN I-Disease
cancer NN I-Disease
, , O
a DT O
malignant JJ B-Disease
melanoma NN I-Disease
, , O
an DT O
oligodendroglioma NN B-Disease
, , O
and CC O
a DT O
carcinosarcoma NN B-Disease
. . O

In IN O
all DT O
, , O
12 CD O
of IN O
16 CD O
kindreds NNS O
manifesting VBG O
BRCA1 NNP O
mutation NN O
or CC O
linkage NN O
contained VBN O
ovarian JJ B-Disease
cancer NN I-Disease
, , O
as IN O
compared VBN O
with IN O
only RB O
6 CD O
of IN O
the DT O
remaining VBG O
31 CD O
families NNS O
( ( O
P NNP O
< NNP O
. . O
1 CD O
) ) O
. . O

The DT O
present JJ O
study NN O
confirms VBZ O
the DT O
involvement NN O
of IN O
BRCA1 NNP O
in IN O
disease NN O
predisposition NN O
for IN O
a DT O
subset NN O
of IN O
hereditary JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
families NNS O
often RB O
characterized VBN O
by IN O
ovarian JJ B-Disease
cancers NNS I-Disease
. . O

Rapid JJ O
detection NN O
of IN O
regionally RB O
clustered VBN O
germ JJ O
- : O
line NN O
BRCA1 NNP O
mutations NNS O
by IN O
multiplex JJ O
heteroduplex JJ O
analysis NN O
. . O

UKCCCR NNP O
Familial NNP O
Ovarian NNP B-Disease
Cancer NNP I-Disease
Study NNP O
Group NNP O
. . O

Germ NNP O
- : O
line NN O
mutations NNS O
of IN O
the DT O
BRCA1 NNP O
gene NN O
are VBP O
responsible JJ O
for IN O
a DT O
substantial JJ O
proportion NN O
of IN O
families NNS O
with IN O
multiple JJ O
cases NNS O
of IN O
early JJ O
- : O
onset NN O
breast NN B-Disease
and CC I-Disease
/ NN I-Disease
or CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
. . O

Since IN O
the DT O
isolation NN O
of IN O
BRCA1 NNP O
last JJ O
year NN O
, , O
> VBP O
65 CD O
distinct JJ O
mutations NNS O
scattered VBD O
throughout IN O
the DT O
coding VBG O
region NN O
have VBP O
been VBN O
detected VBN O
, , O
making VBG O
analysis NN O
of IN O
the DT O
gene NN O
time NN O
consuming VBG O
and CC O
technically RB O
challenging JJ O
. . O

We PRP O
have VBP O
developed VBN O
a DT O
multiplex JJ O
heteroduplex NN O
analysis NN O
that WDT O
is VBZ O
designed VBN O
to TO O
analyze VB O
one CD O
- : O
quarter NN O
of IN O
the DT O
coding VBG O
sequence NN O
in IN O
a DT O
single JJ O
- : O
step NN O
screening JJ O
procedure NN O
and CC O
that DT O
will MD O
detect VB O
approximately RB O
50 CD O
% NN O
of IN O
all DT O
BRCA1 NNP O
mutations NNS O
so RB O
far RB O
reported VBN O
in IN O
breast NN B-Disease
/ NN I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
families NNS O
. . O

We PRP O
have VBP O
used VBN O
this DT O
technique NN O
to TO O
analyze VB O
BRCA1 NNP O
in IN O
162 CD O
families NNS O
with IN O
a DT O
history NN O
of IN O
breast NN B-Disease
and CC I-Disease
/ NN I-Disease
or CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
and CC O
identified VBD O
12 CD O
distinct JJ O
mutations NNS O
in IN O
35 CD O
families NNS O
. . O
. . O

A DT O
previously RB O
undescribed JJ O
mutation NN O
within IN O
the DT O
tetramerisation NN O
domain NN O
of IN O
TP53 NNP O
in IN O
a DT O
family NN O
with IN O
Li NNP B-Disease
- : I-Disease
Fraumeni NNP I-Disease
syndrome NN I-Disease
. . O

We PRP O
report VBP O
details NNS O
of IN O
a DT O
family NN O
with IN O
classic JJ O
Li NNP B-Disease
- : I-Disease
Fraumeni NNP I-Disease
syndrome NN I-Disease
in IN O
which WDT O
there EX O
is VBZ O
a DT O
mutation NN O
in IN O
codon JJ O
344 CD O
of IN O
the DT O
tumour NN B-Disease
suppressor NN O
gene NN O
TP53 NNP O
. . O

Codon NNP O
344 CD O
is VBZ O
a DT O
key JJ O
residue NN O
within IN O
the DT O
tetramerisation NN O
domain NN O
, , O
and CC O
the DT O
amino NN O
acid JJ O
substitution NN O
of IN O
a DT O
proline NN O
for IN O
a DT O
leucine NN O
is VBZ O
predicted VBN O
to TO O
have VB O
profound JJ O
implications NNS O
for IN O
tetramerisation NN O
and CC O
potentially RB O
DNA NNP O
binding NN O
. . O

This DT O
is VBZ O
the DT O
first JJ O
report NN O
of IN O
a DT O
mutation NN O
at IN O
this DT O
residue NN O
in IN O
either DT O
sporadic JJ B-Disease
tumours NN I-Disease
or CC O
in IN O
the DT O
germline NN O
and CC O
the DT O
first JJ O
report NN O
of IN O
a DT O
germline JJ O
mutation NN O
within IN O
the DT O
tetramerisation NN O
domain NN O
. . O

The DT O
family NN O
does VBZ O
not RB O
appear VB O
to TO O
be VB O
remarkable JJ O
in IN O
the DT O
spectrum NN O
of IN O
tumours NNS B-Disease
, , O
and CC O
there EX O
is VBZ O
loss NN O
of IN O
the DT O
wild JJ O
- : O
type NN O
allele NN O
in IN O
a DT O
leiomyosarcoma NN B-Disease
from IN O
the DT O
proband NN O
. . O

A DT O
cell NN O
line NN O
has VBZ O
been VBN O
established VBN O
from IN O
the DT O
tumour NN B-Disease
of IN O
the DT O
proband NN O
and CC O
cytogenetic JJ O
and CC O
molecular JJ O
studies NNS O
carried VBD O
out RP O
, , O
providing VBG O
an DT O
extensive JJ O
analysis NN O
in IN O
this DT O
family NN O
. . O
. . O

The DT O
spectrum NN O
of IN O
RB1 NNP O
germ FW O
- : O
line NN O
mutations NNS O
in IN O
hereditary JJ B-Disease
retinoblastoma NN I-Disease
. . O

We PRP O
have VBP O
searched VBN O
for IN O
germ JJ O
- : O
line NN O
RB1 NNP O
mutations NNS O
in IN O
119 CD O
patients NNS O
with IN O
hereditary JJ B-Disease
retinoblastoma NN I-Disease
. . O

Previous JJ O
investigations NNS O
by IN O
Southern NNP O
blot NN O
hybridization NN O
and CC O
PCR NNP O
fragment VBD O
- : O
length NN O
analysis NN O
had VBD O
revealed VBN O
mutations NNS O
in IN O
48 CD O
patients NNS O
. . O

Here RB O
we PRP O
report VBP O
on IN O
the DT O
analysis NN O
of IN O
the DT O
remaining VBG O
71 CD O
patients NNS O
. . O

By IN O
applying VBG O
heteroduplex JJ O
analysis NN O
, , O
nonisotopic JJ O
SSCP NNP O
, , O
and CC O
direct JJ O
sequencing NN O
, , O
we PRP O
detected VBD O
germ JJ O
- : O
line NN O
mutations NNS O
resulting VBG O
in IN O
premature NN O
termination NN O
codons NNS O
or CC O
disruption NN O
of IN O
splice NN O
signals NNS O
in IN O
51 CD O
( ( O
72 CD O
% NN O
) ) O
of IN O
the DT O
71 CD O
patients NNS O
. . O

Four CD O
patients NNS O
also RB O
showed VBD O
rare JJ O
sequence NN O
variants NNS O
. . O

No DT O
region NN O
of IN O
the DT O
RB1 NNP O
gene NN O
was VBD O
preferentially RB O
involved VBN O
in IN O
single JJ O
base NN O
substitutions NNS O
. . O

Recurrent JJ O
transitions NNS O
were VBD O
observed VBN O
at IN O
most JJS O
of IN O
the DT O
14 CD O
codons NNS O
within IN O
the DT O
RB1 NNP O
. . O

No DT O
mutation NN O
was VBD O
observed VBN O
in IN O
exons NNS O
25 CD O
- : O
27 CD O
, , O
although IN O
this DT O
region NN O
contains VBZ O
two CD O
CGA NNP O
codons NNS O
. . O

This DT O
suggests VBZ O
that IN O
mutations NNS O
within IN O
the DT O
3 CD O
- : O
terminal JJ O
region NN O
of IN O
the DT O
RB1 NNP O
gene NN O
may MD O
not RB O
be VB O
oncogenic JJ O
. . O

When WRB O
these DT O
data NNS O
were VBD O
combined VBN O
with IN O
the DT O
results NNS O
of IN O
our PRP$ O
previous JJ O
investigations NNS O
, , O
mutations NNS O
were VBD O
identified VBN O
in IN O
a DT O
total NN O
of IN O
99 CD O
( ( O
83 CD O
% NN O
) ) O
of IN O
119 CD O
patients NNS O
. . O

The DT O
spectrum NN O
comprises VBZ O
15 CD O
% NN O
large JJ O
deletions NNS O
, , O
26 CD O
% NN O
small JJ O
length NN O
alterations NNS O
, , O
and CC O
42 CD O
% NN O
base NN O
substitutions NNS O
. . O

No DT O
correlation NN O
between IN O
the DT O
location NN O
of IN O
frameshift NN O
or CC O
nonsense JJ O
mutations NNS O
and CC O
phenotypic NN O
features NNS O
, , O
including VBG O
age NN O
at IN O
diagnosis NN O
, , O
the DT O
number NN O
of IN O
tumor NN B-Disease
foci NN O
, , O
and CC O
manifestation NN O
of IN O
nonocular JJ B-Disease
tumors NNS I-Disease
was VBD O
observed VBN O
. . O
. . O

Phenotypic NNP O
characterization NN O
of IN O
individuals NNS O
with IN O
30 CD O
- : O
40 CD O
CAG NNP O
repeats NNS O
in IN O
the DT O
Huntington NNP B-Disease
disease NN I-Disease
( ( O
HD NNP B-Disease
) ) O
gene NN O
reveals NNS O
HD NNP B-Disease
cases NNS O
with IN O
36 CD O
repeats NNS O
and CC O
apparently RB O
normal JJ O
elderly JJ O
individuals NNS O
with IN O
36 CD O
- : O
39 CD O
repeats NNS O
. . O

Abnormal NNP O
CAG NNP O
expansions NNS O
in IN O
the DT O
IT NNP O
- : O
15 CD O
gene NN O
are VBP O
associated VBN O
with IN O
Huntington NNP B-Disease
disease NN I-Disease
( ( O
HD NNP B-Disease
) ) O
. . O

In IN O
the DT O
diagnostic JJ O
setting NN O
it PRP O
is VBZ O
necessary JJ O
to TO O
define VB O
the DT O
limits NNS O
of IN O
the DT O
CAG NNP O
size NN O
ranges VBZ O
on IN O
normal JJ O
and CC O
HD NNP B-Disease
- : O
associated VBN O
chromosomes NNS O
. . O

Most JJS O
large JJ O
analyses NNS O
that WDT O
defined VBD O
the DT O
limits NNS O
of IN O
the DT O
normal JJ O
and CC O
pathological JJ O
size NN O
ranges VBZ O
employed VBN O
PCR NNP O
assays NNS O
, , O
which WDT O
included VBD O
the DT O
CAG NNP O
repeats NNS O
and CC O
a DT O
CCG NNP O
repeat NN O
tract NN O
that WDT O
was VBD O
thought VBN O
to TO O
be VB O
invariant JJ O
. . O

Many JJ O
of IN O
these DT O
experiments NNS O
found VBD O
an DT O
overlap NN O
between IN O
the DT O
normal JJ O
and CC O
disease JJ O
size NN O
ranges NNS O
. . O

Subsequent JJ O
findings NNS O
that IN O
the DT O
CCG NNP O
repeats NNS O
vary VBP O
by IN O
8 CD O
trinucleotide JJ O
lengths NNS O
suggested VBD O
that IN O
the DT O
limits NNS O
of IN O
the DT O
normal JJ O
and CC O
disease JJ O
size NN O
ranges NNS O
should MD O
be VB O
reevaluated VBN O
with IN O
assays NNS O
that WDT O
exclude VBP O
the DT O
CCG NNP O
polymorphism NN O
. . O

Since IN O
patients NNS O
with IN O
between IN O
30 CD O
and CC O
40 CD O
repeats NNS O
are VBP O
rare JJ O
, , O
a DT O
consortium NN O
was VBD O
assembled VBN O
to TO O
collect VB O
such JJ O
individuals NNS O
. . O

All DT O
178 CD O
samples NNS O
were VBD O
reanalyzed VBN O
in IN O
Cambridge NNP O
by IN O
using VBG O
assays NNS O
specific NN O
for IN O
the DT O
CAG NNP O
repeats NNS O
. . O

We PRP O
have VBP O
optimized VBN O
methods NNS O
for IN O
reliable JJ O
sizing NN O
of IN O
CAG NNP O
repeats NNS O
and CC O
show VBP O
cases NNS O
that WDT O
demonstrate VBP O
the DT O
dangers NNS O
of IN O
using VBG O
PCR NNP O
assays VBZ O
that IN O
include VBP O
both DT O
the DT O
CAG NNP O
and CC O
CCG NNP O
polymorphisms NNS O
. . O

Seven NNP O
HD NNP B-Disease
patients NNS O
had VBD O
36 CD O
repeats NNS O
, , O
which WDT O
confirms VBZ O
that IN O
this DT O
allele NN O
is VBZ O
associated VBN O
with IN O
disease NN O
. . O

Individuals NNS O
without IN O
apparent NN O
symptoms NNS O
or CC O
signs NNS O
of IN O
HD NNP B-Disease
were VBD O
found VBN O
at IN O
36 CD O
repeats NNS O
( ( O
aged VBN O
74 CD O
, , O
78 CD O
, , O
79 CD O
, , O
and CC O
87 CD O
years NNS O
) ) O
, , O
37 CD O
repeats NNS O
( ( O
aged VBN O
69 CD O
years NNS O
) ) O
, , O
38 CD O
repeats NNS O
( ( O
aged VBN O
69 CD O
and CC O
90 CD O
years NNS O
) ) O
, , O
and CC O
39 CD O
repeats NNS O
( ( O
aged VBN O
67 CD O
, , O
90 CD O
, , O
and CC O
95 CD O
years NNS O
) ) O
. . O

The DT O
detailed JJ O
case NN O
histories NNS O
of IN O
an DT O
exceptional JJ O
case NN O
from IN O
this DT O
series NN O
will MD O
be VB O
presented VBN O
a DT O
95 CD O
- : O
year NN O
- : O
old JJ O
man NN O
with IN O
39 CD O
repeats NNS O
who WP O
did VBD O
not RB O
have VB O
classical JJ O
features NNS O
of IN O
HD NNP B-Disease
. . O

The DT O
apparently RB O
healthy JJ O
survival NN O
into IN O
old JJ O
age NN O
of IN O
some DT O
individuals NNS O
with IN O
36 CD O
- : O
39 CD O
repeats NNS O
suggests VBZ O
that IN O
the DT O
HD NNP B-Disease
mutation NN O
may MD O
not RB O
always RB O
be VB O
fully RB O
penetrant JJ O
. . O
. . O

Identification NN O
and CC O
expression NN O
of IN O
eight CD O
novel JJ O
mutations NNS O
among IN O
non JJ O
- : O
Jewish JJ O
patients NNS O
with IN O
Canavan NNP B-Disease
disease NN I-Disease
. . O

Canavan NNP B-Disease
disease NN I-Disease
is VBZ O
inherited VBN O
as IN O
an DT O
autosomal JJ O
recessive JJ O
trait NN O
that WDT O
is VBZ O
caused VBN O
by IN O
the DT O
deficiency NN B-Disease
of IN I-Disease
aspartoacylase NN I-Disease
( ( O
ASPA NNP O
) ) O
. . O

The DT O
majority NN O
of IN O
patients NNS O
with IN O
Canavan NNP B-Disease
disease NN I-Disease
are VBP O
from IN O
an DT O
Ashkenazi NNP O
Jewish NNP O
background NN O
. . O

Mutations NNS O
in IN O
ASPA NNP O
that WDT O
lead VBP O
to TO O
loss NN O
of IN O
enzymatic JJ O
activity NN O
have VBP O
been VBN O
identified VBN O
, , O
and CC O
E285A NNP O
and CC O
Y231X NNP O
are VBP O
the DT O
two CD O
predominant JJ O
mutations NNS O
that WDT O
account VBP O
for IN O
97 CD O
% NN O
of IN O
the DT O
mutant JJ O
chromosomes NNS O
in IN O
Ashkenazi NNP O
Jewish JJ O
patients NNS O
. . O

The DT O
current JJ O
study NN O
was VBD O
aimed VBN O
at IN O
finding VBG O
the DT O
molecular JJ O
basis NN O
of IN O
Canavan NNP B-Disease
disease NN I-Disease
in IN O
25 CD O
independent JJ O
patients NNS O
of IN O
non JJ O
- : O
Jewish JJ O
background NN O
. . O

Eight NNP O
novel NN O
and CC O
three CD O
previously RB O
characterized VBN O
mutations NNS O
accounted VBD O
for IN O
80 CD O
% NN O
( ( O
40 CD O
/ RB O
50 CD O
) ) O
of IN O
mutant JJ O
chromosomes NNS O
. . O

The DT O
A305E NNP O
missense NN O
mutation NN O
accounted VBD O
for IN O
48 CD O
% NN O
( ( O
24 CD O
/ RB O
50 CD O
) ) O
of IN O
mutant JJ O
chromosomes NNS O
in IN O
patients NNS O
of IN O
western JJ O
European JJ O
descent NN O
, , O
while IN O
the DT O
two CD O
predominant JJ O
Jewish JJ O
mutations NNS O
each DT O
accounted VBD O
for IN O
a DT O
single JJ O
mutant JJ O
chromosome NN O
. . O

The DT O
eight CD O
novel NN O
mutations NNS O
identified VBD O
included VBD O
1 CD O
- : O
and CC O
4 CD O
- : O
bp NN O
deletions NNS O
( ( O
32 CD O
deltaT NN O
and CC O
876 CD O
deltaAGAA NN O
, , O
respectively RB O
) ) O
and CC O
I16T NNP O
, , O
G27R NNP O
, , O
D114E NNP O
, , O
G123E NNP O
, , O
C152Y NNP O
, , O
and CC O
R168C NNP O
missense NN O
mutations NNS O
. . O

The DT O
homozygous JJ O
32 CD O
deltaT JJ O
deletion NN O
was VBD O
identified VBN O
in IN O
the DT O
only JJ O
known JJ O
patient NN O
of IN O
African NNP O
- : O
American JJ O
origin NN O
with IN O
Canavan NNP B-Disease
disease NN I-Disease
. . O

The DT O
heterozygosity NN O
for IN O
876 CD O
deltaAGAA JJ O
mutation NN O
was VBD O
identified VBN O
in IN O
three CD O
independent JJ O
patients NNS O
from IN O
England NNP O
. . O

Six CD O
single JJ O
- : O
base NN O
changes NNS O
leading VBG O
to TO O
missense VB O
mutations NNS O
were VBD O
identified VBN O
in IN O
patients NNS O
from IN O
Turkey NNP O
( ( O
D114E NNP O
, , O
R168C NNP O
) ) O
, , O
The DT O
Netherlands NNP O
( ( O
I16T NNP O
) ) O
, , O
Germany NNP O
( ( O
G27R NNP O
) ) O
, , O
Ireland NNP O
( ( O
C152Y NNP O
) ) O
, , O
and CC O
Canada NNP O
( ( O
G123E NNP O
) ) O
. . O

A DT O
PCR NNP O
- : O
based VBN O
protocol NN O
is VBZ O
described VBN O
that IN O
was VBD O
used VBN O
to TO O
introduce VB O
mutations NNS O
in IN O
wild JJ O
- : O
type NN O
cDNA NN O
. . O

In IN O
vitro JJ O
expression NN O
of IN O
mutant JJ O
cDNA NN O
clones NNS O
demonstrated VBD O
that IN O
all DT O
of IN O
these DT O
mutations NNS O
led VBD O
to TO O
a DT O
deficiency NN B-Disease
of IN I-Disease
ASPA NNP I-Disease
and CC O
should MD O
therefore VB O
result NN O
in IN O
Canavan NNP B-Disease
disease NN I-Disease
. . O
. . O

Identification NN O
and CC O
chromosomal JJ O
localization NN O
of IN O
Atm NNP O
, , O
the DT O
mouse NN O
homolog NN O
of IN O
the DT O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
gene NN O
. . O

Atm NNP O
, , O
the DT O
mouse NN O
homolog NN O
of IN O
the DT O
human JJ O
ATM NNP O
gene NN O
defective NN O
in IN O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
( ( O
A DT B-Disease
- : I-Disease
T NN I-Disease
) ) O
, , O
has VBZ O
been VBN O
identified VBN O
. . O

The DT O
entire JJ O
coding NN O
sequence NN O
of IN O
the DT O
Atm NNP O
transcript NN O
was VBD O
cloned VBN O
and CC O
found VBN O
to TO O
contain VB O
an DT O
open JJ O
reading NN O
frame NN O
encoding VBG O
a DT O
protein NN O
of IN O
3066 CD O
amino NN O
acids NNS O
with IN O
84 CD O
% NN O
overall JJ O
identity NN O
and CC O
91 CD O
% NN O
similarity NN O
to TO O
the DT O
human JJ O
ATM NNP O
protein NN O
. . O

Variable JJ O
levels NNS O
of IN O
expression NN O
of IN O
Atm NNP O
were VBD O
observed VBN O
in IN O
different JJ O
tissues NNS O
. . O

Fluorescence NN O
in IN O
situ JJ O
hybridization NN O
and CC O
linkage NN O
analysis NN O
located VBD O
the DT O
Atm NNP O
gene NN O
on IN O
mouse NN O
chromosome NN O
9 CD O
, , O
band NN O
9C CD O
, , O
in IN O
a DT O
region NN O
homologous JJ O
to TO O
the DT O
ATM NNP O
region NN O
on IN O
human JJ O
chromosome NN O
11q22 CD O
- : O
q23 NN O
. . O
. . O

The DT O
mouse NN O
homolog NN O
of IN O
the DT O
Wiskott NNP B-Disease
- : I-Disease
Aldrich NNP I-Disease
syndrome VBP I-Disease
protein NN O
( ( O
WASP NNP O
) ) O
gene NN O
is VBZ O
highly RB O
conserved VBN O
and CC O
maps NNS O
near IN O
the DT O
scurfy NN O
( ( O
sf NN O
) ) O
mutation NN O
on IN O
the DT O
X NNP O
chromosome NN O
. . O

The DT O
mouse NN O
WASP NNP O
gene NN O
, , O
the DT O
homolog NN O
of IN O
the DT O
gene NN O
mutated VBN O
in IN O
Wiskott NNP B-Disease
- : I-Disease
Aldrich NNP I-Disease
syndrome NN I-Disease
, , O
has VBZ O
been VBN O
isolated VBN O
and CC O
sequenced VBN O
. . O
the DT O
predicted JJ O
amino NN O
acid JJ O
sequence NN O
is VBZ O
86 CD O
% NN O
identical JJ O
to TO O
the DT O
human JJ O
WASP NNP O
sequence NN O
. . O

A DT O
distinct JJ O
feature NN O
of IN O
the DT O
mouse NN O
gene NN O
is VBZ O
an DT O
expanded JJ O
polymorphic JJ O
GGA NNP O
trinucleotide NN O
repeat NN O
that WDT O
codes VBZ O
for IN O
polyglycine NN O
and CC O
varies NNS O
from IN O
15 CD O
to TO O
17 CD O
triplets NNS O
in IN O
different JJ O
Mus NNP O
musculus NN O
strains NNS O
. . O

The DT O
genomic JJ O
structure NN O
of IN O
the DT O
mouse NN O
WASP NNP O
gene NN O
is VBZ O
expressed VBN O
as IN O
an DT O
approximately RB O
2 CD O
. . O

4 CD O
- : O
kb NN O
mRNA NN O
in IN O
thymus NN O
and CC O
spleen NN O
. . O

Chromosomal JJ O
mapping NN O
in IN O
an DT O
interspecific JJ O
M NNP O
. . O

Musculus NNP O
/ NNP O
M NNP O
. . O
spretus NN O
backcross NN O
placed VBD O
the DT O
Wasp NNP O
locus NN O
near IN O
the DT O
centromere NN O
of IN O
the DT O
mouse NN O
X NNP O
chromosome NN O
, , O
inseparable JJ O
from IN O
Gata1 NNP O
, , O
Tcfe3 NNP O
, , O
and CC O
scurfy NN O
( ( O
sf NN O
) ) O
. . O

This DT O
localization NN O
makes VBZ O
Wasp NNP O
a DT O
candidate NN O
for IN O
involvement NN O
in IN O
scurfy NN O
, , O
a DT O
T NNP O
cell NN O
- : O
mediated VBN O
fatal JJ B-Disease
lymphoreticular JJ I-Disease
disease NN I-Disease
of IN O
mice NN O
that WDT O
has VBZ O
previously RB O
been VBN O
proposed VBN O
as IN O
a DT O
mouse NN O
homolog NN O
of IN O
Wiskott NNP B-Disease
- : I-Disease
Aldrich NNP I-Disease
syndrome NN I-Disease
. . O

Northern NNP O
analysis NN O
of IN O
sf JJ O
tissue NN O
samples NNS O
indicated VBD O
the DT O
presence NN O
of IN O
WASP NNP O
mRNA NN O
in IN O
liver NN O
and CC O
skin NN O
, , O
presumably RB O
as IN O
a DT O
consequence NN O
of IN O
lymphocytic JJ O
infiltration NN O
, , O
but CC O
non JJ O
abnormalities NNS O
in IN O
the DT O
amount NN O
or CC O
size NN O
of IN O
mRNA JJ O
present NN O
. . O

Colchicine NN O
in IN O
breast NN O
milk NN O
of IN O
patients NNS O
with IN O
familial JJ B-Disease
Mediterranean NNP I-Disease
fever NN I-Disease
. . O

OBJECTIVE NNP O
. . O

To TO O
clarify VB O
whether IN O
colchicine NN O
is VBZ O
excreted VBN O
in IN O
breast NN O
milk NN O
, , O
and CC O
to TO O
compare VB O
its PRP$ O
concentrations NNS O
in IN O
the DT O
serum NN O
and CC O
breast NN O
milk NN O
of IN O
lactating VBG O
women NNS O
who WP O
have VBP O
familial JJ B-Disease
Mediterranean NNP I-Disease
fever NN I-Disease
( ( O
FMF NNP B-Disease
) ) O
. . O

METHODS NNP O
. . O

Using VBG O
a DT O
specific JJ O
radioimmunoassay NN O
, , O
we PRP O
determined VBD O
colchicine JJ O
concentrations NNS O
in IN O
the DT O
serum NN O
and CC O
breast NN O
milk NN O
of IN O
4 CD O
patients NNS O
at IN O
various JJ O
time NN O
points NNS O
, , O
following VBG O
oral JJ O
administration NN O
of IN O
the DT O
drug NN O
. . O

The DT O
study NN O
evaluated VBD O
4 CD O
patients NNS O
with IN O
FMF NNP B-Disease
who WP O
had VBD O
been VBN O
taking VBG O
colchicine NN O
on IN O
a DT O
long JJ O
- : O
term NN O
basis NN O
. . O

RESULTS NNP O
. . O

Colchicine NN O
was VBD O
found VBN O
to TO O
be VB O
excreted VBN O
in IN O
breast NN O
milk NN O
. . O

Its PRP$ O
levels NNS O
ranged VBN O
between IN O
1 CD O
. . O

9 CD O
and CC O
8 CD O
. . O

6 CD O
ng JJ O
/ NNP O
ml NN O
, , O
which WDT O
were VBD O
similar JJ O
to TO O
those DT O
found VBN O
in IN O
the DT O
serum NN O
( ( O
parallel JJ O
concentration NN O
time NN O
curves NNS O
) ) O
. . O

However RB O
, , O
there EX O
appeared VBD O
to TO O
be VB O
a DT O
considerable JJ O
variation NN O
in IN O
colchicine NN O
milk NN O
concentration NN O
among IN O
the DT O
different JJ O
patients NNS O
, , O
which WDT O
might MD O
be VB O
related VBN O
to TO O
individual JJ O
breast NN O
milk NN O
composition NN O
and CC O
, , O
possibly RB O
, , O
to TO O
other JJ O
nutritional JJ O
or CC O
metabolic JJ O
factors NNS O
. . O

CONCLUSION NNP O
. . O

The DT O
extensive JJ O
peripheral JJ O
tissue NN O
binding NN O
and CC O
relatively RB O
low JJ O
concentration NN O
of IN O
colchicine NN O
in IN O
breast NN O
milk NN O
suggests VBZ O
that IN O
the DT O
amount NN O
ingested VBN O
by IN O
the DT O
infant NN O
is VBZ O
small JJ O
. . O

Furthermore RB O
, , O
based VBN O
on IN O
our PRP$ O
clinical JJ O
experience NN O
, , O
nursing NN O
appears VBZ O
to TO O
be VB O
safe JJ O
for IN O
lactating VBG O
women NNS O
with IN O
FMF NNP B-Disease
who WP O
continue VBP O
to TO O
take VB O
colchicine NN O
. . O

Abnormal NNP O
myotonic JJ B-Disease
dystrophy NN I-Disease
protein NN O
kinase NN O
levels NNS O
produce VBP O
only RB O
mild JJ O
myopathy NNS B-Disease
in IN O
mice NN O
. . O

Myotonic JJ B-Disease
dystrophy NN I-Disease
( ( O
DM NNP B-Disease
) ) O
is VBZ O
commonly RB O
associated VBN O
with IN O
CTG NNP O
repeat NN O
expansions NNS O
within IN O
the DT O
gene NN O
for IN O
DM NNP O
- : O
protein NN O
kinase NN O
( ( O
DMPK NNP O
) ) O
. . O

The DT O
effect NN O
of IN O
altered JJ O
expression NN O
levels NNS O
of IN O
DMPK NNP O
, , O
which WDT O
is VBZ O
ubiquitously RB O
expressed VBN O
in IN O
all DT O
muscle NN O
cell NN O
lineages VBZ O
during IN O
development NN O
, , O
was VBD O
examined VBN O
by IN O
disrupting VBG O
the DT O
endogenous JJ O
Dmpk NNP O
gene NN O
and CC O
overexpressing VBG O
a DT O
normal JJ O
human JJ O
DMPK NNP O
transgene NN O
in IN O
mice NN O
. . O

Nullizygous NNP O
( ( O
- : O
/ SYM O
- : O
) ) O
mice NN O
showed VBD O
only RB O
inconsistent JJ O
and CC O
minor JJ O
size NN O
changes NNS O
in IN O
head NN O
and CC O
neck NN O
muscle NN O
fibres NNS O
at IN O
older JJR O
age NN O
, , O
animals NNS O
with IN O
the DT O
highest JJS O
DMPK NNP O
transgene NN O
expression NN O
showed VBD O
hypertrophic JJ B-Disease
cardiomyopathy NN I-Disease
and CC O
enhanced VBD O
neonatal JJ O
mortality NN O
. . O

However RB O
, , O
both DT O
models NNS O
lack VBP O
other JJ O
frequent JJ O
DM NNP B-Disease
symptoms NNS O
including VBG O
the DT O
fibre NN O
- : O
type NN O
dependent JJ O
atrophy NN B-Disease
, , O
myotonia NN B-Disease
, , O
cataract NN B-Disease
and CC O
male JJ B-Disease
- : I-Disease
infertility NN I-Disease
. . O

These DT O
results NNS O
strengthen VBP O
the DT O
contention NN O
that WDT O
simple JJ O
loss NN O
- : O
or CC O
gain VB O
- : O
of IN O
- : O
expression NN O
of IN O
DMPK NNP O
is VBZ O
not RB O
the DT O
only JJ O
crucial JJ O
requirement NN O
for IN O
development NN O
of IN O
the DT O
disease NN O
. . O
. . O

Mice NNP O
lacking VBG O
the DT O
myotonic JJ B-Disease
dystrophy NN I-Disease
protein NN O
kinase VBD O
develop VB O
a DT O
late JJ O
onset NN O
progressive JJ O
myopathy NN B-Disease
. . O

Myotonic JJ B-Disease
dystrophy NN I-Disease
( ( O
DM NNP B-Disease
) ) O
is VBZ O
an DT O
autosomal JJ B-Disease
dominant JJ I-Disease
disorder NN I-Disease
resulting VBG O
from IN O
the DT O
expansion NN O
of IN O
a DT O
CTG NNP O
repeat NN O
in IN O
the DT O
3 CD O
untranslated JJ O
region NN O
of IN O
a DT O
putative JJ O
protein NN O
kinase NN O
( ( O
DMPK NNP O
) ) O
. . O

To TO O
elucidate VB O
the DT O
role NN O
of IN O
DMPK NNP O
in IN O
DM NNP B-Disease
pathogenesis NN O
we PRP O
have VBP O
developed VBN O
Dmpk NNP B-Disease
deficient NN I-Disease
( ( O
Dmpk NNP O
- : O
/ SYM O
- : O
) ) O
mice NN O
. . O

Dmpk NNP O
- : O
/ SYM O
- : O
mice NN O
develop VB O
a DT O
late JJ O
- : O
onset NN O
, , O
progressive JJ B-Disease
skeletal NN I-Disease
myopathy NN I-Disease
that WDT O
shares NNS O
some DT O
pathological JJ O
features NNS O
with IN O
DM NNP B-Disease
. . O

Muscles NNS O
from IN O
mature NN O
mice NN O
show NN O
variation NN O
in IN O
fibre JJ O
size NN O
, , O
increased VBD O
fibre JJ B-Disease
degeneration NN I-Disease
and CC O
fibrosis NN B-Disease
. . O

Adult NNP O
Dmpk NNP O
- : O
/ SYM O
- : O
mice NN O
show NN O
ultrastructural JJ O
changes NNS O
in IN O
muscle NN O
and CC O
a DT O
50 CD O
% NN O
decrease NN O
in IN O
force NN O
generation NN O
compared VBN O
to TO O
young JJ O
mice NN O
. . O

Our PRP$ O
results NNS O
indicate VBP O
that IN O
DMPK NNP O
may MD O
be VB O
necessary JJ O
for IN O
the DT O
maintenance NN O
of IN O
skeletal JJ O
muscle NN O
structure NN O
and CC O
function NN O
and CC O
suggest VBP O
that IN O
a DT O
decrease NN O
in IN O
DMPK NNP O
levels NNS O
may MD O
contribute VB O
to TO O
DM NNP B-Disease
pathology NN O
. . O
. . O

The DT O
tumor NN B-Disease
suppressor NN O
gene NN O
Brca1 NNP O
is VBZ O
required VBN O
for IN O
embryonic JJ O
cellular JJ O
proliferation NN O
in IN O
the DT O
mouse NN O
. . O

Mutations NNS O
of IN O
the DT O
BRCA1 NNP O
gone VBN O
in IN O
humans NNS O
are VBP O
associated VBN O
with IN O
predisposition NN O
to TO O
breast VB B-Disease
and CC I-Disease
ovarian JJ I-Disease
cancers NNS I-Disease
. . O

We PRP O
show VBP O
here RB O
that IN O
Brca1 NNP O
+ NNP O
/ NNP O
- : O
mice NN O
are VBP O
normal JJ O
and CC O
fertile JJ O
and CC O
lack JJ O
tumors NNS B-Disease
by IN O
age NN O
eleven JJ O
months NNS O
. . O

Homozygous JJ O
Brca1 NNP O
( ( O
5 CD O
- : O
6 CD O
) ) O
mutant NN O
mice NN O
die NN O
before IN O
day NN O
7 CD O
. . O

5 CD O
of IN O
embryogenesis NN O
. . O

Mutant JJ O
embryos NN O
are VBP O
poorly RB O
developed VBN O
, , O
with IN O
no DT O
evidence NN O
of IN O
mesoderm JJ O
formation NN O
. . O

The DT O
extraembryonic JJ O
region NN O
is VBZ O
abnormal JJ O
, , O
but CC O
aggregation NN O
with IN O
wild JJ O
- : O
type NN O
tetraploid JJ O
embryos NN O
does VBZ O
not RB O
rescue VB O
the DT O
lethality NN O
. . O

In IN O
vivo NN O
, , O
mutant JJ O
embryos NN O
do VBP O
not RB O
exhibit VB O
increased JJ O
apoptosis NN O
but CC O
show NN O
reduced VBD O
cell NN O
proliferation NN O
accompanied VBN O
by IN O
decreased JJ O
expression NN O
of IN O
cyclin NN O
E NNP O
and CC O
mdm SYM O
- : O
2 CD O
, , O
a DT O
regulator NN O
of IN O
p53 NN O
activity NN O
. . O

The DT O
expression NN O
of IN O
cyclin NN O
- : O
dependent JJ O
kinase NN O
inhibitor NN O
p21 NN O
is VBZ O
dramatically RB O
increased VBN O
in IN O
the DT O
mutant JJ O
embryos NN O
. . O

Buttressing VBG O
these DT O
in IN O
vivo NN O
observations NNS O
is VBZ O
the DT O
fact NN O
that IN O
mutant JJ O
blastocyst NN O
growth NN O
is VBZ O
grossly RB O
impaired VBN O
in IN O
vitro NN O
. . O

Thus RB O
, , O
the DT O
death NN O
of IN O
Brca1 NNP O
( ( O
5 CD O
- : O
6 CD O
) ) O
mutant NN O
embryos NN O
prior RB O
to TO O
gastrulation NN O
may MD O
be VB O
due JJ O
to TO O
a DT O
failure NN O
of IN O
the DT O
proliferative JJ O
burst NN O
required VBN O
for IN O
the DT O
development NN O
of IN O
the DT O
different JJ O
germ NN O
layers NNS O
. . O

Increased VBN O
coronary JJ B-Disease
heart NN I-Disease
disease NN I-Disease
in IN O
Japanese JJ O
- : O
American JJ O
men NNS O
with IN O
mutation NN O
in IN O
the DT O
cholesteryl NN O
ester NN O
transfer NN O
protein NN O
gene NN O
despite IN O
increased VBN O
HDL NNP O
levels NNS O
. . O

Plasma NNP O
high JJ O
density NN O
lipoprotein NN O
( ( O
HDL NNP O
) ) O
levels NNS O
are VBP O
strongly RB O
genetically RB O
determined VBN O
and CC O
show VB O
a DT O
general JJ O
inverse NN O
relationship NN O
with IN O
coronary JJ B-Disease
heart NN I-Disease
disease NN I-Disease
( ( O
CHD NNP B-Disease
) ) O
. . O

The DT O
cholesteryl NN O
ester NN O
transfer NN O
protein NN O
( ( O
CETP NNP O
) ) O
mediates VBZ O
the DT O
transfer NN O
of IN O
cholesteryl NN O
esters NNS O
from IN O
HDL NNP O
to TO O
other JJ O
lipoproteins NNS O
and CC O
is VBZ O
a DT O
key JJ O
participant NN O
in IN O
the DT O
reverse NN O
transport NN O
of IN O
cholesterol NN O
from IN O
the DT O
periphery NN O
to TO O
the DT O
liver NN O
. . O

A DT O
high JJ O
prevalence NN O
of IN O
two CD O
different JJ O
CETP NNP O
gene NN O
mutations NNS O
( ( O
D442G NNP O
, , O
5 CD O
. . O
1 CD O
% NN O
; : O
intron CC O
14G CD O
A NNP O
, , O
0 CD O
. . O
5 CD O
% NN O
) ) O
, , O
was VBD O
found VBN O
in IN O
3 CD O
, , O
469 CD O
men NNS O
of IN O
Japanese JJ O
ancestry NN O
in IN O
the DT O
Honolulu NNP O
Heart NNP O
Program NNP O
and CC O
mutations NNS O
were VBD O
associated VBN O
with IN O
decreased JJ O
CETP NNP O
( ( O
- : O
35 CD O
% NN O
) ) O
and CC O
increased VBD O
HDL NNP O
chol NN O
levels NNS O
( ( O
+ VB O
10 CD O
% NN O
for IN O
D442G NNP O
) ) O
. . O

However RB O
, , O
the DT O
overall JJ O
prevalence NN O
of IN O
definite JJ O
CHD NNP B-Disease
was VBD O
21 CD O
% NN O
in IN O
men NNS O
with IN O
mutations NNS O
and CC O
16 CD O
% NN O
in IN O
men NNS O
without IN O
mutations NNS O
. . O

The DT O
relative JJ O
risk NN O
( ( O
RR NNP O
) ) O
of IN O
CHD NNP B-Disease
was VBD O
1 CD O
. . O

43 CD O
in IN O
men NNS O
with IN O
mutations NNS O
( ( O
P NNP O
< NNP O
. . O
5 CD O
) ) O
; : O
after IN O
adjustment NN O
for IN O
CHD NNP B-Disease
risk NN O
factors NNS O
, , O
the DT O
RR NNP O
was VBD O
1 CD O
. . O

55 CD O
( ( O
P NNP O
= NNP O
. . O
2 CD O
) ) O
; : O
after IN O
additional JJ O
adjustment NN O
for IN O
HDL NNP O
levels NNS O
, , O
the DT O
RR NNP O
was VBD O
1 CD O
. . O

68 CD O
( ( O
P NNP O
= NNP O
. . O
8 CD O
) ) O
. . O

Similar JJ O
RR NNP O
values NNS O
were VBD O
obtained VBN O
for IN O
the DT O
D442G NNP O
mutation NN O
alone RB O
. . O

Increased VBN O
CHD NNP B-Disease
in IN O
men NNS O
with IN O
mutations NNS O
was VBD O
primarily RB O
observed VBN O
for IN O
HDL NNP O
chol NN O
41 CD O
- : O
60 CD O
mg NN O
/ NNP O
dl NN O
; : O
for IN O
HDL NNP O
chol NN O
> VBD O
60 CD O
mg NN O
/ NNP O
dl VBZ O
men NNS O
with IN O
and CC O
without IN O
mutations NNS O
had VBD O
low JJ O
CHD NNP B-Disease
prevalence NN O
. . O

Thus RB O
, , O
genetic JJ O
CETP NNP B-Disease
deficiency NN I-Disease
appears VBZ O
to TO O
be VB O
an DT O
independent JJ O
risk NN O
factor NN O
for IN O
CHD NNP B-Disease
, , O
primarily RB O
due JJ O
to TO O
increased VBN O
CHD NNP B-Disease
prevalence NN O
in IN O
men NNS O
with IN O
the DT O
D442G NNP O
mutation NN O
and CC O
HDL NNP O
cholesterol NN O
between IN O
41 CD O
and CC O
60 CD O
mg NN O
/ NNP O
dl NN O
. . O

The DT O
findings NNS O
suggest VBP O
that IN O
both DT O
HDL NNP O
concentration NN O
and CC O
the DT O
dynamics NNS O
of IN O
cholesterol NN O
transport NN O
through IN O
HDL NNP O
( ( O
i NN O
. . O
e NN O
. . O
, , O
reverse VB O
cholesterol NN O
transport NN O
) ) O
determine VBZ O
the DT O
anti JJ O
- : O
atherogenicity NN O
of IN O
the DT O
HDL NNP O
fraction NN O
. . O

Mapping VBG O
the DT O
homolog NN O
of IN O
the DT O
human JJ O
Rb1 NNP O
gene NN O
to TO O
chromosome VB O
14 CD O
of IN O
higher JJR O
primates NNS O
. . O

The DT O
Rb1 NNP O
gene NN O
has VBZ O
been VBN O
implicated VBN O
with IN O
retinoblastoma NN B-Disease
and CC O
is VBZ O
located VBN O
on IN O
human JJ O
Chromosome NNP O
( ( O
Chr NNP O
) ) O
13q14 CD O
. . O

2 CD O
2 CD O
. . O

A DT O
unique JJ O
sequence NN O
human JJ O
Rb1 NNP O
cosmid NN O
DNA NNP O
probe NN O
has VBZ O
been VBN O
used VBN O
to TO O
localize VB O
this DT O
region NN O
on IN O
apes NNS O
Chr NNP O
14 CD O
by IN O
the DT O
FISH NNP O
technique NN O
. . O

The DT O
conservation NN O
of IN O
the DT O
Rb1 NNP O
gene NN O
in IN O
higher JJR O
primates NNS O
at IN O
the DT O
corresponding JJ O
equivalent JJ O
chromosome NN O
locus NN O
( ( O
14q14 CD O
) ) O
of IN O
the DT O
human NN O
may MD O
serve VB O
as IN O
a DT O
phylogenetic JJ O
marker NN O
to TO O
further JJ O
trace NN O
the DT O
evolutionary JJ O
pathway NN O
of IN O
human JJ O
descent NN O
. . O

Wiskott NNP B-Disease
- : I-Disease
Aldrich JJ I-Disease
syndrome NN I-Disease
: : O
no DT O
strict JJ O
genotype NN O
- : O
phenotype NN O
correlations NNS O
but CC O
clustering VBG O
of IN O
missense JJ O
mutations NNS O
in IN O
the DT O
amino NN O
- : O
terminal JJ O
part NN O
of IN O
the DT O
WASP NNP O
gene NN O
product NN O
. . O

The DT O
Wiskott NNP B-Disease
- : I-Disease
Aldrich NNP I-Disease
syndrome VBP I-Disease
protein NN O
( ( O
WASP NNP O
) ) O
gene NN O
was VBD O
found VBN O
to TO O
be VB O
mutated VBN O
in IN O
patients NNS O
presenting VBG O
with IN O
WAS NNP B-Disease
and CC O
in IN O
patients NNS O
showing VBG O
X NNP B-Disease
- : I-Disease
linked VBN I-Disease
thrombocytopenia NN I-Disease
. . O

Mutation NN O
analysis NN O
in IN O
19 CD O
families NNS O
of IN O
German JJ O
, , O
Swiss JJ O
and CC O
Turkish JJ O
descent NN O
by IN O
single JJ O
- : O
strand NN O
conformation NN O
polymorphism NN O
and CC O
sequencing NN O
resulted VBD O
in IN O
the DT O
detection NN O
of IN O
seven CD O
novel NNS O
and CC O
10 CD O
known VBN O
mutations NNS O
. . O

A DT O
striking JJ O
clustering NN O
of IN O
missense JJ O
mutations NNS O
in IN O
the DT O
first JJ O
four CD O
exons NNS O
contrasted VBN O
with IN O
a DT O
random JJ O
distribution NN O
of IN O
nonsense JJ O
mutations NNS O
. . O

More JJR O
than IN O
85 CD O
% NN O
of IN O
all DT O
known VBN O
missense NN O
mutations NNS O
were VBD O
localized VBN O
in IN O
the DT O
amino NN O
- : O
terminal JJ O
stretch NN O
of IN O
the DT O
WASP NNP O
gene NN O
product NN O
; : O
this DT O
region NN O
contained VBD O
a DT O
mutational JJ O
hot JJ O
spot NN O
at IN O
codon NN O
86 CD O
. . O

No DT O
genotype NN O
- : O
phenotype NN O
correlation NN O
emerged VBD O
after IN O
a DT O
comparison NN O
of IN O
the DT O
identified JJ O
mutations NNS O
with IN O
the DT O
resulting VBG O
clinical JJ O
picture NN O
for IN O
a DT O
classical JJ O
WAS NNP B-Disease
phenotype NN O
. . O

A DT O
substitution NN O
at IN O
codon $ O
86 CD O
resulted VBN O
in IN O
an DT O
extremely RB O
variable JJ O
expression NN O
of IN O
the DT O
disease NN O
in IN O
a DT O
large JJ O
Swiss JJ O
family NN O
. . O

An DT O
extended JJ O
homology NN O
search NN O
revealed VBD O
a DT O
distant JJ O
relationship NN O
of IN O
this DT O
stretch NN O
to TO O
the DT O
vasodilator NN O
- : O
stimulated VBN O
phosphoprotein NN O
( ( O
VASP NNP O
) ) O
, , O
which WDT O
is VBZ O
involved VBN O
in IN O
the DT O
maintenance NN O
of IN O
cyto NN O
- : O
architecture NN O
by IN O
interacting VBG O
with IN O
actin JJ O
- : O
like IN O
filaments NNS O
. . O
. . O

Influence NN O
of IN O
PAX6 NNP O
gene NN O
dosage NN O
on IN O
development NN O
: : O
overexpression NN O
causes VBZ O
severe JJ O
eye NN B-Disease
abnormalities NNS I-Disease
. . O

Aniridia NNP B-Disease
in IN O
man NN O
and CC O
Small NNP O
eye NN O
in IN O
mice NNS O
are VBP O
semidominant JJ B-Disease
developmental JJ I-Disease
disorders NNS I-Disease
caused VBN O
by IN O
mutations NNS O
within IN O
the DT O
paired JJ O
box NN O
gene NN O
PAX6 NNP O
. . O

Whereas NNP O
heterozygotes VBZ O
suffer VBP O
from IN O
iris JJ B-Disease
hypoplasia NN I-Disease
, , O
homozygous JJ O
mice NN O
lack NN O
eyes NNS O
and CC O
nasal JJ O
cavities NNS O
and CC O
exhibit NN O
brain NN B-Disease
abnormalities NNS I-Disease
. . O

To TO O
investigate VB O
the DT O
role NN O
of IN O
gene NN O
dosage NN O
in IN O
more JJR O
detail NN O
, , O
we PRP O
have VBP O
generated VBN O
yeast JJ O
artificial JJ O
chromosome NN O
transgenic JJ O
mice NN O
carrying VBG O
the DT O
human JJ O
PAX6 NNP O
locus NN O
. . O

When WRB O
crossed VBN O
onto IN O
the DT O
Small NNP O
eye NN O
background NN O
, , O
the DT O
transgene NN O
rescues VBZ O
the DT O
mutant JJ O
phenotype NN O
. . O

Strikingly RB O
, , O
mice NNS O
carrying VBG O
multiple JJ O
copies NNS O
on IN O
a DT O
wild JJ O
- : O
type NN O
background NN O
show NN O
specific JJ O
developmental JJ B-Disease
abnormalities NNS I-Disease
of IN I-Disease
the DT I-Disease
eye NN I-Disease
, , O
but CC O
not RB O
of IN O
other JJ O
tissues NNS O
expressing VBG O
the DT O
gene NN O
. . O

Thus RB O
, , O
at IN O
least JJS O
five CD O
different JJ O
eye NN O
phenotypes NNS O
are VBP O
associated VBN O
with IN O
changes NNS O
in IN O
PAX6 NNP O
expression NN O
. . O

We PRP O
provide VBP O
evidence NN O
that IN O
not RB O
only RB O
reduced VBN O
, , O
but CC O
also RB O
increased VBD O
levels NNS O
of IN O
transcriptional JJ O
regulators NNS O
can MD O
cause VB O
developmental JJ B-Disease
defects NNS I-Disease
. . O
. . O

Heterodimer NNP O
formation NN O
and CC O
activity NN O
in IN O
the DT O
human JJ O
enzyme NN O
galactose VBD O
- : O
1 CD O
- : O
phosphate NN O
uridylyltransferase NN O
. . O

One CD O
of IN O
the DT O
fundamental JJ O
questions NNS O
concerning VBG O
expression NN O
and CC O
function NN O
of IN O
dimeric JJ O
enzymes NNS O
involves VBZ O
the DT O
impact NN O
of IN O
naturally RB O
occurring VBG O
mutations NNS O
on IN O
subunit NN O
assembly NN O
and CC O
heterodimer NN O
activity NN O
. . O

This DT O
question NN O
is VBZ O
of IN O
particular JJ O
interest NN O
for IN O
the DT O
human JJ O
enzyme NN O
galactose SYM O
- : O
l NN O
- : O
phosphate NN O
uridylyl JJ O
- : O
transferase NN O
( ( O
GALT NNP O
) ) O
, , O
impairment NN O
of IN O
which WDT O
results NNS O
in IN O
the DT O
inherited JJ B-Disease
metabolic JJ I-Disease
disorder NN I-Disease
galactosemia NN B-Disease
, , O
because IN O
many JJ O
if IN O
not RB O
most JJS O
patients NNS O
studied VBN O
to TO O
date NN O
are VBP O
compound VBN O
heterozygotes NNS O
rather RB O
than IN O
true JJ O
molecular JJ O
homozygotes NNS O
. . O

Furthermore RB O
, , O
the DT O
broad JJ O
range NN O
of IN O
phenotypic NN O
severity NN O
observed VBN O
in IN O
these DT O
patients NNS O
raises VBZ O
the DT O
possibility NN O
that IN O
allelic JJ O
combination NN O
, , O
not RB O
just RB O
allelic JJ O
constitution NN O
, , O
may MD O
play VB O
some DT O
role NN O
in IN O
determining VBG O
outcome NN O
. . O

In IN O
the DT O
work NN O
described VBD O
herein RB O
, , O
we PRP O
have VBP O
selected VBN O
two CD O
distinct JJ O
naturally RB O
occurring VBG O
null JJ O
mutations NNS O
of IN O
GALT NNP O
, , O
Q188R NNP O
and CC O
R333W NNP O
, , O
and CC O
asked VBD O
the DT O
questions NNS O
( ( O
i NN O
) ) O
what WDT O
are VBP O
the DT O
impacts NNS O
of IN O
these DT O
mutations NNS O
on IN O
subunit NN O
assembly NN O
, , O
and CC O
( ( O
ii NN O
) ) O
if IN O
heterodimers NNS O
do VBP O
form VB O
, , O
are VBP O
they PRP O
active JJ O
? . O

To TO O
answer VB O
these DT O
questions NNS O
, , O
we PRP O
have VBP O
established VBN O
a DT O
yeast NN O
system NN O
for IN O
the DT O
coexpression NN O
of IN O
epitope NN O
- : O
tagged JJ O
alleles NNS O
of IN O
human JJ O
GALT NNP O
and CC O
investigated VBN O
both PDT O
the DT O
extent NN O
of IN O
specific JJ O
GALT NNP O
subunit NN O
interactions NNS O
and CC O
the DT O
activity NN O
of IN O
defined JJ O
heterodimer NN O
pools NNS O
. . O

We PRP O
have VBP O
found VBN O
that IN O
both DT O
homodimers NNS O
and CC O
heterodimers NNS O
do VBP O
form VB O
involving VBG O
each DT O
of IN O
the DT O
mutant JJ O
subunits NNS O
tested VBN O
and CC O
that IN O
both DT O
heterodimer NN O
pools NNS O
retain VBP O
substantial JJ O
enzymatic JJ O
activity NN O
. . O

These DT O
results NNS O
are VBP O
significant JJ O
not RB O
only RB O
in IN O
terms NNS O
of IN O
their PRP$ O
implications NNS O
for IN O
furthering VBG O
our PRP$ O
understanding NN O
of IN O
galactosemia NN B-Disease
and CC O
GALT NNP O
holoenzyme NN O
structure NN O
- : O
function NN O
relationships NNS O
but CC O
also RB O
because IN O
the DT O
system NN O
described VBD O
may MD O
serve VB O
as IN O
a DT O
model NN O
for IN O
similar JJ O
studies NNS O
of IN O
other JJ O
complexes NNS O
composed VBN O
of IN O
multiple JJ O
subunits NNS O
. . O
. . O

Cleavage NN O
of IN O
huntingtin NN O
by IN O
apopain NN O
, , O
a DT O
proapoptotic JJ O
cysteine NN O
protease NN O
, , O
is VBZ O
modulated VBN O
by IN O
the DT O
polyglutamine NN O
tract NN O
. . O

Apoptosis NN O
has VBZ O
recently RB O
been VBN O
recognized VBN O
as IN O
a DT O
mode NN O
of IN O
cell NN O
death NN O
in IN O
Huntington NNP B-Disease
disease NN I-Disease
( ( O
HD NNP B-Disease
) ) O
. . O

Apopain NNP O
, , O
a DT O
human JJ O
counterpart NN O
of IN O
the DT O
nematode JJ O
cysteine NN O
protease NN O
death NN O
- : O
gene NN O
product NN O
, , O
CED NNP O
- : O
3 CD O
, , O
has VBZ O
a DT O
key JJ O
role NN O
in IN O
proteolytic JJ O
events NNS O
leading VBG O
to TO O
apoptosis NN O
. . O

Here RB O
we PRP O
show VBP O
that IN O
apoptotic JJ O
extracts NNS O
and CC O
apopain VB O
itself PRP O
specifically RB O
cleave VBP O
the DT O
HD NNP B-Disease
gene NN O
product NN O
, , O
huntingtin NN O
. . O

The DT O
rate NN O
of IN O
cleavage NN O
increases NNS O
with IN O
the DT O
length NN O
of IN O
the DT O
huntingtin NN O
polyglutamine NN O
tract NN O
, , O
providing VBG O
an DT O
explanation NN O
for IN O
the DT O
gain NN O
- : O
of IN O
- : O
function NN O
associated VBN O
with IN O
CAG NNP O
expansion NN O
. . O

Our PRP$ O
results NNS O
show VBP O
that IN O
huntingtin NN O
is VBZ O
cleaved VBN O
by IN O
cysteine NN O
proteases NNS O
and CC O
suggest VBP O
that IN O
HD NNP B-Disease
might MD O
be VB O
a DT O
disorder NN B-Disease
of IN I-Disease
inappropriate JJ I-Disease
apoptosis NN I-Disease
. . O
. . O

The DT O
5 CD O
' POS O
end NN O
of IN O
the DT O
BRCA1 NNP O
gene NN O
lies VBZ O
within IN O
a DT O
duplicated JJ O
region NN O
of IN O
human JJ O
chromosome NN O
17q21 CD O
. . O

To TO O
begin VB O
to TO O
address VB O
the DT O
hypothesis NN O
that WDT O
abnormal JJ O
regulation NN O
of IN O
the DT O
breast NN B-Disease
/ JJ I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
susceptibility NN O
gene NN O
BRCA1 NNP O
is VBZ O
a DT O
critical JJ O
step NN O
in IN O
sporadic JJ O
breast NN O
/ NNP O
ovarian JJ O
tumorigenesis NN O
, , O
we PRP O
have VBP O
determined VBN O
the DT O
detailed JJ O
structure NN O
of IN O
the DT O
BRCA1 NNP O
genomic JJ O
region NN O
. . O

We PRP O
show VBP O
that IN O
this DT O
region NN O
of IN O
the DT O
genome NN O
contains VBZ O
a DT O
tandem JJ O
duplication NN O
of IN O
approximately RB O
30 CD O
kilobases NNS O
, , O
which WDT O
results NNS O
in IN O
two CD O
copies NNS O
of IN O
BRCA1 NNP O
exons NNS O
1 CD O
and CC O
2 CD O
, , O
of IN O
exons NNS O
1 CD O
and CC O
3 CD O
of IN O
the DT O
adjacent JJ O
1A1 CD O
- : O
3B CD O
gene NN O
and CC O
of IN O
the DT O
previously RB O
reported VBN O
295 CD O
base NN O
pair NN O
intergenic JJ O
region NN O
. . O

Sequence NNP O
analysis NN O
of IN O
the DT O
duplicated JJ O
exons NNS O
of IN O
BRCA1 NNP O
and CC O
1A1 CD O
- : O
3B CD O
and CC O
flanking VBG O
genomic JJ O
DNA NN O
reveals NNS O
maintenance NN O
of IN O
the DT O
intron NN O
- : O
exon NN O
structure NN O
and CC O
a DT O
high JJ O
degree NN O
of IN O
nucleotide JJ O
sequence NN O
identity NN O
, , O
suggesting VBG O
that IN O
these DT O
are VBP O
non JJ O
- : O
processed VBN O
pseudogenes NNS O
and CC O
that IN O
the DT O
duplication NN O
is VBZ O
a DT O
recent JJ O
event NN O
in IN O
evolutionary JJ O
terms NNS O
. . O

We PRP O
also RB O
show VBP O
that IN O
a DT O
processed JJ O
pseudogene NN O
of IN O
the DT O
acidic JJ O
ribosomal JJ O
phosphoprotein NN O
P1 NNP O
( ( O
ARPP1 NNP O
) ) O
is VBZ O
inserted VBN O
directly RB O
upstream JJ O
of IN O
pseudo JJ O
- : O
BRCA1 NNP O
exon VBZ O
1A CD O
. . O

We PRP O
believe VBP O
that IN O
these DT O
findings NNS O
could MD O
not RB O
only RB O
confound VB O
BRCA1 NNP O
mutation NN O
analysis NN O
, , O
but CC O
could MD O
have VB O
implications NNS O
for IN O
the DT O
normal JJ O
and CC O
abnormal JJ O
regulation NN O
of IN O
BRCA1 NNP O
transcription NN O
, , O
translation NN O
and CC O
function NN O
. . O
. . O

Deletion NN O
of IN O
small JJ O
nuclear JJ O
ribonucleoprotein NN O
polypeptide IN O
N NNP O
( ( O
SNRPN NNP O
) ) O
in IN O
Prader NNP B-Disease
- : I-Disease
Willi NNP I-Disease
syndrome NN I-Disease
detected VBN O
by IN O
fluorescence NN O
in IN O
situ JJ O
hybridization NN O
: : O
two CD O
sibs NN O
with IN O
the DT O
typical JJ O
phenotype NN O
without IN O
a DT O
cytogenetic JJ O
deletion NN O
in IN O
chromosome NN O
15q CD O
. . O

The DT O
small JJ O
nuclear JJ O
ribonucleoprotein NN O
polypeptide IN O
N NNP O
( ( O
SNRPN NNP O
) ) O
gene NN O
is VBZ O
regarded VBN O
as IN O
one CD O
of IN O
the DT O
candidates NNS O
for IN O
Prader NNP B-Disease
- : I-Disease
Willi NNP I-Disease
syndrome NN I-Disease
( ( O
PWS NNP B-Disease
) ) O
. . O

We PRP O
describe VBP O
two CD O
sibs NN O
with IN O
typical JJ O
PWS NNP B-Disease
presenting VBG O
deletion NN O
of IN O
SNRPN NNP O
detected VBN O
by IN O
fluorescence NN O
in IN O
situ JJ O
hybridization NN O
( ( O
FISH NNP O
) ) O
. . O

Neither CC O
a DT O
cytogenetically RB O
detectable JJ O
15q12 CD O
deletion NN O
nor CC O
a DT O
deletion NN O
for IN O
the DT O
D15S11 NNP O
, , O
D15S10 NNP O
, , O
and CC O
GABRB3 NNP O
cosmid VBP O
probes NNS O
were VBD O
found VBN O
in IN O
either DT O
patient NN O
. . O

This DT O
implies VBZ O
a DT O
smaller JJR O
deletion NN O
limited VBD O
to TO O
the DT O
PWS NNP B-Disease
critical JJ O
region NN O
. . O

FISH NN O
with IN O
a DT O
SNRPN NNP O
probe NN O
will MD O
permit VB O
analysis NN O
of IN O
PWS NNP B-Disease
patients NNS O
with IN O
limited JJ O
deletions NNS O
not RB O
detectable JJ O
with IN O
other JJ O
probes NNS O
. . O
. . O

Expression NN O
of IN O
the DT O
von NN B-Disease
Hippel NNP I-Disease
- : I-Disease
Lindau NNP I-Disease
disease VB I-Disease
tumour NN I-Disease
suppressor NN O
gene NN O
during IN O
human JJ O
embryogenesis NN O
. . O

The DT O
von NN B-Disease
Hippel NNP I-Disease
- : I-Disease
Lindau NNP I-Disease
( ( I-Disease
VHL NNP I-Disease
) ) I-Disease
disease NN I-Disease
product NN O
is VBZ O
thought VBN O
to TO O
down VB O
- : O
regulate NN O
transcription NN O
by IN O
antagonizing VBG O
elongin SYM O
- : O
enhanced JJ O
transcriptional JJ O
elongation NN O
. . O

Germline NNP O
VHL NNP B-Disease
gene NN O
mutations NNS O
predispose VBP O
to TO O
the DT O
development NN O
of IN O
retinal JJ B-Disease
, , I-Disease
cerebellar JJ I-Disease
and CC I-Disease
spinal JJ I-Disease
haemangioblastomas NN I-Disease
, , O
renal JJ B-Disease
cell NN I-Disease
carcinoma NN I-Disease
and CC O
phaeochromocytoma NN B-Disease
. . O

In IN O
addition NN O
, , O
somatic JJ O
Inactivation NN O
of IN O
the DT O
VHL NNP B-Disease
gene NN O
is VBZ O
frequent JJ O
in IN O
sporadic JJ B-Disease
renal JJ I-Disease
cell NN I-Disease
carcinoma NN I-Disease
and CC O
haemangioblastoma NN B-Disease
. . O

Regulation NN O
of IN O
transcript JJ O
elongation NN O
is VBZ O
an DT O
important JJ O
control NN O
mechanism NN O
for IN O
gene NN O
expression NN O
and CC O
the DT O
VHL NNP B-Disease
gene NN O
might MD O
modify VB O
the DT O
expression NN O
of IN O
proto NN O
- : O
oncogenes NNS O
and CC O
growth NN O
suppressor NN O
genes NNS O
during IN O
embryogenesis NN O
. . O

We PRP O
therefore RB O
investigated VBD O
the DT O
expression NN O
of IN O
VHL NNP B-Disease
mRNA NN O
during IN O
human JJ O
embryogenesis NN O
by IN O
in IN O
situ JJ O
hybridization NN O
studies NNS O
at IN O
4 CD O
, , O
6 CD O
and CC O
10 CD O
weeks NNS O
post NN O
conception NN O
. . O

Although IN O
VHL NNP B-Disease
mRNA NN O
was VBD O
expressed VBN O
in IN O
all DT O
three CD O
germ NN O
layers NNS O
, , O
strong JJ O
expression NN O
was VBD O
noted VBN O
in IN O
the DT O
central JJ O
nervous JJ O
system NN O
, , O
kidneys NNS O
, , O
testis NN O
and CC O
lung NN O
. . O

Within IN O
the DT O
kidney NN O
, , O
VHL NNP B-Disease
mRNA NN O
was VBD O
differentially RB O
expressed VBN O
within IN O
renal JJ O
tubules NNS O
suggesting VBG O
that IN O
the DT O
VHL NNP B-Disease
gene NN O
product NN O
may MD O
have VB O
a DT O
specific JJ O
role NN O
in IN O
kidney NN O
development NN O
. . O

Two CD O
alternatively RB O
spliced VBD O
VHL NNP B-Disease
mRNAs NNS O
characterized VBN O
by IN O
inclusion NN O
( ( O
isoform VB O
I PRP O
) ) O
or CC O
exclusion NN O
( ( O
isoform VB O
II NNP O
) ) O
of IN O
exon $ O
2 CD O
are VBP O
transcribed VBN O
in IN O
adult NN O
tissues NNS O
. . O

To TO O
investigate VB O
if IN O
the DT O
two CD O
isoforms NNS O
are VBP O
differentially RB O
expressed VBN O
during IN O
embryogenesis NN O
, , O
VHL NNP B-Disease
mRNA NN O
was VBD O
reverse JJ O
transcribed NN O
from IN O
13 CD O
fetal JJ O
tissues NNS O
( ( O
8 CD O
- : O
10 CD O
weeks NNS O
gestation NN O
) ) O
. . O

The DT O
quantitative JJ O
distribution NN O
of IN O
VHL NNP B-Disease
mRNA NN O
within IN O
fetal JJ O
tissues NNS O
reflected VBD O
that IN O
seen VBN O
by IN O
in IN O
situ JJ O
hybridization NN O
and CC O
the DT O
ratio NN O
of IN O
the DT O
two CD O
VHL NNP B-Disease
isoforms NNS O
was VBD O
similar JJ O
between IN O
tissues NNS O
. . O

Although IN O
the DT O
genes NNS O
regulated VBN O
by IN O
the DT O
VHL NNP B-Disease
gene NN O
product NN O
have VBP O
not RB O
yet RB O
been VBN O
identified VBN O
, , O
our PRP$ O
findings NNS O
are VBP O
compatible JJ O
with IN O
the DT O
hypothesis NN O
that WDT O
VHL NNP B-Disease
- : O
mediated VBD O
control NN O
of IN O
transcriptional JJ O
elongation NN O
may MD O
have VB O
a DT O
role NN O
in IN O
normal JJ O
human JJ O
development NN O
. . O
. . O

Genetic JJ O
heterogeneity NN O
in IN O
hereditary JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
: : O
role NN O
of IN O
BRCA1 NNP O
and CC O
BRCA2 NNP O
. . O

The DT O
common JJ O
hereditary JJ O
forms NNS O
of IN O
breast NN B-Disease
cancer NN I-Disease
have VBP O
been VBN O
largely RB O
attributed VBN O
to TO O
the DT O
inheritance NN O
of IN O
mutations NNS O
in IN O
the DT O
BRCA1 NNP O
or CC O
BRCA2 NNP O
genes NNS O
. . O

However RB O
, , O
it PRP O
is VBZ O
not RB O
yet RB O
clear JJ O
what WP O
proportion NN O
of IN O
hereditary JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
is VBZ O
explained VBN O
by IN O
BRCA1 NNP O
and CC O
BRCA2 NNP O
or CC O
by IN O
some DT O
other JJ O
unidentified JJ O
susceptibility NN O
gene NN O
( ( O
s JJ O
) ) O
. . O

We PRP O
describe VBP O
the DT O
proportion NN O
of IN O
hereditary JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
explained VBN O
by IN O
BRCA1 NNP O
or CC O
BRCA2 NNP O
in IN O
a DT O
sample NN O
of IN O
North JJ O
American JJ O
hereditary NN B-Disease
breast NN I-Disease
cancers NNS I-Disease
and CC O
assess VB O
the DT O
evidence NN O
for IN O
additional JJ O
susceptibility NN O
genes NNS O
that WDT O
may MD O
confer VB O
hereditary JJ B-Disease
breast NN I-Disease
or CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
risk NN O
. . O

Twenty NNP O
- : O
three CD O
families NNS O
were VBD O
identified VBN O
through IN O
two CD O
high JJ O
- : O
risk NN O
breast NN B-Disease
cancer NN I-Disease
research NN O
programs NNS O
. . O

Genetic JJ O
analysis NN O
was VBD O
undertaken VBN O
to TO O
establish VB O
linkage NN O
between IN O
the DT O
breast NN B-Disease
or CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
cases NNS O
and CC O
markers NNS O
on IN O
chromosomes NNS O
17q CD O
( ( O
BRCA1 NNP O
) ) O
and CC O
13q CD O
( ( O
BRCA2 NNP O
) ) O
. . O

Mutation NN O
analysis NN O
in IN O
the DT O
BRCA1 NNP O
and CC O
BRCA2 NNP O
genes NNS O
was VBD O
also RB O
undertaken VBN O
in IN O
all DT O
families NNS O
. . O

The DT O
pattern NN O
of IN O
hereditary JJ B-Disease
cancer NN I-Disease
in IN O
14 CD O
( ( O
61 CD O
% NN O
) ) O
of IN O
the DT O
23 CD O
families NNS O
studied VBN O
was VBD O
attributed VBN O
to TO O
BRCA1 NNP O
by IN O
a DT O
combination NN O
of IN O
linkage NN O
and CC O
mutation NN O
analyses NNS O
. . O

No DT O
families NNS O
were VBD O
attributed VBN O
to TO O
BRCA2 NNP O
. . O

Five CD O
families NNS O
( ( O
22 CD O
% NN O
) ) O
provided VBD O
evidence NN O
against IN O
linkage NN O
to TO O
both DT O
BRCA1 NNP O
and CC O
BRCA2 NNP O
. . O

No DT O
BRCA1 NNP O
or CC O
BRCA2 NNP O
mutations NNS O
were VBD O
detected VBN O
in IN O
these DT O
five CD O
families NNS O
. . O

The DT O
BRCA1 NNP O
or CC O
BRCA2 NNP O
status NN O
of IN O
four CD O
families NNS O
( ( O
17 CD O
% NN O
) ) O
could MD O
not RB O
be VB O
determined VBN O
. . O

BRCA1 NNP O
and CC O
BRCA2 NNP O
probably RB O
explain VBP O
the DT O
majority NN O
of IN O
hereditary JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
that WDT O
exists VBZ O
in IN O
the DT O
North JJ O
American JJ O
population NN O
. . O

However RB O
, , O
one CD O
or CC O
more JJR O
additional JJ O
genes NNS O
may MD O
yet RB O
be VB O
found VBN O
that IN O
explain VBP O
some DT O
proportion NN O
of IN O
hereditary JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
. . O
. . O

An DT O
intronic JJ O
mutation NN O
in IN O
a DT O
lariat JJ O
branchpoint NN O
sequence NN O
is VBZ O
a DT O
direct JJ O
cause NN O
of IN O
an DT O
inherited JJ B-Disease
human JJ I-Disease
disorder NN I-Disease
( ( O
fish JJ B-Disease
- : I-Disease
eye NN I-Disease
disease NN I-Disease
) ) O
. . O

The DT O
first JJ O
step NN O
in IN O
the DT O
splicing NN O
of IN O
an DT O
intron NN O
from IN O
nuclear JJ O
precursors NNS O
of IN O
mRNA NN O
results NNS O
in IN O
the DT O
formation NN O
of IN O
a DT O
lariat JJ O
structure NN O
. . O

A DT O
distinct JJ O
intronic JJ O
nucleotide NN O
sequence NN O
, , O
known VBN O
as IN O
the DT O
branchpoint NN O
region NN O
, , O
plays VBZ O
a DT O
central JJ O
role NN O
in IN O
this DT O
process NN O
. . O

We PRP O
here RB O
describe VBZ O
a DT O
point NN O
mutation NN O
in IN O
such JJ O
a DT O
sequence NN O
. . O

Three CD O
sisters NNS O
were VBD O
shown VBN O
to TO O
suffer VB O
from IN O
fish JJ B-Disease
- : I-Disease
eye NN I-Disease
disease NN I-Disease
( ( O
FED NNP B-Disease
) ) O
, , O
a DT O
disorder NN O
which WDT O
is VBZ O
caused VBN O
by IN O
mutations NNS O
in IN O
the DT O
gene NN O
coding VBG O
for IN O
lecithin JJ O
cholesterol NN O
acyltransferase NN O
( ( O
LCAT NNP O
) ) O
. . O

Sequencing VBG O
of IN O
the DT O
LCAT NNP O
gene NN O
of IN O
all DT O
three CD O
probands NNS O
revealed VBD O
compound NN O
heterozygosity NN O
for IN O
a DT O
missense JJ O
mutation NN O
in IN O
exon NN O
4 CD O
which WDT O
is VBZ O
reported VBN O
to TO O
underlie VB O
the DT O
FED NNP B-Disease
phenotype NN O
, , O
and CC O
a DT O
point NN O
mutation NN O
located VBN O
in IN O
intron NN O
4 CD O
( ( O
IVS4 NNP O
T NNP O
- : O
22C CD O
) ) O
. . O

By IN O
performing VBG O
in IN O
vitro JJ O
expression NN O
of IN O
LCAT NNP O
minigenes NNS O
and CC O
reverse VB O
transcriptase NN O
PCR NNP O
on IN O
mRNA NN O
isolated VBN O
from IN O
leukocytes NNS O
of IN O
the DT O
patient NN O
, , O
this DT O
gene NN O
defect NN O
was VBD O
shown VBN O
to TO O
cause VB O
a DT O
null JJ O
allele NN O
as IN O
the DT O
result NN O
of IN O
complete JJ O
intron NN O
retention NN O
. . O

In IN O
conclusion NN O
, , O
we PRP O
demonstrated VBD O
that IN O
a DT O
point NN O
mutation NN O
in IN O
a DT O
lariat JJ O
branchpoint NN O
consensus NN O
sequence NN O
causes VBZ O
a DT O
null JJ O
allele NN O
in IN O
a DT O
patient NN O
with IN O
FED NNP B-Disease
. . O

In IN O
addition NN O
, , O
our PRP$ O
finding VBG O
illustrates VBZ O
the DT O
importance NN O
of IN O
this DT O
sequence NN O
for IN O
normal JJ O
human JJ O
mRNA NN O
processing NN O
. . O

Finally RB O
, , O
this DT O
report NN O
provides VBZ O
a DT O
widely RB O
applicable JJ O
strategy NN O
which WDT O
ensures VBZ O
fast RB O
and CC O
effective JJ O
screening NN O
for IN O
intronic JJ O
defects NNS O
that WDT O
underlie VBP O
differential JJ O
gene NN O
expression NN O
. . O
. . O

Mutations NNS O
associated VBN O
with IN O
variant JJ O
phenotypes NNS O
in IN O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
. . O

We PRP O
have VBP O
identified VBN O
14 CD O
families NNS O
with IN O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
( ( O
A DT B-Disease
- : I-Disease
T NN I-Disease
) ) O
in IN O
which WDT O
mutation NN O
of IN O
the DT O
ATM NNP O
gene NN O
is VBZ O
associated VBN O
with IN O
a DT O
less RBR O
severe JJ O
clinical JJ O
and CC O
cellular JJ O
phenotype NN O
( ( O
approximately RB O
10 CD O
% NN O
- : O
15 CD O
% NN O
of IN O
A NNP B-Disease
- : I-Disease
T NN I-Disease
families NNS O
identified VBN O
in IN O
the DT O
United NNP O
Kingdom NNP O
) ) O
. . O

In IN O
10 CD O
of IN O
these DT O
families NNS O
, , O
all PDT O
the DT O
homozygotes NNS O
have VBP O
a DT O
137 CD O
- : O
bp NN O
insertion NN O
in IN O
their PRP$ O
cDNA NN O
caused VBN O
by IN O
a DT O
point NN O
mutation NN O
in IN O
a DT O
sequence NN O
resembling VBG O
a DT O
splice NN O
- : O
donor NN O
site NN O
. . O

The DT O
second JJ O
A NNP B-Disease
- : I-Disease
T NN I-Disease
allele NN O
has VBZ O
a DT O
different JJ O
mutation NN O
in IN O
each DT O
patient NN O
. . O

We PRP O
show VBP O
that IN O
the DT O
less JJR O
severe JJ O
phenotype NN O
in IN O
these DT O
patients NNS O
is VBZ O
caused VBN O
by IN O
some DT O
degree NN O
of IN O
normal JJ O
splicing NN O
, , O
which WDT O
occurs VBZ O
as IN O
an DT O
alternative JJ O
product NN O
from IN O
the DT O
insertion NN O
- : O
containing VBG O
allele NN O
. . O

The DT O
level NN O
of IN O
the DT O
137 CD O
- : O
bp NN O
PCR NNP O
product NN O
containing VBG O
the DT O
insertion NN O
was VBD O
lowest JJS O
in IN O
two CD O
patients NNS O
who WP O
showed VBD O
a DT O
later JJ O
onset NN O
of IN O
cerebellar JJ B-Disease
ataxia NN I-Disease
. . O

A DT O
further JJ O
four CD O
families NNS O
who WP O
do VBP O
not RB O
have VB O
this DT O
insertion NN O
have VBP O
been VBN O
identified VBN O
. . O

Mutations NNS O
detected VBN O
in IN O
two CD O
of IN O
four CD O
of IN O
these DT O
are VBP O
missense JJ O
mutations NNS O
, , O
normally RB O
rare JJ O
in IN O
A NNP B-Disease
- : I-Disease
T NN I-Disease
patients NNS O
. . O

The DT O
demonstration NN O
of IN O
mutations NNS O
giving VBG O
rise NN O
to TO O
a DT O
slightly RB O
milder JJR O
phenotype NN O
in IN O
A NNP B-Disease
- : I-Disease
T NN I-Disease
raises VBZ O
the DT O
interesting JJ O
question NN O
of IN O
what WP O
range NN O
of IN O
phenotypes NNS O
might MD O
occur VB O
in IN O
individuals NNS O
in IN O
whom WP O
both DT O
mutations NNS O
are VBP O
milder NN O
. . O

One CD O
possibility NN O
might MD O
be VB O
that IN O
individuals NNS O
who WP O
are VBP O
compound VBN O
heterozygotes NNS O
for IN O
ATM NNP O
mutations NNS O
are VBP O
more RBR O
common JJ O
than IN O
we PRP O
realize VBP O
. . O
. . O

Mutation NN O
of IN O
the DT O
VHL NNP O
gene NN O
is VBZ O
associated VBN O
exclusively RB O
with IN O
the DT O
development NN O
of IN O
non JJ B-Disease
- : I-Disease
papillary JJ I-Disease
renal NN I-Disease
cell NN I-Disease
carcinomas NN I-Disease
. . O

To TO O
define VB O
the DT O
possible JJ O
role NN O
of IN O
the DT O
VHL NNP B-Disease
gene NN O
in IN O
the DT O
development NN O
of IN O
sporadic JJ B-Disease
renal JJ I-Disease
cell NN I-Disease
carcinomas NN I-Disease
, , O
91 CD O
different JJ O
parenchymal JJ B-Disease
tumours NN I-Disease
of IN I-Disease
the DT I-Disease
kidney NN I-Disease
have VBP O
been VBN O
investigated VBN O
for IN O
mutation NN O
of IN O
the DT O
VHL NNP B-Disease
gene NN O
by IN O
single JJ O
strand NN O
conformation NN O
polymorphism NN O
( ( O
SSCP NNP O
) ) O
and CC O
/ $ O
or CC O
heteroduplex NN O
( ( O
HD NNP O
) ) O
techniques NNS O
. . O

Chromosome NNP O
3p CD O
deletion NN O
was VBD O
detected VBN O
in IN O
98 CD O
per IN O
cent NN O
of IN O
non JJ B-Disease
- : I-Disease
papillary JJ I-Disease
renal NN I-Disease
cell NN I-Disease
carcinomas NN I-Disease
and CC O
in IN O
25 CD O
per IN O
cent NN O
of IN O
chromophobe NN O
renal JJ B-Disease
cell NN I-Disease
carcinomas NN I-Disease
. . O

In IN O
22 CD O
of IN O
the DT O
43 CD O
non SYM B-Disease
- : I-Disease
papillary JJ I-Disease
renal NN I-Disease
cell NN I-Disease
carcinomas NN I-Disease
, , O
abnormally RB O
migrating VBG O
DNA NNP O
bands NNS O
were VBD O
detected VBN O
by IN O
SSCP NNP O
and CC O
/ NNP O
or CC O
HD NNP O
analysis NN O
. . O

No DT O
mobility NN O
shift NN O
was VBD O
seen VBN O
in IN O
any DT O
of IN O
the DT O
23 CD O
chromophobe NN O
renal NN B-Disease
cell NN I-Disease
carcinomas NN I-Disease
. . O

In IN O
addition NN O
, , O
15 CD O
papillary JJ B-Disease
renal NN I-Disease
cell NN I-Disease
tumours NNS I-Disease
and CC O
ten JJ O
renal JJ B-Disease
oncocytomas NN I-Disease
, , O
which WDT O
are VBP O
characterized VBN O
by IN O
genetic JJ O
changes NNS O
other JJ O
than IN O
loss NN O
of IN O
chromosome NN O
3p CD O
sequences NNS O
, , O
were VBD O
analysed VBN O
for IN O
mutation NN O
of IN O
the DT O
VHL NNP B-Disease
gene NN O
. . O

None NN O
of IN O
these DT O
tumours NNS B-Disease
showed VBD O
abnormal JJ O
migration NN O
patterns NNS O
. . O

The DT O
results NNS O
indicate VBP O
that DT O
mutation NN O
of IN O
the DT O
VHL NNP B-Disease
gene NN O
is VBZ O
associated VBN O
exclusively RB O
with IN O
the DT O
development NN O
of IN O
non JJ B-Disease
- : I-Disease
papillary JJ I-Disease
renal NN I-Disease
cell NN I-Disease
carcinoma NN I-Disease
. . O
. . O

The DT O
Emery NNP B-Disease
- : I-Disease
Dreifuss NNP I-Disease
muscular JJ I-Disease
dystrophy NN I-Disease
protein NN O
, , O
emerin NN O
, , O
is VBZ O
a DT O
nuclear JJ O
membrane NN O
protein NN O
. . O

A DT O
large JJ O
fragment NN O
of IN O
emerin JJ O
cDNA NN O
was VBD O
prepared VBN O
by IN O
PCR NNP O
and CC O
expressed VBD O
as IN O
a DT O
recombinant JJ O
protein NN O
in IN O
Escherichia NNP O
coli NN O
. . O

Using VBG O
this DT O
as IN O
immunogen NN O
, , O
we PRP O
prepared VBD O
a DT O
panel NN O
of IN O
12 CD O
monoclonal JJ O
antibodies NNS O
which WDT O
recognise VBP O
at IN O
least JJS O
four CD O
different JJ O
epitopes NNS O
on IN O
emerin NN O
in IN O
order NN O
to TO O
ensure VB O
that IN O
emerin NN O
can MD O
be VB O
distinguished VBN O
from IN O
non JJ O
- : O
specific JJ O
cross NN O
- : O
reacting NN O
proteins NNS O
. . O

All PDT O
the DT O
mAbs NN O
recognised VBD O
a DT O
34 CD O
kDa NN O
protein NN O
in IN O
all DT O
tissues NNS O
tested VBN O
, , O
though IN O
minor JJ O
emerin SYM O
- : O
related JJ O
bands NNS O
were VBD O
also RB O
detected VBN O
in IN O
some DT O
tissues NNS O
. . O

Immunofluorescence NN O
microscopy NN O
showed VBD O
that IN O
emerin NN O
is VBZ O
located VBN O
at IN O
the DT O
nuclear JJ O
rim NN O
in IN O
all DT O
tissues NNS O
examined VBN O
. . O

A DT O
muscle NN O
biopsy NN O
from IN O
an DT O
Emery NNP B-Disease
- : I-Disease
Dreifuss NNP I-Disease
muscular JJ I-Disease
dystrophy NN I-Disease
( ( O
EMDM NNP B-Disease
) ) O
patient NN O
showed VBD O
complete JJ O
absence NN O
of IN O
emerin NN O
by IN O
both DT O
Western NNP O
blotting NN O
and CC O
immunohistochemistry NN O
, , O
suggesting VBG O
a DT O
simple JJ O
diagnostic JJ O
antibody NN O
test NN O
for IN O
EDMD NNP B-Disease
families NNS O
. . O

Biochemical JJ O
fractionation NN O
of IN O
brain NN O
and CC O
liver NN O
tissues NNS O
showed VBD O
that IN O
emerin NN O
was VBD O
present JJ O
in IN O
nuclei JJ O
purified VBN O
by IN O
centrifugation NN O
through IN O
65 CD O
% NN O
sucrose NN O
and CC O
was VBD O
absent NN O
from IN O
soluble JJ O
fractions NNS O
( ( O
post NN O
- : O
100 CD O
, , O
0 CD O
g NN O
) ) O
. . O

From IN O
these DT O
results NNS O
, , O
together RB O
with IN O
sequence NN O
and CC O
structural JJ O
homologies NNS O
between IN O
emerin NN O
, , O
thymopoietins NNS O
and CC O
the DT O
nuclear JJ O
lamina SYM O
- : O
associated VBN O
protein NN O
, , O
LAP2 NNP O
, , O
we PRP O
suggest VBP O
that IN O
emerin NN O
will MD O
prove VB O
to TO O
be VB O
one CD O
member NN O
of IN O
a DT O
family NN O
of IN O
inner JJ O
nuclear JJ O
membrane NN O
proteins NNS O
. . O
. . O

Mutation NN O
of IN O
MSH3 NNP O
in IN O
endometrial JJ B-Disease
cancer NN I-Disease
and CC O
evidence NN O
for IN O
its PRP$ O
functional JJ O
role NN O
in IN O
heteroduplex JJ O
repair NN O
. . O

Many JJ O
human JJ O
tumours NNS B-Disease
have VBP O
length VBN O
alterations NNS O
in IN O
repetitive JJ O
sequence NN O
elements NNS O
. . O

Although IN O
this DT O
microsatellite JJ B-Disease
instability NN I-Disease
has VBZ O
been VBN O
attributed VBN O
to TO O
mutations NNS O
in IN O
four CD O
DNA NNP O
mismatch NN O
repair NN O
genes NNS O
in IN O
hereditary JJ B-Disease
nonpolyposis NN I-Disease
colorectal NN I-Disease
cancer NN I-Disease
( ( O
HNPCC NNP B-Disease
) ) O
kindreds NNS O
, , O
many JJ O
sporadic JJ B-Disease
tumours NNS I-Disease
exhibit VBP O
instability NN O
but CC O
no DT O
detectable JJ O
mutations NNS O
in IN O
these DT O
genes NNS O
. . O

It PRP O
is VBZ O
therefore RB O
of IN O
interest NN O
to TO O
identify VB O
other JJ O
genes NNS O
that WDT O
contribute VBP O
to TO O
this DT O
instability NN O
. . O

In IN O
yeast NN O
, , O
mutations NNS O
in IN O
several JJ O
genes NNS O
, , O
including VBG O
RTH NNP O
and CC O
MSH3 NNP O
, , O
cause NN O
microsatellite JJ O
instability NN O
. . O

Thus RB O
, , O
we PRP O
screened VBD O
16 CD O
endometrial JJ B-Disease
carcinomas NN I-Disease
with IN O
microsatellite JJ O
instability NN O
for IN O
alterations NNS O
in IN O
FEN1 NNP O
( ( O
the DT O
human JJ O
homolog NN O
of IN O
RTH NNP O
) ) O
and CC O
in IN O
MSH3 NNP O
( ( O
refs VB O
12 CD O
- : O
14 CD O
) ) O
. . O

Although IN O
we PRP O
found VBD O
no DT O
FEN1 NNP O
mutations NNS O
, , O
a DT O
frameshift NN O
mutation NN O
in IN O
MSH3 NNP O
was VBD O
observed VBN O
in IN O
an DT O
endometrial JJ B-Disease
carcinoma NN I-Disease
and CC O
in IN O
an DT O
endometrial JJ B-Disease
carcinoma NN I-Disease
cell NN O
line NN O
. . O

Extracts NNS O
of IN O
the DT O
cell NN O
line NN O
were VBD O
deficient JJ O
in IN O
repair NN O
of IN O
DNA NNP O
substrates VBZ O
containing VBG O
mismatches NNS O
or CC O
extra JJ O
nucleotides NNS O
. . O

Introducing VBG O
chromosome NN O
5 CD O
, , O
encoding VBG O
the DT O
MSH3 NNP O
gene NN O
, , O
into IN O
the DT O
mutant JJ O
cell NN O
line NN O
increased VBD O
the DT O
stability NN O
of IN O
some DT O
but CC O
not RB O
all DT O
microsatellites NNS O
. . O

Extracts NNS O
of IN O
these DT O
cells NNS O
repaired VBD O
certain JJ O
substrates NNS O
containing VBG O
extra JJ O
nucleotides NNS O
, , O
but CC O
were VBD O
deficient JJ O
in IN O
repair NN O
of IN O
those DT O
containing VBG O
mismatches NNS O
or CC O
other JJ O
extra JJ O
nucleotides NNS O
. . O

A DT O
subsequent JJ O
search NN O
revealed VBD O
a DT O
second JJ O
gene NN O
mutation NN O
in IN O
HHUA NNP O
cells NNS O
, , O
a DT O
missense JJ O
mutation NN O
in IN O
the DT O
MSH6 NNP O
gene NN O
. . O

Together RB O
the DT O
data NN O
suggest NN O
that IN O
the DT O
MSH3 NNP O
gene NN O
encodes VBZ O
a DT O
product NN O
that WDT O
functions NNS O
in IN O
repair NN O
of IN O
some DT O
but CC O
not RB O
all DT O
pre SYM O
- : O
mutational JJ O
intermediates NNS O
, , O
its PRP$ O
mutation NN O
in IN O
tumours NNS B-Disease
can MD O
result VB O
in IN O
genomic JJ O
instability NN O
and CC O
, , O
as IN O
in IN O
yeast NN O
, , O
MSH3 NNP O
and CC O
MSH6 NNP O
are VBP O
partially RB O
redundant JJ O
for IN O
mismatch NN O
repair NN O
. . O
. . O

Comparative JJ O
genome NN O
mapping NN O
of IN O
the DT O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
region NN O
in IN O
mouse NN O
, , O
rat NN O
, , O
and CC O
Syrian JJ O
hamster NN O
. . O

Chromosomal JJ O
locations NNS O
of IN O
the DT O
Atm NNP O
( ( O
ataxia SYM B-Disease
- : I-Disease
telangiectasia NN I-Disease
( ( O
AT NNP B-Disease
) ) O
- : O
mutated VBN O
) ) O
and CC O
Acat1 NNP O
( ( O
mitochondrial JJ O
acetoacetyl NN O
- : O
CoA NNP O
thiolase NN O
) ) O
genes NNS O
in IN O
mouse NN O
, , O
rat NN O
, , O
and CC O
Syrian JJ O
hamster NN O
were VBD O
determined VBN O
by IN O
direct JJ O
R NNP O
- : O
banding VBG O
FISH NNP O
. . O

Both DT O
genes NNS O
were VBD O
colocalized VBN O
to TO O
the DT O
C NNP O
- : O
D NNP O
band NN O
of IN O
mouse NN O
chromosome NN O
9 CD O
, , O
the DT O
proximal JJ O
end NN O
of IN O
q24 NN O
. . O

1 CD O
of IN O
rat NN O
chromosome NN O
8 CD O
, , O
and CC O
qa4 SYM O
- : O
qa5 NN O
of IN O
Syrian JJ O
hamster NN O
chromosome NN O
12 CD O
. . O

The DT O
regions NNS O
in IN O
the DT O
mouse NN O
and CC O
rat NN O
were VBD O
homologous JJ O
to TO O
human JJ O
chromosome NN O
11q CD O
. . O

Fine NNP O
genetic JJ O
linkage NN O
mapping NN O
of IN O
the DT O
mouse NN O
AT NNP B-Disease
region NN O
was VBD O
performed VBN O
using VBG O
the DT O
interspecific JJ O
backcross NN O
mice NN O
. . O

Atm NNP O
, , O
Acat1 NNP O
, , O
and CC O
Npat NNP O
, , O
which WDT O
is VBZ O
a DT O
new JJ O
gene NN O
isolated VBN O
from IN O
the DT O
AT NNP O
region NN O
, , O
and CC O
12 CD O
flanking VBG O
microsatellite JJ O
DNA NN O
markers NNS O
were VBD O
examined VBN O
. . O

No DT O
recombinations NNS O
were VBD O
found VBN O
among IN O
the DT O
Atm NNP O
, , O
Npat NNP O
, , O
Acat1 NNP O
, , O
and CC O
D9Mit6 NNP O
loci NN O
, , O
and CC O
these DT O
loci NNS O
were VBD O
mapped VBN O
2 CD O
. . O

0 CD O
cM JJ O
distal NN O
to TO O
D9Mit99 NNP O
and CC O
1 CD O
. . O

3 CD O
cM NN O
proximal NN O
to TO O
D9Mit102 NNP O
. . O

Comparison NNP O
of IN O
the DT O
linkage NN O
map NN O
of IN O
mouse NN O
chromosome NN O
9 CD O
( ( O
MMU9 NNP O
) ) O
and CC O
that IN O
of IN O
human JJ O
chromosome NN O
11 CD O
( ( O
HSA11 NNP O
) ) O
indicates VBZ O
that IN O
there EX O
is VBZ O
a DT O
chromosomal JJ O
rearrangement NN O
due JJ O
to TO O
an DT O
inversion NN O
between IN O
Ets1 NNP O
and CC O
Atm NNP O
- : O
Npat NNP O
- : O
Acat1 NN O
and CC O
that IN O
the DT O
inversion NN O
of IN O
MMU9 NNP O
originated VBD O
from IN O
the DT O
chromosomal JJ O
breakage NN O
at IN O
the DT O
boundary NN O
between IN O
Gria4 NNP O
and CC O
Atm NNP O
- : O
Npat NNP O
- : O
Acat1 NN O
on IN O
HSA11 NNP O
. . O

This DT O
type NN O
of IN O
inversion NN O
appeared VBD O
to TO O
be VB O
conserved VBN O
in IN O
the DT O
three CD O
rodent NN O
species NNS O
, , O
mouse NN O
, , O
rat NN O
, , O
and CC O
Syrian JJ O
hamster NN O
, , O
using VBG O
additional JJ O
comparative JJ O
mapping NN O
data NNS O
with IN O
the DT O
Rck NNP O
gene NN O

An DT O
animal JJ O
model NN O
for IN O
Norrie NNP B-Disease
disease NN I-Disease
( ( O
ND NNP B-Disease
) ) O
: : O
gene NN O
targeting NN O
of IN O
the DT O
mouse NN O
ND NNP B-Disease
gene NN O
. . O

In IN O
order NN O
to TO O
elucidate VB O
the DT O
cellular JJ O
and CC O
molecular JJ O
processes NNS O
which WDT O
are VBP O
involved VBN O
in IN O
Norrie NNP B-Disease
disease NN I-Disease
( ( O
ND NNP B-Disease
) ) O
, , O
we PRP O
have VBP O
used VBN O
gene NN O
targeting VBG O
technology NN O
to TO O
generate VB O
ND NNP B-Disease
mutant JJ O
mice NN O
. . O

The DT O
murine NN O
homologue NN O
of IN O
the DT O
ND NNP B-Disease
gene NN O
was VBD O
cloned VBN O
and CC O
shown VBN O
to TO O
encode VB O
a DT O
polypeptide NN O
that WDT O
shares NNS O
94 CD O
% NN O
of IN O
the DT O
amino NN O
acid JJ O
sequence NN O
with IN O
its PRP$ O
human JJ O
counterpart NN O
. . O

RNA NNP O
in IN O
situ JJ O
hybridization NN O
revealed VBD O
expression NN O
in IN O
retina NN O
, , O
brain NN O
and CC O
the DT O
olfactory NN O
bulb NN O
and CC O
epithelium NN O
of IN O
2 CD O
week NN O
old JJ O
mice NN O
. . O

Hemizygous JJ O
mice NN O
carrying VBG O
a DT O
replacement NN O
mutation NN O
in IN O
exon JJ O
2 CD O
of IN O
the DT O
ND NNP B-Disease
gene NN O
developed VBD O
retrolental JJ O
structures NNS O
in IN O
the DT O
vitreous JJ O
body NN O
and CC O
showed VBD O
an DT O
overall JJ O
disorganization NN O
of IN O
the DT O
retinal JJ O
ganglion NN O
cell NN O
layer NN O
. . O

The DT O
outer NN O
plexiform NN O
layer NN O
disappears VBZ O
occasionally RB O
, , O
resulting VBG O
in IN O
a DT O
juxtaposed JJ O
inner NN O
and CC O
outer NN O
nuclear JJ O
layer NN O
. . O

At IN O
the DT O
same JJ O
regions NNS O
, , O
the DT O
outer NN O
segments NNS O
of IN O
the DT O
photoreceptor NN O
cell NN O
layer NN O
are VBP O
no RB O
longer RBR O
present JJ O
. . O

These DT O
ocular JJ O
findings NNS O
are VBP O
consistent JJ O
with IN O
observations NNS O
in IN O
ND NNP B-Disease
patients NNS O
and CC O
the DT O
generated VBN O
mouse NN O
line NN O
provides VBZ O
a DT O
faithful JJ O
model NN O
for IN O
study NN O
of IN O
early JJ O
pathogenic JJ O
events NNS O
in IN O
this DT O
severe JJ O
X NNP B-Disease
- : I-Disease
linked VBD I-Disease
recessive JJ I-Disease
neurological JJ I-Disease
disorder NN I-Disease
. . O
. . O

The DT O
hybrid JJ O
PAX3 NNP O
- : O
FKHR NNP O
fusion NN O
protein NN O
of IN O
alveolar JJ B-Disease
rhabdomyosarcoma NN I-Disease
transforms NNS O
fibroblasts NNS O
in IN O
culture NN O
. . O

Pediatric NNP B-Disease
alveolar JJ I-Disease
rhabdomyosarcoma NN I-Disease
is VBZ O
characterized VBN O
by IN O
a DT O
chromosomal JJ O
translocation NN O
that WDT O
fuses VBZ O
parts NNS O
of IN O
the DT O
PAX3 NNP O
and CC O
FKHR NNP O
genes NNS O
. . O

PAX3 NNP O
codes NNS O
for IN O
a DT O
transcriptional JJ O
regulator NN O
that WDT O
controls VBZ O
developmental JJ O
programs NNS O
, , O
and CC O
FKHR NNP O
codes NNS O
for IN O
a DT O
forkhead JJ O
- : O
winged VBD O
helix NN O
protein NN O
, , O
also RB O
a DT O
likely JJ O
transcription NN O
factor NN O
. . O

The DT O
PAX3 NNP O
- : O
FKHR NNP O
fusion NN O
product NN O
retains VBZ O
the DT O
DNA NN O
binding VBG O
domains NNS O
of IN O
the DT O
PAX3 NNP O
protein NN O
and CC O
the DT O
putative JJ O
activator NN O
domain NN O
of IN O
the DT O
FKHR NNP O
protein NN O
. . O

The DT O
PAX3 NNP O
- : O
FKHR NNP O
protein NN O
has VBZ O
been VBN O
shown VBN O
to TO O
function VB O
as IN O
a DT O
transcriptional JJ O
activator NN O
. . O

Using VBG O
the DT O
RCAS NNP O
retroviral JJ O
vector NN O
, , O
we PRP O
have VBP O
introduced VBN O
the DT O
PAX3 NNP O
- : O
FKHR NNP O
gene NN O
into IN O
chicken JJ O
embryo NN O
fibroblasts NNS O
. . O

Expression NN O
of IN O
the DT O
PAX3 NNP O
- : O
FKHR NNP O
protein NN O
in IN O
these DT O
cells NNS O
leads VBZ O
to TO O
transformation VB O
the DT O
cells NNS O
become VBP O
enlarged JJ O
, , O
grow VB O
tightly RB O
packed VBN O
and CC O
in IN O
multiple JJ O
layers NNS O
, , O
and CC O
acquire VB O
the DT O
ability NN O
for IN O
anchorage NN O
- : O
independent JJ O
growth NN O
. . O

This DT O
cellular JJ O
transformation NN O
in IN O
vitro NN O
will MD O
facilitate VB O
studies NNS O
on IN O
the DT O
mechanism NN O
of IN O
PAX3 NNP O
- : O
FKHR NNP O
- : O
induced JJ O
oncogenesis NN O
. . O
. . O

Somatic JJ O
- : O
cell NN O
selection NN O
is VBZ O
a DT O
major JJ O
determinant NN O
of IN O
the DT O
blood NN O
- : O
cell NN O
phenotype NN O
in IN O
heterozygotes NNS O
for IN O
glucose JJ O
- : O
6 CD O
- : O
phosphate NN O
dehydrogenase NN O
mutations NNS O
causing VBG O
severe JJ O
enzyme JJ B-Disease
deficiency NN I-Disease
. . O

X LS O
- : O
chromosome NN O
inactivation NN O
in IN O
mammals NNS O
is VBZ O
regarded VBN O
as IN O
an DT O
essentially RB O
random JJ O
process NN O
, , O
but CC O
the DT O
resulting JJ O
somatic JJ O
- : O
cell NN O
mosaicism NN O
creates VBZ O
the DT O
opportunity NN O
for IN O
cell NN O
selection NN O
. . O

In IN O
most JJS O
people NNS O
with IN O
red JJ O
- : O
blood NN O
- : O
cell NN O
glucose JJ B-Disease
- : I-Disease
6 CD I-Disease
- : I-Disease
phosphate NN I-Disease
dehydrogenase NN I-Disease
( ( I-Disease
G6PD NNP I-Disease
) ) I-Disease
deficiency NN I-Disease
, , O
the DT O
enzyme NN O
- : O
deficient NN O
phenotype NN O
is VBZ O
only RB O
moderately RB O
expressed VBN O
in IN O
nucleated JJ O
cells NNS O
. . O

However RB O
, , O
in IN O
a DT O
small JJ O
subset NN O
of IN O
hemizygous JJ O
males NNS O
who WP O
suffer VBP O
from IN O
chronic JJ B-Disease
nonspherocytic JJ I-Disease
hemolytic JJ I-Disease
anemia NN I-Disease
, , O
the DT O
underlying JJ O
mutations NNS O
( ( O
designated JJ O
class NN O
I PRP O
) ) O
cause NN O
more RBR O
- : O
severe JJ O
G6PD NNP B-Disease
deficiency NN I-Disease
, , O
and CC O
this DT O
might MD O
provide VB O
an DT O
opportunity NN O
for IN O
selection NN O
in IN O
heterozygous JJ O
females NNS O
during IN O
development NN O
. . O

In IN O
order NN O
to TO O
test VB O
this DT O
possibility NN O
we PRP O
have VBP O
analyzed VBN O
four CD O
heterozygotes NNS O
for IN O
class NN O
I PRP O
G6PD VBP O
mutations NNS O
two CD O
with IN O
G6PD NNP O
Portici NNP O
( ( O
1178G CD O
- : O
- : O
> VB O
A DT O
) ) O
and CC O
two CD O
with IN O
G6PD NNP O
Bari NNP O
( ( O
1187C CD O
- : O
- : O
> NN O
T NNP O
) ) O
. . O

We PRP O
found VBD O
that IN O
in IN O
fractionated JJ O
blood NN O
cell NN O
types NNS O
( ( O
including VBG O
erythroid NN O
, , O
myeloid NN O
, , O
and CC O
lymphoid NN O
cell NN O
lineages NNS O
) ) O
there EX O
was VBD O
a DT O
significant JJ O
excess NN O
of IN O
G6PD NNP O
- : O
normal JJ O
cells NNS O
. . O

The DT O
significant JJ O
concordance NN O
that IN O
we PRP O
have VBP O
observed VBN O
in IN O
the DT O
degree NN O
of IN O
imbalance NN O
in IN O
the DT O
different JJ O
blood NN O
- : O
cell NN O
lineages VBZ O
indicates VBZ O
that IN O
a DT O
selective JJ O
mechanism NN O
is VBZ O
likely JJ O
to TO O
operate VB O
at IN O
the DT O
level NN O
of IN O
pluripotent JJ O
blood NN O
stem NN O
cells NNS O
. . O

Thus RB O
, , O
it PRP O
appears VBZ O
that IN O
severe JJ O
G6PD NNP B-Disease
deficiency NN I-Disease
affects VBZ O
adversely RB O
the DT O
proliferation NN O
or CC O
the DT O
survival NN O
of IN O
nucleated JJ O
blood NN O
cells NNS O
and CC O
that IN O
this DT O
phenotypic NN O
characteristic NN O
is VBZ O
critical JJ O
during IN O
hematopoiesis NN O
. . O
. . O

Analysis NN O
of IN O
meiotic JJ O
segregation NN O
, , O
using VBG O
single JJ O
- : O
sperm JJ O
typing NN O
: : O
meiotic JJ O
drive NN O
at IN O
the DT O
myotonic JJ B-Disease
dystrophy NN I-Disease
locus NN O
. . O

Meiotic JJ O
drive NN O
at IN O
the DT O
myotonic JJ B-Disease
dystrophy NN I-Disease
( ( O
DM NNP B-Disease
) ) O
locus NN O
has VBZ O
recently RB O
been VBN O
suggested VBN O
as IN O
being VBG O
responsible JJ O
for IN O
maintaining VBG O
the DT O
frequency NN O
, , O
in IN O
the DT O
human JJ O
population NN O
, , O
of IN O
DM NNP B-Disease
chromosomes NNS O
capable JJ O
of IN O
expansion NN O
to TO O
the DT O
disease NN O
state NN O
. . O

In IN O
order NN O
to TO O
test VB O
this DT O
hypothesis NN O
, , O
we PRP O
have VBP O
studied VBN O
samples NNS O
of IN O
single JJ O
sperm NN O
from IN O
three CD O
individuals NNS O
heterozygous JJ O
at IN O
the DT O
DM NNP B-Disease
locus NN O
, , O
each DT O
with IN O
one CD O
allele NN O
larger JJR O
and CC O
one CD O
allele NN O
smaller JJR O
than IN O
19 CD O
CTG NNP O
repeats NNS O
. . O

To TO O
guard VB O
against IN O
the DT O
possible JJ O
problem NN O
of IN O
differential JJ O
PCR NNP O
amplification NN O
rates NNS O
based VBN O
on IN O
the DT O
lengths NNS O
of IN O
the DT O
alleles NNS O
, , O
the DT O
sperm NN O
were VBD O
also RB O
typed VBN O
at IN O
another DT O
closely RB O
linked VBN O
marker NN O
whose WP$ O
allele JJ O
size NN O
was VBD O
unrelated JJ O
to TO O
the DT O
allele JJ O
size NN O
at IN O
the DT O
DM NNP B-Disease
locus NN O
. . O

Using VBG O
statistical JJ O
models NNS O
specifically RB O
designed VBN O
to TO O
study VB O
single JJ O
- : O
sperm JJ O
segregation NN O
data NNS O
, , O
we PRP O
find VBP O
no DT O
evidence NN O
of IN O
meiotic JJ O
segregation NN O
distortion NN O
. . O

The DT O
upper JJ O
limit NN O
of IN O
the DT O
two CD O
- : O
sided VBD O
95 CD O
% NN O
confidence NN O
interval NN O
for IN O
the DT O
estimate NN O
of IN O
the DT O
common JJ O
segregation NN O
probability NN O
for IN O
the DT O
three CD O
donors NNS O
is VBZ O
at IN O
or CC O
below IN O
. . O

515 CD O
for IN O
all DT O
models NNS O
considered VBN O
, , O
and CC O
no DT O
statistically RB O
significant JJ O
difference NN O
from IN O
. . O

5 CD O
is VBZ O
detected VBN O
in IN O
any DT O
of IN O
the DT O
models NNS O
. . O

This DT O
suggests VBZ O
that IN O
any DT O
greater JJR O
amount NN O
of IN O
segregation NN O
distortion NN O
at IN O
the DT O
myotonic JJ B-Disease
dystrophy NN I-Disease
locus NN O
must MD O
result VB O
from IN O
events NNS O
following VBG O
sperm JJ O
ejaculation NN O
. . O

LPP NNP O
, , O
the DT O
preferred JJ O
fusion NN O
partner NN O
gene NN O
of IN O
HMGIC NNP O
in IN O
lipomas NN B-Disease
, , O
is VBZ O
a DT O
novel JJ O
member NN O
of IN O
the DT O
LIM NNP O
protein NN O
gene NN O
family NN O
. . O

A DT O
major JJ O
cytogenetic JJ O
subgroup NN O
of IN O
lipomas NN B-Disease
is VBZ O
characterized VBN O
by IN O
recurrent JJ O
chromosome NN O
aberrations NNS O
, , O
mainly RB O
translocations NNS O
, , O
that IN O
involve VBP O
chromosome NN O
segment NN O
12q13 CD O
- : O
q15 NN O
. . O

Multiple JJ O
chromosomes NNS O
have VBP O
been VBN O
found VBN O
as IN O
the DT O
translocation NN O
partners NNS O
of IN O
chromosome NN O
12 CD O
but CC O
3q27 CD O
- : O
q28 NN O
is VBZ O
preferentially RB O
involved VBN O
. . O

In IN O
previous JJ O
studies NNS O
, , O
it PRP O
has VBZ O
been VBN O
shown VBN O
that IN O
the DT O
high JJ O
mobility NN O
group NN O
( ( O
HMG NNP O
) ) O
protein VBP O
gene NN O
HMGIC NNP O
at IN O
12q15 CD O
is VBZ O
consistently RB O
rearranged VBN O
as IN O
a DT O
consequence NN O
of IN O
these DT O
translocations NNS O
. . O

Here RB O
, , O
we PRP O
report VBP O
the DT O
identification NN O
and CC O
characterization NN O
of IN O
the DT O
chromosome NN O
3 CD O
- : O
derived VBN O
translocation NN O
partner NN O
gene NN O
, , O
which WDT O
we PRP O
have VBP O
designated VBN O
LPP NNP O
( ( O
lipoma JJ B-Disease
preferred VBN O
partner NN O
gene NN O
) ) O
. . O

Using VBG O
3 CD O
- : O
RACE JJ O
analysis NN O
of IN O
HMGIC NNP O
fusion NN O
transcripts NNS O
in IN O
lipoma NN B-Disease
cell NN O
line NN O
Li NNP O
- : O
501 CD O
/ NN O
SV40 NNP O
, , O
ectopic VBZ O
genetic JJ O
sequences NNS O
were VBD O
obtained VBN O
, , O
which WDT O
by IN O
CASH NNP O
( ( O
chromosome JJ O
assignment NN O
using VBG O
somatic JJ O
cell NN O
hybrids NNS O
) ) O
and CC O
FISH NNP O
( ( O
fluorescence NN O
in IN O
situ JJ O
hybridization NN O
) ) O
analysis NN O
were VBD O
found VBN O
to TO O
originate VB O
from IN O
chromosome NN O
segment NN O
3q27 CD O
- : O
q28 NN O
. . O

In IN O
Northern NNP O
blot NN O
analysis NN O
, , O
an DT O
mRNA NN O
of IN O
over IN O
10 CD O
kb NN O
was VBD O
detected VBN O
by IN O
these DT O
ectopic NNS O
sequences NNS O
in IN O
a DT O
variety NN O
of IN O
human JJ O
tissues NNS O
but CC O
not RB O
in IN O
brain NN O
and CC O
peripheral JJ O
blood NN O
leukocytes NNS O
. . O

Upon IN O
partial JJ O
cDNA NN O
cloning NN O
, , O
features NNS O
of IN O
the DT O
genetic JJ O
organization NN O
of IN O
LPP NNP O
were VBD O
established VBN O
. . O

The DT O
gene NN O
was VBD O
found VBN O
to TO O
span VB O
a DT O
genomic JJ O
region NN O
of IN O
over IN O
400 CD O
kb NNS O
. . O

Nucleotide NNP O
sequence NN O
analysis NN O
of IN O
a DT O
composite JJ O
cDNA NN O
of IN O
LPP NNP O
revealed VBD O
an DT O
open JJ O
reading NN O
frame NN O
of IN O
1836 CD O
nucleotides NNS O
encoding VBG O
a DT O
proline NN O
- : O
rich JJ O
protein NN O
containing VBG O
a DT O
leucine JJ O
- : O
zipper NN O
motif NN O
in IN O
its PRP$ O
amino NN O
- : O
terminal JJ O
region NN O
and CC O
three CD O
LIM NNP O
domains VBZ O
in IN O
its PRP$ O
carboxy JJ O
- : O
terminal JJ O
region NN O
. . O

The DT O
LPP NNP O
- : O
encoded VBD O
protein NN O
should MD O
be VB O
classified VBN O
as IN O
a DT O
novel JJ O
member NN O
of IN O
the DT O
group NN O
3 CD O
proteins NNS O
of IN O
the DT O
LIM NNP O
protein NN O
gene NN O
family NN O
. . O

Using VBG O
reverse JJ O
transcriptase NN O
combined VBN O
with IN O
polymerase NN O
chain NN O
reactions NNS O
in IN O
the DT O
analysis NN O
of IN O
a DT O
number NN O
of IN O
lipoma NN B-Disease
cell NN O
lines NNS O
and CC O
primary JJ B-Disease
lipomas NN I-Disease
, , O
it PRP O
appeared VBD O
that IN O
LPP NNP O
is VBZ O
frequently RB O
rearranged VBN O
also RB O
in IN O
cases NNS O
without IN O
a DT O
cytogenetically RB O
detectable JJ O
involvement NN O
of IN O
3q27 CD O
- : O
q28 NN O
. . O

Two CD O
alternative JJ O
HMGIC NNP O
/ NNP O
LPP NNP O
hybrid JJ O
transcripts NNS O
have VBP O
been VBN O
detected VBN O
; : O
the DT O
difference NN O
between IN O
them PRP O
is VBZ O
mainly RB O
the DT O
presence NN O
of IN O
either CC O
two CD O
or CC O
three CD O
LIM NNP O
domains NNS O
in IN O
the DT O
predicted JJ O
HMGI NNP O
- : O
C NNP O
/ NNP O
LPP NNP O
fusion NN O
proteins NNS O
. . O
. . O

Absence NN O
of IN O
disease NN O
phenotype NN O
and CC O
intergenerational JJ O
stability NN O
of IN O
the DT O
CAG NNP O
repeat NN O
in IN O
transgenic JJ O
mice NN O
expressing VBG O
the DT O
human JJ O
Huntington NNP B-Disease
disease NN I-Disease
transcript NN O
. . O

The DT O
mutation NN O
underlying VBG O
Huntington NNP B-Disease
disease NN I-Disease
( ( O
HD NNP B-Disease
) ) O
is VBZ O
CAG JJ O
expansion NN O
in IN O
the DT O
first JJ O
exon NN O
of IN O
the DT O
HD NNP B-Disease
gene NN O
. . O

In IN O
order NN O
to TO O
investigate VB O
the DT O
role NN O
of IN O
CAG NNP O
expansion NN O
in IN O
the DT O
pathogenesis NN O
of IN O
HD NNP B-Disease
, , O
we PRP O
have VBP O
produced VBN O
transgenic JJ O
mice NN O
containing VBG O
the DT O
full JJ O
length NN O
human JJ O
HD NNP B-Disease
cDNA NN O
with IN O
44 CD O
CAG NNP O
repeats NNS O
. . O

By IN O
1 CD O
year NN O
, , O
these DT O
mice NNS O
have VBP O
no DT O
behavioral JJ B-Disease
abnormalities NNS I-Disease
and CC O
morphometric JJ O
analysis NN O
at IN O
6 CD O
( ( O
one CD O
animal NN O
) ) O
and CC O
9 CD O
( ( O
two CD O
animals NNS O
) ) O
months NNS O
age NN O
revealed VBD O
no DT O
changes NNS O
. . O

Despite IN O
high JJ O
levels NNS O
of IN O
mRNA NN O
expression NN O
, , O
there EX O
was VBD O
no DT O
evidence NN O
of IN O
the DT O
HD NNP B-Disease
gene NN O
product NN O
in IN O
any DT O
of IN O
these DT O
transgenic JJ O
mice NN O
. . O

In IN O
vitro JJ O
transfection NN O
studies NNS O
indicated VBD O
that IN O
the DT O
inclusion NN O
of IN O
120 CD O
bp NN O
of IN O
the DT O
5 CD O
UTR NNP O
in IN O
the DT O
cDNA NN O
construct NN O
and CC O
the DT O
presence NN O
of IN O
a DT O
frameshift JJ O
mutation NN O
at IN O
nucleotide JJ O
2349 CD O
prevented JJ O
expression NN O
of IN O
the DT O
HD NNP B-Disease
cDNA NN O
. . O

These DT O
findings NNS O
suggest VBP O
that IN O
the DT O
pathogenesis NN O
of IN O
HD NNP B-Disease
is VBZ O
not RB O
mediated VBN O
through IN O
DNA NNP O
- : O
protein NN O
interaction NN O
and CC O
that DT O
presence NN O
of IN O
the DT O
RNA NNP O
transcript NN O
with IN O
an DT O
expanded VBN O
CAG NNP O
repeat NN O
is VBZ O
insufficient JJ O
to TO O
cause VB O
the DT O
disease NN O
. . O

Rather RB O
, , O
translation NN O
of IN O
the DT O
CAG NNP O
is VBZ O
crucial JJ O
for IN O
the DT O
pathogenesis NN O
of IN O
HD NNP B-Disease
. . O

In IN O
contrast NN O
to TO O
that DT O
seen VBN O
in IN O
humans NNS O
, , O
the DT O
CAG NNP O
repeat NN O
in IN O
these DT O
mice NN O
was VBD O
remarkably RB O
stable JJ O
in IN O
97 CD O
meioses NNS O
. . O

This DT O
suggests VBZ O
that IN O
genomic JJ O
sequences NNS O
may MD O
play VB O
a DT O
critical JJ O
role NN O
in IN O
influencing VBG O
repeat NN O
instability NN O
. . O
. . O

FISH NNP O
studies NNS O
in IN O
a DT O
patient NN O
with IN O
sporadic JJ B-Disease
aniridia NN I-Disease
and CC O
t NN O
( ( O
7 CD O
; : O
11 CD O
) ) O
( ( O
q31 UH O
. . O
2 CD O
; : O
p13 NN O
) ) O
. . O

A DT O
2 CD O
year NN O
old JJ O
female NN O
presenting VBG O
with IN O
bilateral JJ B-Disease
sporadic JJ I-Disease
aniridia NN I-Disease
was VBD O
found VBN O
to TO O
have VB O
an DT O
apparently RB O
balanced JJ O
reciprocal JJ O
translocation NN O
with IN O
a DT O
chromosome NN O
11 CD O
breakpoint NN O
within IN O
band NN O
p13 NN O
. . O

Fluorescence NN O
in IN O
situ JJ O
hybridisation NN O
( ( O
FISH NNP O
) ) O
studies NNS O
with IN O
distal JJ O
11p13 CD O
specific JJ O
cosmids NNS O
showed VBD O
that IN O
the DT O
chromosome NN O
11 CD O
breakpoint NN O
lay NN O
between IN O
the DT O
aniridia NN B-Disease
( ( O
PAX6 NNP O
) ) O
locus NN O
and CC O
a DT O
region NN O
approximately RB O
100 CD O
kb NNS O
distal JJ O
to TO O
PAX6 NNP O
defined VBN O
by IN O
the DT O
cosmid NN O
FO2121 NNP O
. . O

Although IN O
this DT O
patient NN O
did VBD O
not RB O
have VB O
a DT O
detectable JJ O
deletion NN O
within IN O
PAX6 NNP O
, , O
her PRP$ O
aniridia NN B-Disease
may MD O
have VB O
resulted VBN O
from IN O
a DT O
disruption NN O
of IN O
the DT O
distal JJ O
chromatin NN O
domain NN O
containing VBG O
either CC O
enhancers NNS O
or CC O
regulators NNS O
for IN O
PAX6 NNP O
. . O

This DT O
case NN O
may MD O
therefore RB O
be VB O
another DT O
example NN O
of IN O
aniridia NN B-Disease
caused VBN O
by IN O
a DT O
position NN O
effect NN O
as IN O
recently RB O
described VBN O
in IN O
two CD O
familial JJ B-Disease
aniridia NN I-Disease
patients NNS O
in IN O
which WDT O
the DT O
phenotype NN O
cosegregated VBD O
with IN O
chromosome NN B-Disease
abnormalities NNS I-Disease
with IN O
11p13 CD O
breakpoints NNS O
. . O
. . O

Muscle NNP O
expression NN O
of IN O
glucose JJ B-Disease
- : I-Disease
6 CD I-Disease
- : I-Disease
phosphate NN I-Disease
dehydrogenase NN I-Disease
deficiency NN I-Disease
in IN O
different JJ O
variants NNS O
. . O

Muscle NNP O
expression NN O
of IN O
G6PD NNP B-Disease
deficiency NN I-Disease
has VBZ O
been VBN O
investigated VBN O
in IN O
Mediterranean NNP O
, , O
Seattle NNP O
- : O
like NN O
and CC O
A NNP O
- : O
variants NNS O
. . O

G6PD NNP O
activity NN O
was VBD O
detected VBN O
in IN O
samples NNS O
obtained VBN O
from IN O
biopsies NNS O
on IN O
the DT O
quadriceps JJ O
muscle NN O
of IN O
seven CD O
males NNS O
and CC O
one CD O
female NN O
. . O

The DT O
type NN O
of IN O
genetic JJ O
variant NN O
was VBD O
determined VBN O
by IN O
molecular JJ O
analysis NN O
of IN O
DNA NNP O
, , O
extracted VBD O
from IN O
blood NN O
samples NNS O
. . O

All DT O
variants NNS O
showed VBD O
the DT O
enzyme NN O
defect NN O
in IN O
muscle NN O
. . O

A DT O
statistically RB O
significant JJ O
relationship NN O
was VBD O
found VBN O
in IN O
the DT O
activity NN O
of IN O
G6PD NNP O
between IN O
erythrocytes NNS O
and CC O
muscle NN O
of IN O
the DT O
male JJ O
subjects NNS O
( ( O
r VB O
= RB O
0 CD O
. . O
968 CD O
; : O
p NN O
= VBZ O
0 CD O
. . O
8 CD O
) ) O
. . O

The DT O
equation NN O
for IN O
the DT O
best JJS O
fit JJ O
line NN O
was VBD O
Y NNP O
= NNP O
0 CD O
. . O

390X CD O
+ JJ O
0 CD O
. . O

198 CD O
198 CD O
. . O

The DT O
results NNS O
suggest VBP O
that IN O
, , O
for IN O
a DT O
given VBN O
variant NN O
, , O
the DT O
extent NN O
of IN O
the DT O
enzyme NN O
defect NN O
in IN O
muscle NN O
may MD O
be VB O
determined VBN O
, , O
using VBG O
this DT O
equation NN O
, , O
from IN O
the DT O
G6PD NNP O
activity NN O
of IN O
erythrocytes NNS O

Gene NNP O
therapy NN O
for IN O
phenylketonuria NN B-Disease
. . O

Classical JJ O
phenylketonuria NN B-Disease
( ( O
PKU NNP B-Disease
) ) O
is VBZ O
an DT O
autosomal JJ B-Disease
recessive JJ I-Disease
disorder NN I-Disease
caused VBN O
by IN O
a DT O
deficiency NN B-Disease
of IN I-Disease
hepatic JJ I-Disease
phenylalanine NN I-Disease
hydroxylase NN I-Disease
( ( O
PAH NNP O
) ) O
. . O

Limitations NNS O
of IN O
the DT O
current JJ O
dietary JJ O
treatment NN O
for IN O
PKU NNP B-Disease
have VBP O
led VBN O
to TO O
the DT O
development NN O
of IN O
potential JJ O
treatments NNS O
based VBN O
on IN O
somatic JJ O
gene NN O
transfer NN O
. . O

Three CD O
different JJ O
vector NN O
systems NNS O
have VBP O
been VBN O
examined VBN O
. . O

Vectors NNS O
derived VBD O
from IN O
a DT O
recombinant JJ O
retrovirus NN O
or CC O
a DT O
DNA NN O
/ JJ O
protein NN O
complex NN O
can MD O
efficiently RB O
transduce VB O
the DT O
PAH NNP O
cDNA NN O
into IN O
PAH NNP B-Disease
- : I-Disease
deficient NN I-Disease
hepatocytes NNS O
in IN O
vitro NN O
, , O
but CC O
the DT O
application NN O
of IN O
these DT O
vector NN O
systems NNS O
is VBZ O
presently RB O
limited VBN O
by IN O
their PRP$ O
low JJ O
transduction NN O
efficiency NN O
in IN O
vivo NN O
. . O

In IN O
contrast NN O
, , O
a DT O
vector NN O
derived VBN O
from IN O
a DT O
recombinant JJ O
adenovirus NN O
can MD O
restore VB O
10 CD O
% NN O
- : O
80 CD O
% NN O
of IN O
normal JJ O
hepatic JJ O
PAH NNP O
activity NN O
into IN O
PAH NNP B-Disease
- : I-Disease
deficient NN I-Disease
mice NN O
, , O
which WDT O
completely RB O
normalizes VBZ O
serum JJ O
phenylalanine NN O
levels NNS O
. . O

This DT O
treatment NN O
is VBZ O
transient JJ O
and CC O
cannot JJ O
be VB O
effectively RB O
re JJ O
- : O
administered VBN O
due JJ O
to TO O
the DT O
presence NN O
of IN O
neutralizing VBG O
antibodies NNS O
directed VBN O
against IN O
the DT O
recombinant JJ O
adenoviral JJ O
vector NN O
. . O

However RB O
, , O
these DT O
findings NNS O
suggest VBP O
that IN O
PKU NNP B-Disease
can MD O
be VB O
completely RB O
corrected VBN O
by IN O
somatic JJ O
gene NN O
therapy NN O
, , O
and CC O
provide VB O
some DT O
direction NN O
for IN O
the DT O
future NN O
development NN O
of IN O
adenoviral JJ O
vectors NNS O
. . O
. . O

Exon NNP O
- : O
intron NN O
structure NN O
of IN O
the DT O
human JJ O
neuronal JJ O
nicotinic JJ O
acetylcholine NN O
receptor NN O
alpha VBD O
4 CD O
subunit NN O
( ( O
CHRNA4 NNP O
) ) O
. . O

The DT O
human JJ O
neuronal JJ O
nicotinic JJ O
acetylcholine NN O
receptor NN O
alpha VBD O
4 CD O
subunit NN O
gene NN O
( ( O
CHRNA4 NNP O
) ) O
is VBZ O
located VBN O
in IN O
the DT O
candidate NN O
region NN O
for IN O
three CD O
different JJ O
phenotypes NNS O
benign JJ B-Disease
familial JJ I-Disease
neonatal JJ I-Disease
convulsions NNS I-Disease
, , O
autosomal JJ B-Disease
dominant JJ I-Disease
nocturnal JJ I-Disease
frontal NN I-Disease
lobe NN I-Disease
epilepsy NN I-Disease
, , O
and CC O
low JJ O
- : O
voltage NN O
EEG NNP O
. . O

Recently RB O
, , O
a DT O
missense JJ O
mutation NN O
in IN O
transmembrane NN O
domain VBP O
2 CD O
of IN O
CHRNA4 NNP O
was VBD O
found VBN O
to TO O
be VB O
associated VBN O
with IN O
autosomal JJ B-Disease
dominant JJ I-Disease
nocturnal JJ I-Disease
frontal NN I-Disease
lobe NN I-Disease
epilepsy NN I-Disease
in IN O
one CD O
extended VBD O
pedigree NN O
. . O

We PRP O
have VBP O
determined VBN O
the DT O
genomic JJ O
organization NN O
of IN O
CHRNA4 NNP O
, , O
which WDT O
consists VBZ O
of IN O
six CD O
exons NNS O
distributed VBN O
over IN O
approximately RB O
17 CD O
kb NNS O
of IN O
genomic JJ O
DNA NNP O
. . O

The DT O
nucleotide JJ O
sequence NN O
obtained VBN O
from IN O
the DT O
genomic JJ O
regions NNS O
adjacent VBP O
to TO O
the DT O
exon NN O
boundaries NNS O
enabled VBD O
us PRP O
to TO O
develop VB O
a DT O
set NN O
of IN O
primer NN O
pairs NNS O
for IN O
PCR NNP O
amplification NN O
of IN O
the DT O
complete JJ O
coding NN O
region NN O
. . O

The DT O
sequence NN O
analysis NN O
provides VBZ O
the DT O
basis NN O
for IN O
a DT O
comprehensive JJ O
mutation NN O
screening NN O
of IN O
CHRNA4 NNP O
in IN O
the DT O
above JJ O
- : O
mentioned VBN O
phenotypes NNS O
and CC O
possibly RB O
in IN O
other JJ O
types NNS O
of IN O
idiopathic JJ B-Disease
epilepsies NNS I-Disease
. . O
. . O

Ashkenazi NNP O
Jewish NNP O
population NN O
frequencies NNS O
for IN O
common JJ O
mutations NNS O
in IN O
BRCA1 NNP O
and CC O
BRCA2 NNP O
. . O

BRCA1 NNP O
and CC O
BRCA2 NNP O
are VBP O
the DT O
two CD O
major JJ O
identified VBN O
causes NNS O
of IN O
inherited JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
, , O
with IN O
mutations NNS O
in IN O
either DT O
gene NN O
conferring VBG O
up RP O
to TO O
80 CD O
- : O
90 CD O
% NN O
lifetime NN O
risk NN O
of IN O
breast NN B-Disease
cancer NN I-Disease
in IN O
carrier NN O
females NNS O
. . O

Mutations NNS O
in IN O
BRCA1 NNP O
account NN O
for IN O
approximately RB O
45 CD O
% NN O
of IN O
familial JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
and CC O
90 CD O
% NN O
of IN O
inherited JJ B-Disease
breast NN I-Disease
/ JJ I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
, , O
whereas JJ O
mutations NNS O
in IN O
BRCA2 NNP O
account NN O
for IN O
a DT O
comparable JJ O
percentage NN O
of IN O
inherited JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
cases NNS O
. . O

Over IN O
85 CD O
distinct JJ O
BRCA1 NNP O
mutations NNS O
and CC O
a DT O
growing VBG O
list NN O
of IN O
BRCA2 NNP O
mutations NNS O
have VBP O
been VBN O
identified VBN O
, , O
with IN O
the DT O
majority NN O
resulting VBG O
in IN O
protein NN O
truncation NN O
. . O

A DT O
specific JJ O
BRCA1 NNP O
mutation NN O
, , O
185delAG CD O
, , O
has VBZ O
a DT O
reported VBN O
increased VBN O
carrier NN O
frequency NN O
of IN O
approximately RB O
0 CD O
. . O

9 CD O
% NN O
in IN O
the DT O
Ashkenazi NNP O
Jewish NNP O
population NN O
, , O
but CC O
is VBZ O
also RB O
found VBN O
in IN O
rare JJ O
non NN O
- : O
Jewish JJ O
patients NNS O
with IN O
a DT O
different JJ O
haplotype NN O
. . O

The DT O
6174delT CD O
mutation NN O
in IN O
BRCA2 NNP O
was VBD O
recently RB O
identified VBN O
as IN O
a DT O
frequent JJ O
mutation NN O
in IN O
8 CD O
out IN O
of IN O
107 CD O
Ashkenazi NNP O
Jewish JJ O
women NNS O
diagnosed VBN O
with IN O
breast NN B-Disease
cancer NN I-Disease
by IN O
age NN O
50 CD O
( ( O
ref NN O
. . O
8 CD O
) ) O
, , O
as RB O
well RB O
as IN O
in IN O
three CD O
Ashkenazi NNP O
male NN B-Disease
breast NN I-Disease
cancer NN I-Disease
patients NNS O
. . O

We PRP O
have VBP O
conducted VBN O
a DT O
large JJ O
- : O
scale NN O
population NN O
study NN O
to TO O
investigate VB O
the DT O
prevalence NN O
of IN O
specific JJ O
BRCA1 NNP O
and CC O
BRCA2 NNP O
mutations NNS O
in IN O
Ashkenazi NNP O
Jewish JJ O
individuals NNS O
who WP O
were VBD O
unselected VBN O
for IN O
breast NN B-Disease
cancer NN I-Disease
. . O

BRCA1 NNP O
mutation NN O
screening VBG O
on IN O
approximately RB O
3 CD O
, , O
0 CD O
Ashkenazi NNP O
Jewish NNP O
samples NNS O
determined VBD O
a DT O
carrier NN O
frequency NN O
of IN O
1 CD O
. . O

9 CD O
% NN O
for IN O
the DT O
185delAG CD O
mutation NN O
and CC O
0 CD O
. . O

13 CD O
% NN O
for IN O
the DT O
5382insC CD O
mutation NN O
. . O

BRCA2 NNP O
analysis NN O
on IN O
3 CD O
, , O
85 CD O
individuals NNS O
from IN O
the DT O
same JJ O
population NN O
showed VBD O
a DT O
carrier NN O
frequency NN O
of IN O
1 CD O
. . O

52 CD O
% NN O
for IN O
the DT O
6174delT CD O
mutation NN O
. . O

This DT O
expanded VBN O
population NN O
- : O
based VBN O
study NN O
confirms VBZ O
that IN O
the DT O
BRCA1 NNP O
185delAG CD O
mutation NN O
and CC O
the DT O
BRCA2 NNP O
6174delT CD O
mutation NN O
constitute VB O
the DT O
two CD O
most JJS O
frequent JJ O
mutation NN O
alleles NNS O
predisposing VBG O
to TO O
hereditary JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
among IN O
the DT O
Ashkenazim NNP O
, , O
and CC O
suggests VBZ O
a DT O
relatively RB O
lower JJR O
penetrance NN O
for IN O
the DT O
6174delT CD O
mutation NN O
in IN O
BRCA2 NNP O

Dual JJ O
roles NNS O
of IN O
ATM NNP O
in IN O
the DT O
cellular JJ O
response NN O
to TO O
radiation NN O
and CC O
in IN O
cell NN O
growth NN O
control NN O
. . O

The DT O
gene NN O
mutated VBN O
in IN O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
( ( O
AT NNP B-Disease
) ) O
patients NNS O
, , O
denoted VBN O
ATM NNP O
, , O
encodes VBZ O
a DT O
putative JJ O
protein NN O
or CC O
lipid JJ O
kinase NN O
. . O

To TO O
elucidate VB O
the DT O
functions NNS O
of IN O
ATM NNP O
, , O
we PRP O
disrupted VBD O
the DT O
mouse NN O
ATM NNP O
gene NN O
through IN O
homologous JJ O
recombination NN O
in IN O
mice NN O
. . O

Consistent JJ O
with IN O
cellular JJ O
defects NNS O
of IN O
AT NNP B-Disease
patients NNS O
, , O
the DT O
ATM NNP O
- : O
/ SYM O
- : O
cells NNS O
are VBP O
hypersensitive JJ O
to TO O
gamma VB O
- : O
irradiation NN O
and CC O
defective JJ O
in IN O
cell NN O
- : O
cycle NN O
arrest NN O
following VBG O
radiation NN O
, , O
correlating VBG O
with IN O
a DT O
defective JJ O
up RP O
- : O
regulation NN O
of IN O
p53 NN O
. . O

In IN O
addition NN O
, , O
ATM NNP O
- : O
/ SYM O
- : O
mouse NN O
thymocytes NNS O
are VBP O
more RBR O
resistant JJ O
to TO O
apoptosis VB O
induced VBN O
by IN O
gamma JJ O
- : O
irradiation NN O
than IN O
normal JJ O
thymocytes NNS O
. . O

ATM NNP O
- : O
/ SYM O
- : O
fibroblasts NNS O
are VBP O
inefficient JJ O
in IN O
G1 NNP O
to TO O
S NNP O
- : O
phase NN O
progression NN O
following VBG O
serum JJ O
stimulation NN O
and CC O
senesce NN O
after IN O
only RB O
a DT O
few JJ O
passages NNS O
in IN O
culture NN O
. . O

They PRP O
have VBP O
an DT O
increased VBN O
constitutive JJ O
level NN O
of IN O
p21CP1 JJ O
/ NNP O
WAF1 NNP O
. . O

The DT O
ATM NNP O
protein NN O
is VBZ O
therefore RB O
critical JJ O
both DT O
for IN O
cellular JJ O
responses NNS O
to TO O
ionizing VBG O
radiation NN O
and CC O
for IN O
normal JJ O
cell NN O
- : O
cycle NN O
progression NN O
. . O

ATM NNP O
+ NNP O
/ NNP O
- : O
fibroblasts NNS O
and CC O
thymocytes NNS O
showed VBD O
intermediately RB O
defective JJ O
responses NNS O
to TO O
irradiation VB O
but CC O
no DT O
growth NN O
defect NN O
, , O
suggesting VBG O
that IN O
the DT O
increased JJ O
cancer NN B-Disease
risk NN O
of IN O
AT NNP B-Disease
heterozygotes NNS O
could MD O
be VB O
attributable JJ O
to TO O
poor JJ O
checkpoint NN O
function NN O
. . O
. . O

Targeted VBN O
disruption NN O
of IN O
ATM NNP O
leads VBZ O
to TO O
growth NN B-Disease
retardation NN I-Disease
, , O
chromosomal JJ B-Disease
fragmentation NN I-Disease
during IN I-Disease
meiosis NN I-Disease
, , O
immune JJ B-Disease
defects NNS I-Disease
, , O
and CC O
thymic JJ B-Disease
lymphoma NN I-Disease
. . O

ATM NNP O
, , O
the DT O
gene NN O
mutated VBN O
in IN O
the DT O
inherited JJ B-Disease
human JJ I-Disease
disease NN I-Disease
ataxia SYM B-Disease
- : I-Disease
telangiectasia NN I-Disease
, , O
is VBZ O
a DT O
member NN O
of IN O
a DT O
family NN O
of IN O
kinases NNS O
involved VBN O
in IN O
DNA NNP O
metabolism NN O
and CC O
cell NN O
- : O
cycle NN O
checkpoint NN O
control NN O
. . O

To TO O
help VB O
clarify VB O
the DT O
physiological JJ O
roles NNS O
of IN O
the DT O
ATM NNP O
protein NN O
, , O
we PRP O
disrupted VBD O
the DT O
ATM NNP O
gene NN O
in IN O
mice NNS O
through IN O
homologous JJ O
recombination NN O
. . O

Initial JJ O
evaluation NN O
of IN O
the DT O
ATM NNP O
knockout NN O
animals NNS O
indicates VBZ O
that IN O
inactivation NN O
of IN O
the DT O
mouse NN O
ATM NNP O
gene NN O
recreates VBZ O
much RB O
of IN O
the DT O
phenotype NN O
of IN O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
. . O

The DT O
homozygous JJ O
mutant NN O
( ( O
ATM NNP O
- : O
/ SYM O
- : O
) ) O
mice NN O
are VBP O
viable JJ O
, , O
growth NN O
- : O
retarded VBN O
, , O
and CC O
infertile NN O
. . O

The DT O
infertility NN B-Disease
of IN O
ATM NNP O
- : O
/ SYM O
- : O
mice NN O
results NNS O
from IN O
meiotic JJ O
failure NN O
. . O

Meiosis NN O
is VBZ O
arrested VBN O
at IN O
the DT O
zygotene NN O
/ NNP O
pachytene NN O
stage NN O
of IN O
prophase NN O
I PRP O
as IN O
a DT O
result NN O
of IN O
abnormal JJ O
chromosomal JJ O
synapsis NN O
and CC O
subsequent JJ O
chromosome NN O
fragmentation NN O
. . O

Immune NNP B-Disease
defects NNS I-Disease
also RB O
are VBP O
evident JJ O
in IN O
ATM NNP O
- : O
/ SYM O
- : O
mice NN O
, , O
including VBG O
reduced JJ O
numbers NNS O
of IN O
B220 NNP O
+ NNP O
CD43 NNP O
- : O
pre NN O
- : O
B NNP O
cells NNS O
, , O
thymocytes NNS O
, , O
and CC O
peripheral JJ O
T NNP O
cells NNS O
, , O
as RB O
well RB O
as IN O
functional JJ O
impairment NN O
of IN O
T NNP O
- : O
cell NN O
- : O
dependent NN O
immune JJ O
responses NNS O
. . O

The DT O
cerebella NN O
of IN O
ATM NNP O
- : O
/ SYM O
- : O
mice NN O
appear IN O
normal JJ O
by IN O
histologic JJ O
examination NN O
at IN O
3 CD O
to TO O
4 CD O
months NNS O
and CC O
the DT O
mice NNS O
have VBP O
no DT O
gross JJ O
behavioral JJ B-Disease
abnormalities NNS I-Disease
. . O

The DT O
majority NN O
of IN O
mutant JJ O
mice NNS O
rapidly RB O
develop VBP O
thymic JJ B-Disease
lymphomas NN I-Disease
and CC O
die NN O
before IN O
4 CD O
months NNS O
of IN O
age NN O
. . O

These DT O
findings NNS O
indicate VBP O
that IN O
the DT O
ATM NNP O
gene NN O
product NN O
plays VBZ O
an DT O
essential JJ O
role NN O
in IN O
a DT O
diverse JJ O
group NN O
of IN O
cellular JJ O
processes NNS O
, , O
including VBG O
meiosis NN O
, , O
the DT O
normal JJ O
growth NN O
of IN O
somatic JJ O
tissues NNS O
, , O
immune NN O
development NN O
, , O
and CC O
tumor NN B-Disease
suppression NN O
. . O
. . O

Cloning VBG O
and CC O
characterization NN O
of IN O
human JJ O
very RB O
- : O
long JJ O
- : O
chain NN O
acyl IN O
- : O
CoA NNP O
dehydrogenase NN O
cDNA NN O
, , O
chromosomal JJ O
assignment NN O
of IN O
the DT O
gene NN O
and CC O
identification NN O
in IN O
four CD O
patients NNS O
of IN O
nine CD O
different JJ O
mutations NNS O
within IN O
the DT O
VLCAD NNP O
gene NN O
. . O

Very RB O
- : O
long JJ O
- : O
chain NN O
acyl IN O
- : O
CoA NNP O
dehydrogenase NN O
( ( O
VLCAD NNP O
) ) O
is VBZ O
one CD O
of IN O
four CD O
straight JJ O
- : O
chain NN O
acyl IN O
- : O
CoA NNP O
dehydrogenase NN O
( ( O
ACD NNP O
) ) O
enzymes NNS O
, , O
which WDT O
are VBP O
all DT O
nuclear JJ O
encoded VBN O
mitochondrial JJ O
flavoproteins NNS O
catalyzing VBG O
the DT O
initial JJ O
step NN O
in IN O
fatty JJ O
acid NN O
beta SYM O
- : O
oxidation NN O
. . O

We PRP O
have VBP O
used VBN O
the DT O
very RB O
fast RB O
, , O
Rapid NNP O
Amplification NNP O
of IN O
cDNA NN O
Ends NNP O
( ( O
RACE NNP O
) ) O
based VBN O
strategy NN O
to TO O
obtain VB O
the DT O
sequence NN O
of IN O
cDNAs NN O
encoding VBG O
human JJ O
VLCAD NNP O
from IN O
placenta NN O
and CC O
fibroblasts NNS O
. . O

Alignment NN O
of IN O
the DT O
predicted VBN O
amino NN O
acid JJ O
sequence NN O
of IN O
human JJ O
VLCAD NNP O
with IN O
those DT O
of IN O
the DT O
other JJ O
human JJ O
ACD NNP O
enzymes NNS O
revealed VBD O
extensive JJ O
sequence NN O
homology NN O
. . O

Moreover RB O
, , O
human JJ O
VLCAD NNP O
and CC O
human JJ O
acyl NN O
- : O
CoA NNP O
oxidase NN O
showed VBD O
extensive JJ O
sequence NN O
homology NN O
corroborating VBG O
the DT O
notion NN O
that IN O
these DT O
genes NNS O
are VBP O
evolutionarily RB O
related VBN O
. . O

Southern NNP O
blot NN O
analysis NN O
of IN O
genomic JJ O
DNA NN O
from IN O
hybrid JJ O
cell NN O
lines NNS O
was VBD O
used VBN O
to TO O
localize VB O
the DT O
VLCAD NNP O
gene NN O
to TO O
human JJ O
chromosome NN O
17p11 CD O
. . O

2 CD O
- : O
p11 NN O
. . O

13105 CD O
. . O

Using VBG O
Northern NNP O
and CC O
Western NNP O
blot NN O
analysis NN O
to TO O
investigate VB O
the DT O
tissue NN O
specific JJ O
distribution NN O
of IN O
VLCAD NNP O
mRNA NN O
and CC O
protein NN O
in IN O
several JJ O
human JJ O
tissues NNS O
we PRP O
showed VBD O
that IN O
VLCAD NNP O
is VBZ O
most RBS O
abundant JJ O
in IN O
heart NN O
and CC O
skeletal JJ O
muscle NN O
. . O

This DT O
agrees VBZ O
well RB O
with IN O
the DT O
fact NN O
that IN O
cardiac NN O
and CC O
muscle NN O
symptoms NNS O
are VBP O
characteristic JJ O
for IN O
patients NNS O
with IN O
VLCAD NNP B-Disease
deficiency NN I-Disease
. . O

Northern NNP O
blot NN O
analysis NN O
and CC O
sequencing NN O
of IN O
cloned JJ O
PCR NNP O
amplified VBD O
VLCAD NNP O
cDNA NN O
from IN O
four CD O
unrelated JJ O
patients NNS O
with IN O
VLCAD NNP B-Disease
deficiency NN I-Disease
showed VBD O
that IN O
VLCAD NNP O
mRNA NN O
was VBD O
undetectable JJ O
in IN O
one CD O
patient NN O
and CC O
that IN O
the DT O
other JJ O
three CD O
have VBP O
mutations NNS O
in IN O
both DT O
VLCAD NNP O
alleles NNS O
. . O

Western JJ O
blot NN O
analysis NN O
of IN O
patient NN O
fibroblasts NNS O
showed VBD O
that IN O
the DT O
identified JJ O
mutations NNS O
result VBP O
in IN O
severely RB O
reduced JJ O
amounts NNS O
of IN O
VLCAD NNP O
protein NN O
. . O

Molecular JJ O
bases NNS O
of IN O
combined JJ B-Disease
subtotal JJ I-Disease
deficiencies NNS I-Disease
of IN I-Disease
C6 NNP I-Disease
and CC I-Disease
C7 NNP I-Disease
: : O
their PRP$ O
effects NNS O
in IN O
combination NN O
with IN O
other JJ O
C6 NNP B-Disease
and CC I-Disease
C7 NNP I-Disease
deficiencies NNS I-Disease
. . O

Combined VBN B-Disease
subtotal JJ I-Disease
deficiency NN I-Disease
of IN I-Disease
C6 NNP I-Disease
and CC I-Disease
C7 NNP I-Disease
, , O
in IN O
which WDT O
both DT O
proteins NNS O
are VBP O
expressed VBN O
at IN O
very RB O
low JJ O
levels NNS O
, , O
has VBZ O
been VBN O
observed VBN O
in IN O
homozygous JJ O
form NN O
in IN O
two CD O
families NNS O
. . O

A DT O
defect NN O
at IN O
the DT O
5 CD O
splice NN O
donor NN O
site NN O
of IN O
intron JJ O
15 CD O
of IN O
the DT O
C6 NNP O
gene NN O
explains VBZ O
the DT O
low JJ O
molecular JJ O
weight NN O
of IN O
the DT O
C6 NNP O
protein NN O
and CC O
is VBZ O
probably RB O
responsible JJ O
for IN O
its PRP$ O
low JJ O
expressed VBN O
concentration NN O
. . O

The DT O
C7 NNP O
defect NN O
is VBZ O
more RBR O
enigmatic JJ O
the DT O
protein NN O
is VBZ O
of IN O
normal JJ O
molecular JJ O
weight NN O
, , O
low JJ O
circulating VBG O
concentration NN O
, , O
and CC O
altered VBD O
isoelectric JJ O
point NN O
. . O

An DT O
Arg NNP O
> NNP O
Ser NNP O
codon NN O
substitution NN O
in IN O
exon JJ O
11 CD O
is VBZ O
the DT O
only JJ O
molecular JJ O
alteration NN O
within IN O
the DT O
mature NN O
C7 NNP O
protein NN O
. . O

These DT O
defects NNS O
are VBP O
associated VBN O
with IN O
a DT O
characteristic JJ O
set NN O
of IN O
polymorphic JJ O
DNA NNP O
markers NNS O
in IN O
the DT O
C6 NNP O
/ NNP O
C7 NNP O
region NN O
, , O
forming VBG O
a DT O
distinct JJ O
haplotype NN O
. . O

The DT O
haplotype NN O
has VBZ O
been VBN O
found VBN O
in IN O
combination NN O
with IN O
a DT O
number NN O
of IN O
other JJ O
haplotypes NNS O
containing VBG O
defective JJ O
genes NNS O
that WDT O
lead VBP O
either DT O
to TO O
C6 NNP B-Disease
or CC I-Disease
C7 NNP I-Disease
deficiency NN I-Disease
, , O
but CC O
with IN O
different JJ O
consequences NNS O
. . O

Where WRB O
it PRP O
is VBZ O
combined VBN O
with IN O
a DT O
C6 NNP B-Disease
- : I-Disease
deficient NN I-Disease
gene NN O
, , O
the DT O
serum NN O
C7 NNP O
levels NNS O
can MD O
be VB O
surprisingly RB O
high JJ O
, , O
possibly RB O
because IN O
there EX O
is VBZ O
no DT O
C6 NNP O
generating VBG O
C56 NNP O
to TO O
consume VB O
the DT O
C7 NNP O
. . O

In IN O
contrast NN O
, , O
where WRB O
the DT O
C7 NNP O
genes NNS O
are VBP O
both DT O
defective JJ O
( ( O
but CC O
still RB O
partially RB O
functional JJ O
) ) O
, , O
there EX O
may MD O
be VB O
a DT O
profound JJ O
deficit NN O
of IN O
circulating VBG O
C7 NNP O
because IN O
there EX O
is VBZ O
ample JJ O
C6 NNP O
to TO O
produce VB O
C56 NNP O
and CC O
consume VB O
the DT O
already RB O
small JJ O
amount NN O
of IN O
C7 NNP O
. . O

Each DT O
molecular JJ O
defect NN O
has VBZ O
also RB O
been VBN O
found VBN O
in IN O
isolation NN O
and CC O
has VBZ O
the DT O
expected VBN O
effect NN O
. . O
. . O

Genetic JJ O
bases NNS O
of IN O
human JJ O
complement NN B-Disease
C7 NNP I-Disease
deficiency NN I-Disease
. . O

Complement NNP B-Disease
C7 NNP I-Disease
deficiency NN I-Disease
( ( O
C7D NNP B-Disease
) ) O
is VBZ O
associated VBN O
frequently RB O
with IN O
recurrent JJ O
bacterial JJ B-Disease
infections NNS I-Disease
, , O
especially RB O
meningitis NNS B-Disease
caused VBN O
by IN O
Neisseria NNP B-Disease
meningitidis NN I-Disease
. . O

We PRP O
report VBP O
in IN O
this DT O
work NN O
the DT O
molecular JJ O
bases NNS O
of IN O
C7D NNP B-Disease
in IN O
two CD O
unrelated JJ O
Japanese JJ O
males NNS O
. . O

We PRP O
used VBD O
exon SYM O
- : O
specific JJ O
PCR NNP O
/ NNP O
single JJ O
- : O
strand NN O
conformation NN O
polymorphism NN O
analysis NN O
as IN O
a DT O
screening JJ O
step NN O
for IN O
mutations NNS O
. . O

Subsequent JJ O
direct JJ O
sequencing NN O
of IN O
the DT O
target NN O
exons NNS O
identified VBN O
homozygous JJ O
mutations NNS O
in IN O
exon JJ O
16 CD O
of IN O
case NN O
1 CD O
and CC O
in IN O
exon JJ O
15 CD O
of IN O
case NN O
2 CD O
. . O

The DT O
mutation NN O
of IN O
case NN O
1 CD O
was VBD O
a DT O
homozygous JJ O
T NNP O
to TO O
A DT O
transversion NN O
at IN O
nucleotide JJ O
2250 CD O
, , O
the DT O
third JJ O
nucleotide NN O
of IN O
the DT O
codon NN O
TGT NNP O
for IN O
Cys728 NNP O
, , O
leading VBG O
to TO O
a DT O
stop JJ O
codon NN O
TGA NNP O
( ( O
C728X NNP O
) ) O
. . O

In IN O
case NN O
2 CD O
, , O
a DT O
homozygous JJ O
2 CD O
- : O
bp NN O
deletion NN O
( ( O
2137delTG CD O
/ RB O
2138delGT CD O
/ JJ O
2139delTG CD O
) ) O
caused VBD O
a DT O
frameshift NN O
, , O
generating VBG O
a DT O
premature NN O
termination NN O
codon VBZ O
4 CD O
to TO O
6 CD O
nucleotides NNS O
downstream NN O
. . O

Family RB O
study NN O
in IN O
case NN O
1 CD O
confirmed VBD O
the DT O
genetic JJ O
nature NN O
of IN O
the DT O
defect NN O
. . O

Moreover RB O
, , O
we PRP O
detected VBD O
a DT O
novel JJ O
polymorphism NN O
in IN O
intron NN O
11 CD O
that IN O
presumably NN O
is VBZ O
linked VBN O
to TO O
the DT O
mutation NN O
responsible JJ O
for IN O
C7D NNP B-Disease
in IN O
case NN O
1 CD O
. . O

Our PRP$ O
results NNS O
indicate VBP O
that IN O
the DT O
pathogenesis NN O
of IN O
C7D NNP B-Disease
is VBZ O
heterogeneous JJ O
like IN O
most JJS O
of IN O
the DT O
other JJ O
deficiencies NNS B-Disease
of IN I-Disease
complement JJ I-Disease
components NNS I-Disease
. . O
. . O

HPRT NNP B-Disease
- : I-Disease
APRT NNP I-Disease
- : I-Disease
deficient NN I-Disease
mice NNS O
are VBP O
not RB O
a DT O
model NN O
for IN O
lesch JJ B-Disease
- : I-Disease
nyhan JJ I-Disease
syndrome NN I-Disease
. . O

Complete JJ B-Disease
hypoxanthine NN I-Disease
- : I-Disease
guanine NN I-Disease
phosphoribosyl NN I-Disease
- : I-Disease
transferase NN I-Disease
( ( I-Disease
HPRT NNP I-Disease
) ) I-Disease
deficiency NN I-Disease
in IN O
humans NNS O
results NNS O
in IN O
the DT O
Lesch NNP B-Disease
- : I-Disease
Nyhan NNP I-Disease
syndrome NN I-Disease
which WDT O
is VBZ O
characterized VBN O
, , O
among IN O
other JJ O
features NNS O
, , O
by IN O
compulsive JJ O
self NN O
- : O
injurious JJ O
behavior NN O
. . O

HPRT NNP B-Disease
- : I-Disease
deficient NN I-Disease
mice NN O
generated VBD O
using VBG O
mouse NN O
embryonic JJ O
stem NN O
cells NNS O
exhibit VBP O
none NN O
of IN O
the DT O
behavioral JJ O
symptoms NNS O
associated VBN O
with IN O
the DT O
Lesch NNP B-Disease
- : I-Disease
Nyhan NNP I-Disease
syndrome NN I-Disease
. . O

Administration NN O
of IN O
drugs NNS O
that WDT O
inhibit VBP O
adenine JJ O
phosphoribosyltransferase NN O
( ( O
APRT NNP O
) ) O
in IN O
HPRT NNP B-Disease
- : I-Disease
deficient NN I-Disease
mice NN O
has VBZ O
produced VBN O
the DT O
suggestion NN O
that IN O
deficiency NN B-Disease
of IN I-Disease
APRT NNP I-Disease
in IN O
combination NN O
with IN O
HPRT NNP B-Disease
- : I-Disease
deficiency NN I-Disease
in IN O
mice NN O
may MD O
lead VB O
to TO O
self VB O
- : O
mutilation NN O
behavior NN O
[ NNP O
C NNP O
. . O
L NNP O
. . O
Wu NNP O
and CC O
D NNP O
. . O
W NNP O
. . O
Melton NNP O
( ( O
1993 CD O
) ) O
Nature NN O
Genet NNP O
. . O
3 CD O
, , O
235 CD O
- : O
240 CD O
] NN O
. . O

To TO O
test VB O
this DT O
proposition NN O
, , O
we PRP O
bred VBD O
HPRT NNP B-Disease
- : I-Disease
APRT NNP I-Disease
- : I-Disease
deficient NN I-Disease
mice NN O
. . O

Although IN O
the DT O
doubly RB O
- : O
deficient NN O
mice NN O
excrete JJ O
adenine NN O
and CC O
its PRP$ O
highly RB O
insoluble JJ O
derivative NN O
, , O
2 CD O
, , O
8 CD O
- : O
dihydroxyadenine NN O
, , O
which WDT O
are VBP O
also RB O
associated VBN O
with IN O
human JJ O
APRT NNP B-Disease
deficiency NN I-Disease
, , O
additional JJ O
abnormalities NNS O
or CC O
any DT O
self JJ O
- : O
injurious JJ O
behavior NN O
were VBD O
not RB O
detected VBN O
. . O

Thus RB O
, , O
APRT NNP B-Disease
- : I-Disease
HPRT NNP I-Disease
- : I-Disease
deficient NN I-Disease
mice NN O
, , O
which WDT O
are VBP O
devoid NNS O
of IN O
any DT O
purine JJ O
salvage NN O
pathways NNS O
, , O
show VBP O
no DT O
novel JJ O
phenotype NN O
and CC O
are VBP O
not RB O
a DT O
model NN O
for IN O
the DT O
behavioral JJ B-Disease
abnormalities NNS I-Disease
associated VBN O
with IN O
the DT O
Lesch NNP B-Disease
- : I-Disease
Nyhan NNP I-Disease
syndrome NN I-Disease
as IN O
previously RB O
suggested VBN O

Somatic JJ O
alterations NNS O
of IN O
the DT O
DPC4 NNP O
gene NN O
in IN O
human JJ O
colorectal NN B-Disease
cancers NNS I-Disease
in IN O
vivo NN O
. . O

BACKGROUND NNP O
& CC O
AIMS NNP O
The DT O
chromosome NN O
region NN O
18q21 CD O
has VBZ O
been VBN O
shown VBN O
to TO O
be VB O
frequently RB O
deleted VBN O
in IN O
colorectal JJ B-Disease
cancers NNS I-Disease
, , O
and CC O
such JJ O
frequent JJ O
allelic JJ O
loss NN O
is VBZ O
a DT O
hallmark NN O
of IN O
the DT O
presence NN O
of IN O
a DT O
tumor NN O
- : O
suppressor NN O
gene NN O
. . O

The DT O
DPC4 NNP O
gene NN O
, , O
which WDT O
is VBZ O
located VBN O
at IN O
18q21 CD O
, , O
has VBZ O
been VBN O
identified VBN O
as IN O
a DT O
tumor NN O
- : O
suppressor NN O
gene NN O
from IN O
examination NN O
of IN O
pancreatic JJ B-Disease
cancers NNS I-Disease
. . O

The DT O
aim NN O
of IN O
the DT O
present JJ O
study NN O
was VBD O
to TO O
determine VB O
if IN O
it PRP O
might MD O
also RB O
be VB O
altered VBN O
in IN O
colorectal JJ B-Disease
cancers NNS I-Disease
. . O

METHODS NNP O
Mutation NNP O
analyses NNS O
of IN O
the DT O
DPC4 NNP O
gene NN O
were VBD O
performed VBN O
on IN O
complementary JJ O
DNA NN O
samples NNS O
from IN O
31 CD O
primary JJ O
colorectal JJ B-Disease
cancer NN I-Disease
specimens VBZ O
using VBG O
a DT O
combination NN O
of IN O
polymerase NN O
chain NN O
reaction NN O
, , O
single JJ O
- : O
strand NN O
conformation NN O
polymorphism NN O
, , O
and CC O
DNA NNP O
sequencing NN O
. . O

RESULTS NNP O
Four NNP O
missense NN O
mutations NNS O
producing VBG O
amino NN O
acid JJ O
substitutions NNS O
and CC O
a DT O
somatic JJ O
12 CD O
- : O
base NN O
pair NN O
deletion NN O
in IN O
the DT O
coding JJ O
region NN O
of IN O
the DT O
DPC4 NNP O
gene NN O
were VBD O
detected VBN O
in IN O
the DT O
31 CD O
cancers NNS B-Disease
( ( O
16 CD O
% NN O
; : O
5 CD O
of IN O
31 CD O
) ) O
. . O

CONCLUSIONS NNP O
The DT O
DPC4 NNP O
gene NN O
may MD O
play VB O
a DT O
role NN O
as IN O
a DT O
tumor NN O
- : O
suppressor NN O
gene NN O
in IN O
a DT O
fraction NN O
of IN O
colorectal JJ B-Disease
cancers NNS I-Disease
; : O
however RB O
, , O
while IN O
allelic JJ O
loss NN O
at IN O
18q21 CD O
is VBZ O
very RB O
often RB O
seen VBN O
in IN O
colorectal JJ B-Disease
cancers NNS I-Disease
, , O
only RB O
a DT O
minority NN O
show NN O
DPC4 NNP O
mutations NNS O
, , O
suggesting VBG O
that IN O
there EX O
might MD O
be VB O
another DT O
tumor NN O
- : O
suppressor NN O
gene NN O
in IN O
this DT O
chromosome NN O
region NN O
. . O
. . O

Pleiotropic NNP O
defects NNS O
in IN O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
protein SYM O
- : O
deficient NN O
mice NN O
. . O

We PRP O
have VBP O
generated VBN O
a DT O
mouse NN O
model NN O
for IN O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
by IN O
using VBG O
gene NN O
targeting VBG O
to TO O
generate VB O
mice NN O
that WDT O
do VBP O
not RB O
express VB O
the DT O
Atm NNP O
protein NN O
. . O

Atm NNP O
- : O
deficient NN O
mice NN O
are VBP O
retarded VBN O
in IN O
growth NN O
, , O
do VBP O
not RB O
produce VB O
mature JJ O
sperm NN O
, , O
and CC O
exhibit NN O
severe JJ O
defects NNS O
in IN O
T NNP O
cell NN O
maturation NN O
while IN O
going VBG O
on IN O
to TO O
develop VB O
thymomas NN B-Disease
. . O

Atm NNP O
- : O
deficient NN O
fibroblasts NNS O
grow VBP O
poorly RB O
in IN O
culture NN O
and CC O
display VB O
a DT O
high JJ O
level NN O
of IN O
double JJ O
- : O
stranded VBD O
chromosome NN O
breaks NNS O
. . O

Atm NNP O
- : O
deficient NN O
thymocytes VBZ O
undergo RB O
spontaneous JJ O
apoptosis NN O
in IN O
vitro NN O
significantly RB O
more RBR O
than IN O
controls NNS O
. . O

Atm NNP O
- : O
deficient NN O
mice NN O
then RB O
exhibit VBD O
many JJ O
of IN O
the DT O
same JJ O
symptoms NNS O
found VBN O
in IN O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
patients NNS O
and CC O
in IN O
cells NNS O
derived VBN O
from IN O
them PRP O
. . O

Furthermore RB O
, , O
we PRP O
demonstrate VBP O
that IN O
the DT O
Atm NNP O
protein NN O
exists VBZ O
as IN O
two CD O
discrete JJ O
molecular JJ O
species NNS O
, , O
and CC O
that IN O
loss NN O
of IN O
one CD O
or CC O
of IN O
both DT O
of IN O
these DT O
can MD O
lead VB O
to TO O
the DT O
development NN O
of IN O
the DT O
disease NN O
. . O
. . O

The DT O
DCC NNP O
protein NN O
and CC O
prognosis NN O
in IN O
colorectal JJ B-Disease
cancer NN I-Disease
. . O

BACKGROUND NNP O
Allelic NNP O
loss NN O
of IN O
chromosome NN O
18q CD O
predicts VBZ O
a DT O
poor JJ O
outcome NN O
in IN O
patients NNS O
with IN O
stage NN B-Disease
II NNP I-Disease
colorectal NN I-Disease
cancer NN I-Disease
. . O

Although IN O
the DT O
specific JJ O
gene NN O
inactivated VBN O
by IN O
this DT O
allelic JJ O
loss NN O
has VBZ O
not RB O
been VBN O
elucidated VBN O
, , O
the DT O
DCC NNP O
( ( O
deleted VBN O
in IN O
colorectal JJ B-Disease
cancer NN I-Disease
) ) O
gene NN O
is VBZ O
a DT O
candidate NN O
. . O

We PRP O
investigated VBD O
whether IN O
the DT O
expression NN O
of IN O
the DT O
DCC NNP O
protein NN O
in IN O
tumor NN B-Disease
cells NNS O
is VBZ O
a DT O
prognostic JJ O
marker NN O
in IN O
colorectal JJ B-Disease
carcinoma NN I-Disease
. . O

METHODS NNP O
The DT O
expression NN O
of IN O
DCC NNP O
was VBD O
evaluated VBN O
immunohistochemically RB O
in IN O
132 CD O
paraffin NN O
- : O
embedded VBD O
samples NNS O
from IN O
patients NNS O
with IN O
curatively RB O
resected VBN O
stage NN B-Disease
II NNP I-Disease
and CC I-Disease
III NNP I-Disease
colorectal JJ I-Disease
carcinomas NN I-Disease
. . O

The DT O
Cox NNP O
proportional JJ O
- : O
hazards NNS O
model NN O
was VBD O
used VBN O
to TO O
adjust VB O
for IN O
covariates NNS O
including VBG O
age NN O
, , O
sex NN O
, , O
tumor NN B-Disease
site NN O
, , O
degree NN O
of IN O
tumor NN B-Disease
differentiation NN O
, , O
and CC O
use NN O
of IN O
adjuvant JJ O
therapy NN O
. . O

RESULTS VB O
The DT O
expression NN O
of IN O
DCC NNP O
was VBD O
a DT O
strong JJ O
positive JJ O
predictive JJ O
factor NN O
for IN O
survival NN O
in IN O
both DT O
stage NN B-Disease
II NNP I-Disease
and CC I-Disease
stage NN I-Disease
III NNP I-Disease
colorectal JJ I-Disease
carcinomas NN I-Disease
. . O

In IN O
patients NNS O
with IN O
stage NN O
II NNP O
disease NN O
whose WP$ O
tumors NNS B-Disease
expressed VBD O
DCC NNP O
, , O
the DT O
five CD O
- : O
year NN O
survival NN O
rate NN O
was VBD O
94 CD O
. . O

3 CD O
percent NN O
, , O
whereas NNS O
in IN O
patients NNS O
with IN O
DCC NNP B-Disease
- : I-Disease
negative JJ I-Disease
tumors NNS I-Disease
, , O
the DT O
survival NN O
rate NN O
was VBD O
61 CD O
. . O

6 CD O
percent NN O
( ( O
P NNP O
< VBZ O
0 CD O
. . O
1 CD O
) ) O
. . O

In IN O
patients NNS O
with IN O
stage NN B-Disease
III NNP I-Disease
disease NN I-Disease
, , O
the DT O
respective JJ O
survival NN O
rates NNS O
were VBD O
59 CD O
. . O

3 CD O
percent NN O
and CC O
33 CD O
. . O

2 CD O
percent NN O
( ( O
P NNP O
= VBZ O
0 CD O
. . O
3 CD O
) ) O
. . O

CONCLUSIONS NNP O
DCC NNP O
is VBZ O
a DT O
prognostic JJ O
marker NN O
in IN O
patients NNS O
with IN O
stage NN B-Disease
II NNP I-Disease
or CC I-Disease
stage NN I-Disease
III NNP I-Disease
colorectal JJ I-Disease
cancer NN I-Disease
. . O

In IN O
stage NN B-Disease
II NNP I-Disease
colorectal NN I-Disease
carcinomas NN I-Disease
, , O
the DT O
absence NN O
of IN O
DCC NNP O
identifies VBZ O
a DT O
subgroup NN O
of IN O
patients NNS O
with IN O
lesions NNS O
that WDT O
behave VBP O
like IN O
stage NN B-Disease
III NNP I-Disease
cancers NNS I-Disease
. . O

These DT O
findings NNS O
may MD O
thus RB O
have VB O
therapeutic JJ O
implications NNS O
in IN O
this DT O
group NN O
of IN O
patients NNS O

Association NNP O
of IN O
anxiety NN B-Disease
- : I-Disease
related JJ I-Disease
traits NNS I-Disease
with IN O
a DT O
polymorphism NN O
in IN O
the DT O
serotonin NN O
transporter NN O
gene NN O
regulatory JJ O
region NN O
. . O

Transporter NNP O
- : O
facilitated VBD O
uptake NN O
of IN O
serotonin NN O
( ( O
5 CD O
- : O
hydroxytryptamine NN O
or CC O
5 CD O
- : O
HT NN O
) ) O
has VBZ O
been VBN O
implicated VBN O
in IN O
anxiety NN B-Disease
in IN O
humans NNS O
and CC O
animal JJ O
models NNS O
and CC O
is VBZ O
the DT O
site NN O
of IN O
action NN O
of IN O
widely RB O
used VBN O
uptake JJ O
- : O
inhibiting NN O
antidepressant NN O
and CC O
antianxiety NN O
drugs NNS O
. . O

Human NNP O
5 CD O
- : O
HT NN O
transporter NN O
( ( O
5 CD O
- : O
HTT NN O
) ) O
gene NN O
transcription NN O
is VBZ O
modulated VBN O
by IN O
a DT O
common JJ O
polymorphism NN O
in IN O
its PRP$ O
upstream JJ O
regulatory JJ O
region NN O
. . O

The DT O
short JJ O
variant NN O
of IN O
the DT O
polymorphism NN O
reduces VBZ O
the DT O
transcriptional JJ O
efficiency NN O
of IN O
the DT O
5 CD O
- : O
HTT NNP O
gene NN O
promoter NN O
, , O
resulting VBG O
in IN O
decreased JJ O
5 CD O
- : O
HTT NNP O
expression NN O
and CC O
5 CD O
- : O
HT NNP O
uptake VBP O
in IN O
lymphoblasts NNS O
. . O

Association NNP O
studies NNS O
in IN O
two CD O
independent JJ O
samples NNS O
totaling VBG O
505 CD O
individuals NNS O
revealed VBD O
that IN O
the DT O
5 CD O
- : O
HTT NNP O
polymorphism NN O
accounts NNS O
for IN O
3 CD O
to TO O
4 CD O
percent NN O
of IN O
total JJ O
variation NN O
and CC O
7 CD O
to TO O
9 CD O
percent NN O
of IN O
inherited JJ O
variance NN O
in IN O
anxiety NN B-Disease
- : I-Disease
related JJ I-Disease
personality NN I-Disease
traits NNS I-Disease
in IN O
individuals NNS O
as RB O
well RB O
as IN O
sibships NNS O
. . O
. . O

Phenotypic NNP O
and CC O
genotypic VB O
overlap NN O
between IN O
atelosteogenesis NN B-Disease
type NN I-Disease
2 CD I-Disease
and CC O
diastrophic JJ B-Disease
dysplasia NN I-Disease
. . O

Mutations NNS O
in IN O
the DT O
diastrophic JJ B-Disease
dysplasia NN I-Disease
sulfate NN O
transporter NN O
gene NN O
DTDST NNP O
have VBP O
been VBN O
associated VBN O
with IN O
a DT O
family NN O
of IN O
chondrodysplasias NN B-Disease
that WDT O
comprises VBZ O
, , O
in IN O
order NN O
of IN O
increasing VBG O
severity NN O
, , O
diastrophic JJ B-Disease
dysplasia NN I-Disease
( ( O
DTD NNP B-Disease
) ) O
, , O
atelosteogenesis NN B-Disease
type NN I-Disease
2 CD I-Disease
( ( O
AO2 NNP B-Disease
) ) O
, , O
and CC O
achondrogenesis NN B-Disease
type NN I-Disease
1B CD I-Disease
( ( O
ACG1B NNP B-Disease
) ) O
. . O

To TO O
learn VB O
more JJR O
about IN O
the DT O
molecular JJ O
basis NN O
of IN O
DTDST NNP B-Disease
chondrodysplasias NN I-Disease
and CC O
about IN O
genotype JJ O
- : O
phenotype NN O
correlations NNS O
, , O
we PRP O
studied VBD O
fibroblast JJ O
cultures NNS O
of IN O
three CD O
new JJ O
patients NNS O
one CD O
with IN O
AO NNP B-Disease
- : I-Disease
2 CD I-Disease
, , O
one CD O
with IN O
DTD NNP B-Disease
, , O
and CC O
one CD O
with IN O
an DT O
intermediate JJ O
phenotype NN O
( ( O
AO2 NNP B-Disease
/ NNP O
DTD NNP B-Disease
) ) O
. . O

Reduced VBN O
incorporation NN O
of IN O
inorganic JJ O
sulfate NN O
into IN O
macromolecules NNS O
was VBD O
found VBN O
in IN O
all DT O
three CD O
. . O

Each DT O
of IN O
the DT O
three CD O
patients NNS O
was VBD O
found VBN O
to TO O
be VB O
heterozygous JJ O
for IN O
a DT O
c862t JJ O
transition NN O
predicting VBG O
a DT O
R279W NNP O
substitution NN O
in IN O
the DT O
third JJ O
extracellular JJ O
loop NN O
of IN O
DTDST NNP O
. . O

In IN O
two CD O
patients NNS O
( ( O
DTD NNP B-Disease
and CC O
AO2 NNP B-Disease
/ NNP O
DTD NNP B-Disease
) ) O
, , O
no DT O
other JJ O
structural JJ O
mutation NN O
was VBD O
found VBN O
, , O
but CC O
polymerase NN O
chain NN O
reaction NN O
amplification NN O
and CC O
single JJ O
- : O
strand NN O
conformation NN O
polymorphism NN O
analysis NN O
of IN O
fibroblast NN O
cDNA NN O
showed VBD O
reduced VBN O
mRNA NN O
levels NNS O
of IN O
the DT O
wild JJ O
- : O
type NN O
DTDST NNP O
allele IN O
these DT O
two CD O
patients NNS O
may MD O
be VB O
compound VBN O
heterozygotes NNS O
for IN O
the DT O
"""" NNP O
Finnish NNP O
"""" NNP O
mutation NN O
( ( O
as IN O
yet RB O
uncharacterized VBN O
at IN O
the DT O
DNA NNP O
level NN O
) ) O
, , O
which WDT O
causes VBZ O
reduced JJ O
expression NN O
of IN O
DTDST NNP O
. . O

The DT O
third JJ O
patient NN O
( ( O
with IN O
AO2 NNP B-Disease
) ) O
had VBD O
the DT O
R279W NNP O
mutation NN O
compounded VBD O
with IN O
a DT O
novel JJ O
mutation NN O
, , O
the DT O
deletion NN O
of IN O
cytosine NN O
418 CD O
( ( O
delta JJ O
c418 NN O
) ) O
, , O
predicting VBG O
a DT O
frameshift NN O
with IN O
premature JJ O
termination NN O
. . O

Also RB O
the DT O
delta NN O
c418 NN O
allele NN O
was VBD O
underrepresented VBN O
in IN O
the DT O
cDNA NN O
, , O
in IN O
accordance NN O
with IN O
previous JJ O
observations NNS O
that IN O
premature NN O
stop VB O
codons NNS O
reduce VB O
mRNA NN O
levels NNS O
. . O

The DT O
presence NN O
of IN O
the DT O
DTDST NNP O
R279W NNP O
mutation NN O
in IN O
a DT O
total NN O
of IN O
11 CD O
patients NNS O
with IN O
AO2 NNP B-Disease
or CC O
DTD NNP B-Disease
emphasizes VBZ O
the DT O
overlap NN O
between IN O
these DT O
conditions NNS O
. . O

This DT O
mutation NN O
has VBZ O
not RB O
been VBN O
found VBN O
so RB O
far RB O
in IN O
8 CD O
analyzed JJ O
ACG1B NNP B-Disease
patients NNS O
, , O
suggesting VBG O
that IN O
it PRP O
allows VBZ O
some DT O
residual JJ O
activity NN O
of IN O
the DT O
sulfate NN O
transporter NN O
. . O
. . O

Identification NN O
of IN O
WASP NNP O
mutations NNS O
, , O
mutation NN O
hotspots NNS O
and CC O
genotype JJ O
- : O
phenotype NN O
disparities NNS O
in IN O
24 CD O
patients NNS O
with IN O
the DT O
Wiskott NNP B-Disease
- : I-Disease
Aldrich NNP I-Disease
syndrome NN I-Disease
. . O

The DT O
Wiskott NNP B-Disease
- : I-Disease
Aldrich NNP I-Disease
syndrome NN I-Disease
( ( O
WAS NNP B-Disease
) ) O
, , O
an DT O
X NNP B-Disease
- : I-Disease
linked VBN I-Disease
immunodeficiency NN I-Disease
disease NN I-Disease
caused VBN O
by IN O
mutation NN O
in IN O
the DT O
recently RB O
isolated VBN O
gene NN O
encoding VBG O
WAS NNP B-Disease
protein NN O
( ( O
WASP NNP O
) ) O
, , O
is VBZ O
known VBN O
to TO O
be VB O
associated VBN O
with IN O
extensive JJ O
clinical JJ O
heterogeneity NN O
. . O

Cumulative JJ O
mutation NN O
data NNS O
have VBP O
revealed VBN O
that IN O
WASP NNP O
genotypes NNS O
are VBP O
also RB O
highly RB O
variable JJ O
among IN O
WAS JJ B-Disease
patients NNS O
, , O
but CC O
the DT O
relationship NN O
of IN O
phenotype NN O
with IN O
genotype NN O
in IN O
this DT O
disease NN O
remains VBZ O
unclear JJ O
. . O

To TO O
address VB O
this DT O
issue NN O
we PRP O
characterized VBD O
WASP NNP O
mutations NNS O
in IN O
24 CD O
unrelated JJ O
WAS NNP B-Disease
patients NNS O
, , O
including VBG O
18 CD O
boys NNS O
with IN O
severe JJ O
classical NN O
WAS NNP B-Disease
and CC O
6 CD O
boys NNS O
expressing VBG O
mild JJ O
forms NNS O
of IN O
the DT O
disease NN O
, , O
and CC O
then RB O
examined VBD O
the DT O
degree NN O
of IN O
correlation NN O
of IN O
these DT O
as RB O
well RB O
as IN O
all DT O
previously RB O
published VBN O
WASP NNP O
mutations NNS O
with IN O
disease NN O
severity NN O
. . O

By IN O
analysis NN O
of IN O
these DT O
compiled VBN O
mutation NN O
data NNS O
, , O
we PRP O
demonstrated VBD O
clustering VBG O
of IN O
WASP NNP O
mutations NNS O
within IN O
the DT O
four CD O
most JJS O
N NNP O
- : O
terminal JJ O
exons NNS O
of IN O
the DT O
gene NN O
and CC O
also RB O
identified VBD O
several JJ O
sites NNS O
within IN O
this DT O
region NN O
as IN O
hotspots NNS O
for IN O
WASP NNP O
mutation NN O
. . O

These DT O
characteristics NNS O
were VBD O
observed VBN O
, , O
however RB O
, , O
in IN O
both DT O
severe JJ O
and CC O
mild JJ O
cases NNS O
of IN O
the DT O
disease NN O
. . O

Similarly RB O
, , O
while IN O
the DT O
cumulative JJ O
data NNS O
revealed VBD O
a DT O
predominance NN O
of IN O
missense JJ O
mutations NNS O
among IN O
the DT O
WASP NNP O
gene NN O
lesions NNS O
observed VBN O
in IN O
boys NNS O
with IN O
isolated JJ B-Disease
thrombocytopenia NN I-Disease
, , O
missense JJ O
mutations NNS O
were VBD O
not RB O
exclusively RB O
associated VBN O
with IN O
milder NN O
WAS NNP B-Disease
phenotypes NNS O
, , O
but CC O
also RB O
comprised VBD O
a DT O
substantial JJ O
portion NN O
( ( O
38 CD O
% NN O
) ) O
of IN O
the DT O
WASP NNP O
gene NN O
defects NNS O
found VBN O
in IN O
patients NNS O
with IN O
severe JJ O
disease NN O
. . O

These DT O
findings NNS O
, , O
as RB O
well RB O
as IN O
the DT O
detection NN O
of IN O
identical JJ O
WASP NNP O
mutations NNS O
in IN O
patients NNS O
with IN O
disparate JJ O
phenotypes NNS O
, , O
reveal VB O
a DT O
lack NN O
of IN O
phenotype JJ O
concordance NN O
with IN O
genotype NN O
in IN O
WAS NNP B-Disease
and CC O
thus RB O
imply VB O
that DT O
phenotypic NN O
outcome NN O
in IN O
this DT O
disease NN O
cannot NN O
be VB O
reliably RB O
predicted VBN O
solely RB O
on IN O
the DT O
basis NN O
of IN O
WASP NNP O
genotypes NNS O
. . O
. . O

Germline NNP O
mutations NNS O
in IN O
the DT O
3 CD O
' POS O
part NN O
of IN O
APC NNP B-Disease
exon FW O
15 CD O
do VBP O
not RB O
result VB O
in IN O
truncated JJ O
proteins NNS O
and CC O
are VBP O
associated VBN O
with IN O
attenuated JJ O
adenomatous JJ B-Disease
polyposis NN I-Disease
coli NN I-Disease
. . O

Familial NNP B-Disease
adenomatous JJ I-Disease
polyposis NN I-Disease
( ( O
FAP NNP B-Disease
) ) O
is VBZ O
an DT O
inherited JJ O
predisposition NN O
to TO O
colorectal JJ B-Disease
cancer NN I-Disease
characterized VBN O
by IN O
the DT O
development NN O
of IN O
numerous JJ O
adenomatous JJ B-Disease
polyps NNS I-Disease
predominantly RB O
in IN O
the DT O
colorectal JJ O
region NN O
. . O

Germline NNP O
mutations NNS O
in IN O
the DT O
adenomatous JJ B-Disease
polyposis NN I-Disease
coli NN I-Disease
( ( O
APC NNP B-Disease
) ) O
gene NN O
are VBP O
responsible JJ O
for IN O
most JJS O
cases NNS O
of IN O
FAP NNP B-Disease
. . O

Mutations NNS O
at IN O
the DT O
5 CD O
end NN O
of IN O
APC NNP B-Disease
are VBP O
known VBN O
to TO O
be VB O
associated VBN O
with IN O
a DT O
relatively RB O
mild JJ O
form NN O
of IN O
the DT O
disease NN O
, , O
called VBN O
attenuated VBD B-Disease
adenomatous JJ I-Disease
polyposis NN I-Disease
coli NN I-Disease
( ( O
AAPC NNP B-Disease
) ) O
. . O

We PRP O
identified VBD O
a DT O
frameshift JJ O
mutation NN O
in IN O
the DT O
3 CD O
part NN O
of IN O
exon NN O
15 CD O
, , O
resulting VBG O
in IN O
a DT O
stop JJ O
codon NN O
at IN O
1862 CD O
, , O
in IN O
a DT O
large JJ O
Dutch NN O
kindred VBD O
with IN O
AAPC NNP B-Disease
. . O

Western JJ O
blot NN O
analysis NN O
of IN O
lymphoblastoid NN O
cell NN O
lines NNS O
derived VBN O
from IN O
affected JJ O
family NN O
members NNS O
from IN O
this DT O
kindred VBN O
, , O
as RB O
well RB O
as IN O
from IN O
a DT O
previously RB O
reported VBN O
Swiss JJ O
family NN O
carrying VBG O
a DT O
frameshift NN O
mutation NN O
at IN O
codon NN O
1987 CD O
and CC O
displaying VBG O
a DT O
similar JJ O
attenuated JJ O
phenotype NN O
, , O
showed VBD O
only RB O
the DT O
wild JJ O
- : O
type NN O
APC NNP B-Disease
protein NN O
. . O

Our PRP$ O
study NN O
indicates VBZ O
that IN O
chain NN O
- : O
terminating NN O
mutations NNS O
located VBN O
in IN O
the DT O
3 CD O
part NN O
of IN O
APC NNP B-Disease
do VBP O
not RB O
result VB O
in IN O
detectable JJ O
truncated JJ O
polypeptides NNS O
and CC O
we PRP O
hypothesize VBP O
that IN O
this DT O
is VBZ O
likely JJ O
to TO O
be VB O
the DT O
basis NN O
for IN O
the DT O
observed JJ O
AAPC NNP B-Disease
phenotype NN O
. . O
. . O

Complete JJ O
genomic JJ O
sequence NN O
and CC O
analysis NN O
of IN O
117 CD O
kb NN O
of IN O
human JJ O
DNA NNP O
containing VBG O
the DT O
gene NN O
BRCA1 NNP O
. . O

Over IN O
100 CD O
distinct JJ O
disease NN O
- : O
associated VBN O
mutations NNS O
have VBP O
been VBN O
identified VBN O
in IN O
the DT O
breast NN B-Disease
- : I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
susceptibility NN O
gene NN O
BRCA1 NNP O
. . O

Loss NNP O
of IN O
the DT O
wild JJ O
- : O
type NN O
allele NN O
in IN O
> JJ O
90 CD O
% NN O
of IN O
tumors NNS B-Disease
from IN O
patients NNS O
with IN O
inherited JJ O
BRCA1 NNP O
mutations NNS O
indicates VBZ O
tumor JJ B-Disease
suppressive JJ O
function NN O
. . O

The DT O
low JJ O
incidence NN O
of IN O
somatic JJ O
mutations NNS O
suggests VBZ O
that IN O
BRCA1 NNP O
inactivation NN O
in IN O
sporadic JJ O
tumors NNS B-Disease
occurs VBN O
by IN O
alternative JJ O
mechanisms NNS O
, , O
such JJ O
as IN O
interstitial JJ O
chromosomal JJ O
deletion NN O
or CC O
reduced JJ O
transcription NN O
. . O

To TO O
identify VB O
possible JJ O
features NNS O
of IN O
the DT O
BRCA1 NNP O
genomic JJ O
region NN O
that WDT O
may MD O
contribute VB O
to TO O
chromosomal JJ O
instability NN O
as RB O
well RB O
as IN O
potential JJ O
transcriptional JJ O
regulatory JJ O
elements NNS O
, , O
a DT O
117 CD O
, , O
143 CD O
- : O
bp NN O
DNA NNP O
sequence NN O
encompassing VBG O
BRCA1 NNP O
was VBD O
obtained VBN O
by IN O
random JJ O
sequencing NN O
of IN O
four CD O
cosmids NNS O
identified VBN O
from IN O
a DT O
human JJ O
chromosome NN O
17 CD O
specific JJ O
library NN O
. . O

The DT O
24 CD O
exons NNS O
of IN O
BRCA1 NNP O
span VBP O
an DT O
81 CD O
- : O
kb NN O
region NN O
that WDT O
has VBZ O
an DT O
unusually RB O
high JJ O
density NN O
of IN O
Alu NNP O
repetitive JJ O
DNA NNP O
( ( O
41 CD O
. . O
5 CD O
% NN O
) ) O
, , O
but CC O
relatively RB O
low JJ O
density NN O
( ( O
4 CD O
. . O
8 CD O
% NN O
) ) O
of IN O
other JJ O
repetitive JJ O
sequences NNS O
. . O

BRCA1 NNP O
intron NN O
lengths NNS O
range VBP O
in IN O
size NN O
from IN O
403 CD O
bp NN O
to TO O
9 CD O
. . O

2 CD O
kb NN O
and CC O
contain VB O
the DT O
intragenic JJ O
microsatellite NN O
markers NNS O
D17S1323 NNP O
, , O
D17S1322 NNP O
, , O
and CC O
D17S855 NNP O
, , O
which WDT O
localize VBP O
to TO O
introns NNS O
12 CD O
, , O
19 CD O
, , O
and CC O
20 CD O
, , O
respectively RB O
. . O

In IN O
addition NN O
to TO O
BRCA1 NNP O
, , O
the DT O
contig NN O
contains VBZ O
two CD O
complete JJ O
genes NNS O
Rho7 NNP O
, , O
a DT O
member NN O
of IN O
the DT O
rho JJ O
family NN O
of IN O
GTP NNP O
binding VBG O
proteins NNS O
, , O
and CC O
VAT1 NNP O
, , O
an DT O
abundant JJ O
membrane NN O
protein NN O
of IN O
cholinergic JJ O
synaptic JJ O
vesicles NNS O
. . O

Partial JJ O
sequences NNS O
of IN O
the DT O
1A1 CD O
- : O
3B CD O
B NNP O
- : O
box NN O
protein NN O
pseudogene NN O
and CC O
IFP NNP O
35 CD O
, , O
an DT O
interferon NN O
induced VBD O
leucine JJ O
zipper NN O
protein NN O
, , O
reside VB O
within IN O
the DT O
contig NN O
. . O

An DT O
L21 NNP O
ribosomal NN O
protein NN O
pseudogene NN O
is VBZ O
embedded VBN O
in IN O
BRCA1 NNP O
intron NN O
13 CD O
. . O

The DT O
order NN O
of IN O
genes NNS O
on IN O
the DT O
chromosome NN O
is VBZ O
centromere JJ O
- : O
1FP CD O
35 CD O
- : O
VAT1 NNP O
- : O
Rho7 NNP O
- : O
BRCA1 NNP O
- : O
1A1 CD O
- : O
3B CD O
- : O
telomere NN O

Identification NN O
of IN O
a DT O
RING NNP O
protein NN O
that WDT O
can MD O
interact VB O
in IN O
vivo NN O
with IN O
the DT O
BRCA1 NNP O
gene NN O
product NN O
. . O

The DT O
hereditary JJ B-Disease
breast NN I-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
gene NN O
, , O
BRCA1 NNP O
, , O
encodes VBZ O
a DT O
large JJ O
polypeptide NN O
that WDT O
contains VBZ O
the DT O
cysteine NN O
- : O
rich JJ O
RING NNP O
motif NN O
, , O
a DT O
zinc NN O
- : O
binding NN O
domain NN O
found VBD O
in IN O
a DT O
variety NN O
of IN O
regulatory JJ O
proteins NNS O
. . O

Here RB O
we PRP O
describe VBP O
a DT O
novel JJ O
protein NN O
that WDT O
interacts VBZ O
in IN O
vivo NN O
with IN O
the DT O
N NNP O
- : O
terminal JJ O
region NN O
of IN O
BRCA1 NNP O
. . O

This DT O
BRCA1 NNP O
- : O
associated VBD O
RING NNP O
domain NN O
( ( O
BARD1 NNP O
) ) O
protein NN O
contains VBZ O
an DT O
N NNP O
- : O
terminal JJ O
RING NN O
motif NN O
, , O
three CD O
tandem NN O
ankyrin NN O
repeats NNS O
, , O
and CC O
a DT O
C NNP O
- : O
terminal JJ O
sequence NN O
with IN O
significant JJ O
homology NN O
to TO O
the DT O
phylogenetically RB O
conserved VBN O
BRCT NNP O
domains VBZ O
that IN O
lie NN O
near IN O
the DT O
C NNP O
terminus NN O
of IN O
BRCA1 NNP O
. . O

The DT O
BARD1 NNP O
/ NNP O
BRCA1 NNP O
interaction NN O
is VBZ O
disrupted VBN O
by IN O
BRCA1 NNP O
missense NN O
mutations NNS O
that WDT O
segregate VBP O
with IN O
breast NN B-Disease
cancer NN I-Disease
susceptibility NN O
, , O
indicating VBG O
that IN O
BARD1 NNP O
may MD O
be VB O
involved VBN O
in IN O
mediating VBG O
tumour JJ B-Disease
suppression NN O
by IN O
BRCA1 NNP O
. . O
. . O

Detection NN O
of IN O
heterozygous JJ O
mutations NNS O
in IN O
BRCA1 NNP O
using VBG O
high JJ O
density NN O
oligonucleotide VBP O
arrays NNS O
and CC O
two CD O
- : O
colour NN O
fluorescence NN O
analysis NN O
. . O

The DT O
ability NN O
to TO O
scan VB O
a DT O
large JJ O
gene NN O
rapidly RB O
and CC O
accurately RB O
for IN O
all DT O
possible JJ O
heterozygous JJ O
mutations NNS O
in IN O
large JJ O
numbers NNS O
of IN O
patient NN O
samples NNS O
will MD O
be VB O
critical JJ O
for IN O
the DT O
future NN O
of IN O
medicine NN O
. . O

We PRP O
have VBP O
designed VBN O
high JJ O
- : O
density NN O
arrays VBZ O
consisting VBG O
of IN O
over IN O
96 CD O
, , O
600 CD O
oligonucleotides NNS O
20 CD O
- : O
nucleotides NNS O
( ( O
nt NN O
) ) O
in IN O
length NN O
to TO O
screen VB O
for IN O
a DT O
wide JJ O
range NN O
of IN O
heterozygous JJ O
mutations NNS O
in IN O
the DT O
3 CD O
. . O

45 CD O
- : O
kilobases NNS O
( ( O
kb NN O
) ) O
exon VBZ O
11 CD O
of IN O
the DT O
hereditary JJ B-Disease
breast NN I-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
gene NN O
BRCA1 NNP O
. . O

Reference NN O
and CC O
test NN O
samples NNS O
were VBD O
co JJ O
- : O
hybridized VBN O
to TO O
these DT O
arrays NNS O
and CC O
differences NNS O
in IN O
hybridization NN O
patterns NNS O
quantitated VBN O
by IN O
two CD O
- : O
colour NN O
analysis NN O
. . O

Fourteen NNP O
of IN O
fifteen JJ O
patient NN O
samples NNS O
with IN O
known JJ O
mutations NNS O
were VBD O
accurately RB O
diagnosed VBN O
, , O
and CC O
no DT O
false JJ O
positive JJ O
mutations NNS O
were VBD O
identified VBN O
in IN O
20 CD O
control NN O
samples NNS O
. . O

Eight CD O
single JJ O
nucleotide RB O
polymorphisms NNS O
were VBD O
also RB O
readily RB O
detected VBN O
. . O

DNA NN O
chip NN O
- : O
based VBN O
assays NNS O
may MD O
provide VB O
a DT O
valuable JJ O
new JJ O
technology NN O
for IN O
high JJ O
- : O
throughput NN O
cost NN O
- : O
efficient JJ O
detection NN O
of IN O
genetic JJ O
alterations NNS O
. . O

Autosomal NNP O
dominant JJ O
primary JJ O
hyperparathyroidism NN B-Disease
and CC I-Disease
jaw JJ I-Disease
tumor NN I-Disease
syndrome NN I-Disease
associated VBN O
with IN O
renal JJ B-Disease
hamartomas NN I-Disease
and CC O
cystic JJ B-Disease
kidney NN I-Disease
disease NN I-Disease
: : O
linkage NN O
to TO O
1q21 CD O
- : O
q32 NN O
and CC O
loss NN O
of IN O
the DT O
wild JJ O
type NN O
allele NN O
in IN O
renal JJ B-Disease
hamartomas NN I-Disease
. . O

Hereditary JJ B-Disease
hyperparathyroidism NN I-Disease
- : I-Disease
jaw NN I-Disease
tumor NN I-Disease
syndrome NN I-Disease
( ( O
HPT NNP B-Disease
- : I-Disease
JT NN I-Disease
) ) O
is VBZ O
an DT O
autosomal JJ B-Disease
dominant JJ I-Disease
disease NN I-Disease
( ( O
OMIM NNP O
145001 CD O
) ) O
that WDT O
has VBZ O
recently RB O
been VBN O
mapped VBN O
to TO O
chromosomal VB O
region NN O
1q21 CD O
- : O
q32 NN O
( ( O
HRPT2 NNP O
) ) O
. . O

Here RB O
we PRP O
report VBP O
two CD O
families NNS O
with IN O
HPT NNP B-Disease
- : I-Disease
JT NNP I-Disease
syndrome NN I-Disease
in IN O
which WDT O
adult VBP B-Disease
renal JJ I-Disease
hamartomas NN I-Disease
or CC O
cystic JJ B-Disease
kidney NN I-Disease
disease NN I-Disease
were VBD O
prominent JJ O
associated VBN O
features NNS O
, , O
possibly RB O
representing VBG O
a DT O
new JJ O
phenotypic NN O
variant NN O
of IN O
the DT O
HPT NNP B-Disease
- : I-Disease
JT NNP I-Disease
syndrome NN I-Disease
. . O

In IN O
the DT O
first JJ O
family NN O
, , O
renal JJ B-Disease
lesions NNS I-Disease
were VBD O
present JJ O
in IN O
five CD O
out IN O
of IN O
six CD O
affected JJ O
individuals NNS O
, , O
whereas NNS O
HPT NNP B-Disease
and CC O
JT NNP B-Disease
were VBD O
seen VBN O
in IN O
four CD O
and CC O
two CD O
cases NNS O
, , O
respectively RB O
. . O

In IN O
the DT O
second JJ O
family NN O
, , O
JT NNP B-Disease
was VBD O
found VBN O
in IN O
three CD O
of IN O
the DT O
five CD O
affected JJ O
individuals NNS O
and CC O
two CD O
affected VBD O
members NNS O
also RB O
exhibited VBD O
polycystic JJ B-Disease
kidney NN I-Disease
disease NN I-Disease
. . O

The DT O
possibility NN O
of IN O
the DT O
latter JJ O
cosegregating NN O
as IN O
a DT O
separate JJ O
autosomal JJ O
dominant JJ O
gene NN O
can MD O
not RB O
be VB O
ruled VBN O
out RP O
. . O

A DT O
sex NN O
- : O
dependent JJ O
penetrance NN O
of IN O
primary JJ B-Disease
HPT NNP I-Disease
, , O
resulting VBG O
in IN O
predominantly RB O
male JJ O
- : O
affected JJ O
cases NNS O
was VBD O
evident JJ O
in IN O
the DT O
two CD O
families NNS O
. . O

Twenty NNP O
microsatellite NN O
markers NNS O
in IN O
the DT O
HRPT2 NNP O
region NN O
were VBD O
typed VBN O
, , O
in IN O
addition NN O
to TO O
markers NNS O
in IN O
the DT O
multiple JJ B-Disease
endocrine NN I-Disease
neoplasia NN I-Disease
( ( I-Disease
MEN NNP I-Disease
) ) I-Disease
types VBZ I-Disease
1 CD I-Disease
and CC I-Disease
2 CD I-Disease
regions NNS O
at IN O
11q13 CD O
and CC O
10q11 CD O
. . O

The DT O
disease NN O
in IN O
these DT O
two CD O
kindreds NNS O
was VBD O
linked VBN O
to TO O
five CD O
markers NNS O
in IN O
the DT O
1q21 CD O
- : O
q32 NN O
region NN O
( ( O
logarithm JJ O
- : O
of IN O
- : O
odds NNS O
scores VBZ O
3 CD O
. . O
2 CD O
- : O
4 CD O
2 CD O
- : O
4 CD O
. . O
2 CD O
) ) O
, , O
whereas JJ O
linkage NN O
to TO O
the DT O
MEN1 NNP B-Disease
and CC O
MEN2 NNP B-Disease
regions NNS O
was VBD O
excluded VBN O
. . O

Meiotic JJ O
recombinations NNS O
detected VBN O
in IN O
affected JJ O
individuals NNS O
placed VBD O
the DT O
locus NN O
telomeric NN O
of IN O
D1S215 NNP O
, , O
thus RB O
narrowing VBG O
the DT O
HRPT2 NNP O
region NN O
from IN O
> $ O
60 CD O
to TO O
approximately RB O
34 CD O
centimorgans NNS O
. . O

Loss NNP O
of IN O
heterozygosity NN O
was VBD O
studied VBN O
in IN O
seven CD O
renal JJ B-Disease
hamartomas NNS I-Disease
from IN O
two CD O
affected JJ O
individuals NNS O
in IN O
the DT O
first JJ O
family NN O
, , O
as RB O
well RB O
as IN O
in IN O
a DT O
jaw NN B-Disease
tumor NN I-Disease
and CC O
a DT O
parathyroid JJ B-Disease
tumor NN I-Disease
from IN O
the DT O
second JJ O
family NN O
. . O

All DT O
renal JJ B-Disease
hamartomas NN I-Disease
showed VBD O
loss NN O
of IN O
heterozygosity NN O
at IN O
the DT O
1q21 CD O
- : O
q32 JJ O
region NN O
. . O

The DT O
losses NNS O
invariably RB O
involved VBD O
the DT O
wild JJ O
type NN O
allele NN O
derived VBN O
from IN O
the DT O
unaffected JJ O
parent NN O
, , O
suggesting VBG O
the DT O
inactivation NN O
of IN O
a DT O
tumor NN B-Disease
suppressor NN O
gene NN O
in IN O
this DT O
region NN O

Independent NNP O
origin NN O
of IN O
single JJ O
and CC O
double JJ O
mutations NNS O
in IN O
the DT O
human JJ O
glucose NN O
6 CD O
- : O
phosphate NN O
dehydrogenase NN O
gene NN O
. . O

The DT O
vast JJ O
majority NN O
of IN O
both DT O
polymorphic JJ O
and CC O
sporadic JJ O
G6PD NNP O
variants NNS O
are VBP O
due JJ O
to TO O
single JJ O
missense NN O
mutations NNS O
. . O

In IN O
the DT O
four CD O
polymorphic JJ O
variants NNS O
that WDT O
have VBP O
two CD O
point NN O
mutations NNS O
, , O
one CD O
of IN O
the DT O
mutations NNS O
is VBZ O
always RB O
376 CD O
A NNP O
- : O
- : O
> NN O
G NNP O
( ( O
126 CD O
Asn NNP O
- : O
- : O
> JJ O
Asp NNP O
) ) O
, , O
which WDT O
on IN O
its PRP$ O
own JJ O
gives VBZ O
rise NN O
to TO O
the DT O
nondeficient JJ O
polymorphic JJ O
variant NN O
, , O
G6PD NNP O
A NNP O
. . O

In IN O
a DT O
study NN O
of IN O
G6PD NNP B-Disease
deficient NN I-Disease
patients NNS O
who WP O
presented VBD O
with IN O
clinical JJ O
favism NN B-Disease
in IN O
Spain NNP O
, , O
we PRP O
have VBP O
found VBN O
a DT O
new JJ O
polymorphic JJ O
variant NN O
that IN O
we PRP O
have VBP O
called VBN O
G6PD NNP O
Malaga NNP O
, , O
whose WP$ O
only JJ O
abnormality NN O
is VBZ O
a DT O
542 CD O
A NNP O
- : O
- : O
> NN O
T NNP O
( ( O
181 CD O
Asp NNP O
- : O
- : O
> NN O
Val NNP O
) ) O
mutation NN O
. . O

This DT O
is VBZ O
the DT O
same JJ O
mutation NN O
as IN O
previously RB O
found VBN O
in IN O
association NN O
with IN O
the DT O
mutation NN O
of IN O
G6PD NNP O
A NNP O
in IN O
the DT O
double JJ O
mutant NN O
, , O
G6PD NNP O
Santamaria NNP O
. . O

G6PD NNP O
Malaga NNP O
is VBZ O
associated VBN O
with IN O
enzyme JJ B-Disease
deficiency NN I-Disease
( ( O
class NN O
III NNP O
) ) O
, , O
and CC O
the DT O
enzymic JJ O
properties NNS O
of IN O
G6PD NNP O
Malaga NNP O
and CC O
G6PD NNP O
Santamaria NNP O
are VBP O
quite RB O
similar JJ O
, , O
indicating VBG O
that IN O
in IN O
this DT O
case NN O
the DT O
effects NNS O
of IN O
the DT O
two CD O
mutations NNS O
are VBP O
additive JJ O
rather RB O
than IN O
synergistic JJ O
. . O

G6PD NNP O
Santamaria NNP O
might MD O
have VB O
been VBN O
produced VBN O
by IN O
recombination NN O
between IN O
G6PD NNP O
A NNP O
and CC O
G6PD NNP O
Malaga NNP O
; : O
however RB O
haplotype NN O
analysis NN O
, , O
including VBG O
the DT O
use NN O
of IN O
a DT O
new JJ O
silent JJ O
polymorphism NN O
, , O
suggests VBZ O
that IN O
the DT O
same JJ O
542 CD O
A NNP O
- : O
- : O
> NN O
T NNP O
mutation NN O
has VBZ O
taken VBN O
place NN O
independently RB O
in IN O
a DT O
G6PD NNP O
B NNP O
gene NN O
to TO O
give VB O
G6PD NNP O
Malaga NNP O
and CC O
in IN O
a DT O
G6PD NNP O
A NNP O
gene NN O
to TO O
give VB O
G6PD NNP O
Santamaria NNP O
. . O

These DT O
findings NNS O
help VBP O
to TO O
outline VB O
the DT O
relationship NN O
and CC O
evolution NN O
of IN O
mutations NNS O
in IN O
the DT O
human JJ O
G6PD NNP O
locus NN O
. . O
. . O

BRCA1 NNP O
R841W NNP O
: : O
a DT O
strong JJ O
candidate NN O
for IN O
a DT O
common JJ O
mutation NN O
with IN O
moderate JJ O
phenotype NN O
. . O

BRCA1 NNP O
mutations NNS O
cause VBP O
increased VBN O
risk NN O
for IN O
breast NN B-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
, , O
frequently RB O
of IN O
early JJ O
onset NN O
. . O

Many JJ O
different JJ O
mutations NNS O
occur VBP O
in IN O
BRCA1 NNP O
, , O
including VBG O
several JJ O
examples NNS O
of IN O
recurrent NN O
mutations NNS O
, , O
each DT O
of IN O
which WDT O
accounts NNS O
for IN O
a DT O
significant JJ O
number NN O
of IN O
families NNS O
with IN O
heritable JJ O
cancer NN B-Disease
predisposition NN O
. . O

These DT O
common JJ O
mutations NNS O
have VBP O
an DT O
etiological JJ O
role NN O
in IN O
many JJ O
breast NN B-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
cases NNS O
and CC O
provide VB O
the DT O
opportunity NN O
to TO O
examine VB O
genotype JJ O
- : O
phenotype NN O
correlations NNS O
and CC O
genotype JJ O
- : O
environment NN O
interactions NNS O
in IN O
individuals NNS O
with IN O
the DT O
identical JJ O
BRCA1 NNP O
lesion NN O
. . O

We PRP O
report VBP O
a DT O
novel JJ O
missense NN O
change NN O
in IN O
BRCA1 NNP O
, , O
2640 CD O
C NNP O
- : O
- : O
> NN O
T NNP O
( ( O
R841W NNP O
) ) O
, , O
found VBN O
in IN O
3 CD O
cases NNS O
from IN O
a DT O
subject JJ O
group NN O
of IN O
305 CD O
breast NN B-Disease
and CC I-Disease
79 CD I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
cases NNS O
from IN O
Orange NNP O
County NNP O
, , O
CA NNP O
. . O

These DT O
are VBP O
consecutive JJ O
, , O
population NN O
- : O
based VBN O
cases NNS O
not RB O
selected VBN O
for IN O
age NN O
or CC O
family NN O
history NN O
. . O

In IN O
all DT O
three CD O
cases NNS O
, , O
there EX O
is VBZ O
a DT O
strong JJ O
family NN O
history NN O
of IN O
breast NN B-Disease
, , I-Disease
ovarian JJ I-Disease
, , I-Disease
or CC I-Disease
other JJ I-Disease
cancers NNS I-Disease
possibly RB O
related VBN O
to TO O
a DT O
BRCA1 NNP O
defect NN O
and CC O
family NN O
members NNS O
showed VBD O
a DT O
high JJ O
concordance NN O
of IN O
cancer NN B-Disease
incidence NN O
with IN O
the DT O
presence NN O
of IN O
R841W NNP O
. . O

The DT O
age NN O
of IN O
cancer NN B-Disease
onset NN O
was VBD O
not RB O
always RB O
distinct VBP O
from IN O
typical JJ O
sporadic JJ O
cases NNS O
. . O

Testing VBG O
of IN O
a DT O
sample NN O
of IN O
413 CD O
unrelated JJ O
individuals NNS O
to TO O
examine VB O
the DT O
hypothesis NN O
that WDT O
R841W NNP O
might MD O
be VB O
a DT O
rare JJ O
polymorphism NN O
detected VBD O
one CD O
additional JJ O
instance NN O
in IN O
a DT O
woman NN O
with IN O
breast NN B-Disease
cancer NN I-Disease
diagnosed VBN O
at IN O
age NN O
77 CD O
years NNS O
, , O
and CC O
cancer NN B-Disease
in IN O
one CD O
parent NN O
. . O

R841W NN O
is VBZ O
likely JJ O
to TO O
be VB O
an DT O
etiologically RB O
significant JJ O
lesion NN O
with IN O
involvement NN O
in IN O
close JJ O
to TO O
1 CD O
% NN O
( ( O
95 CD O
% NN O
confidence NN O
interval NN O
of IN O
0 CD O
- : O
1 CD O
. . O
7 CD O
% NN O
) ) O
of IN O
all DT O
breast NN B-Disease
and CC I-Disease
ovarian JJ I-Disease
cancers NNS I-Disease
in IN O
this DT O
population NN O
. . O

Ataxia NNP B-Disease
- : I-Disease
telangiectasia NN I-Disease
: : O
founder NN O
effect NN O
among IN O
north JJ O
African JJ O
Jews NNP O
. . O

The DT O
ATM NNP O
gene NN O
is VBZ O
responsible JJ O
for IN O
the DT O
autosomal JJ B-Disease
recessive JJ I-Disease
disorder NN I-Disease
ataxia SYM B-Disease
- : I-Disease
telangiectasia NN I-Disease
( ( O
A DT B-Disease
- : I-Disease
T NN I-Disease
) ) O
, , O
characterized VBN O
by IN O
cerebellar JJ B-Disease
degeneration NN I-Disease
, , O
immunodeficiency NN B-Disease
and CC O
cancer NN B-Disease
predisposition NN I-Disease
. . O

A DT B-Disease
- : I-Disease
T NN I-Disease
carriers NNS O
were VBD O
reported VBN O
to TO O
be VB O
moderately RB O
cancer NN B-Disease
- : I-Disease
prone NN I-Disease
. . O

A DT O
wide JJ O
variety NN O
of IN O
A NNP B-Disease
- : I-Disease
T NN I-Disease
mutations NNS O
, , O
most JJS O
of IN O
which WDT O
are VBP O
unique JJ O
to TO O
single JJ O
families NNS O
, , O
were VBD O
identified VBN O
in IN O
various JJ O
ethnic JJ O
groups NNS O
, , O
precluding VBG O
carrier NN O
screening VBG O
with IN O
mutation NN O
- : O
specific JJ O
assays NNS O
. . O

However RB O
, , O
a DT O
single JJ O
mutation NN O
was VBD O
observed VBN O
in IN O
32 CD O
/ JJ O
33 CD O
defective JJ O
ATM NNP O
alleles NNS O
in IN O
Jewish NNP O
A NNP B-Disease
- : I-Disease
T NNP I-Disease
families NNS O
of IN O
North JJ O
African JJ O
origin NN O
, , O
coming VBG O
from IN O
various JJ O
regions NNS O
of IN O
Morocco NNP O
and CC O
Tunisia NNP O
. . O

This DT O
mutation NN O
, , O
103C CD O
- : O
- : O
> NN O
T NNP O
, , O
results NNS O
in IN O
a DT O
stop JJ O
codon NN O
at IN O
position NN O
35 CD O
of IN O
the DT O
ATM NNP O
protein NN O
. . O

In IN O
keeping VBG O
with IN O
the DT O
nature NN O
of IN O
this DT O
mutation NN O
, , O
various JJ O
antibodies NNS O
directed VBN O
against IN O
the DT O
ATM NNP O
protein NN O
failed VBD O
to TO O
defect VB O
this DT O
protein NN O
in IN O
patient JJ O
cells NNS O
. . O

A DT O
rapid JJ O
carrier NN O
detection NN O
assay RB O
detected VBD O
this DT O
mutation NN O
in IN O
three CD O
out IN O
of IN O
488 CD O
ATM NNP O
alleles NNS O
of IN O
Jewish JJ O
Moroccan NNP O
or CC O
Tunisian JJ O
origin NN O
. . O

This DT O
founder NN O
effect NN O
provides VBZ O
a DT O
unique JJ O
opportunity NN O
for IN O
population NN O
- : O
based VBN O
screening NN O
for IN O
A NNP B-Disease
- : I-Disease
T NN I-Disease
carriers NNS O
in IN O
a DT O
large JJ O
Jewish NNP O
community NN O
. . O
. . O

Mutation NNP O
analysis NN O
of IN O
BRCA1 NNP O
and CC O
BRCA2 NNP O
in IN O
a DT O
male JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
population NN O
. . O

A DT O
population NN O
- : O
based VBN O
series NN O
of IN O
54 CD O
male JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
cases NNS O
from IN O
Southern NNP O
California NNP O
were VBD O
analyzed VBN O
for IN O
germ JJ O
- : O
line NN O
mutations NNS O
in IN O
the DT O
inherited JJ B-Disease
breast NN I-Disease
/ JJ I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
genes NNS O
, , O
BRCA1 NNP O
and CC O
BRCA2 NNP O
. . O

Nine NNP O
( ( O
17 CD O
% NN O
) ) O
of IN O
the DT O
patients NNS O
had VBD O
a DT O
family NN O
history NN O
of IN O
breast NN B-Disease
and CC I-Disease
/ NN I-Disease
or CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
in IN O
at IN O
least JJS O
one CD O
first JJ O
- : O
degree NN O
relative NN O
. . O

A DT O
further JJ O
seven CD O
( ( O
13 CD O
% NN O
) ) O
of IN O
the DT O
patients NNS O
reported VBD O
breast JJ B-Disease
/ JJ I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
in IN O
at IN O
least JJS O
one CD O
second JJ O
- : O
degree NN O
relative NN O
and CC O
in IN O
no DT O
first JJ O
- : O
degree NN O
relatives NNS O
. . O

No DT O
germ JJ O
- : O
line NN O
BRCA1 NNP O
mutations NNS O
were VBD O
found VBN O
. . O

Two CD O
male JJ B-Disease
breast NN I-Disease
cancer NN I-Disease
patients NNS O
( ( O
4 CD O
% NN O
of IN O
the DT O
total NN O
) ) O
were VBD O
found VBN O
to TO O
carry VB O
novel JJ O
truncating VBG O
mutations NNS O
in IN O
the DT O
BRCA2 NNP O
gene NN O
. . O

Only RB O
one CD O
of IN O
the DT O
two CD O
male NN B-Disease
breast NN I-Disease
cancer NN I-Disease
patients NNS O
carrying VBG O
a DT O
BRCA2 NNP O
mutation NN O
had VBD O
a DT O
family NN O
history NN O
of IN O
cancer NN B-Disease
, , O
with IN O
one CD O
case NN O
of IN O
ovarian JJ B-Disease
cancer NN I-Disease
in IN O
a DT O
first JJ O
- : O
degree NN O
relative NN O
. . O

The DT O
remaining VBG O
eight CD O
cases NNS O
( ( O
89 CD O
% NN O
) ) O
of IN O
male NN B-Disease
breast NN I-Disease
cancer NN I-Disease
with IN O
a DT O
family NN O
history NN O
of IN O
breast NN B-Disease
/ JJ I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
in IN O
first JJ O
- : O
degree NN O
relatives NNS O
remain VBP O
unaccounted JJ O
for IN O
by IN O
mutations NNS O
in IN O
either CC O
the DT O
BRCA1 NNP O
gene NN O
or CC O
the DT O
BRCA2 NNP O
gene NN O
. . O
. . O

Molecular JJ O
basis NN O
for IN O
Duarte NNP B-Disease
and CC I-Disease
Los NNP I-Disease
Angeles NNP I-Disease
variant NN I-Disease
galactosemia NN I-Disease
. . O

Human NNP O
orythrocytes VBZ O
that WDT O
are VBP O
homozygous JJ O
for IN O
the DT O
Duarte NNP B-Disease
enzyme NN I-Disease
variant NN I-Disease
of IN I-Disease
galactosemia NN I-Disease
( ( O
D NNP O
/ NNP O
D NNP O
) ) O
have VBP O
a DT O
characteristic JJ O
isoform NN O
on IN O
isoelectric JJ O
focusing NN O
and CC O
50 CD O
% NN O
reduction NN O
in IN O
galactose JJ O
- : O
1 CD O
- : O
phosphate NN O
uridyltransferase NN O
( ( O
GALT NNP O
) ) O
enzyme NN O
activity NN O
. . O

The DT O
Duarte NNP O
biochemical JJ O
phenotype NN O
has VBZ O
a DT O
molecular JJ O
genotype NN O
of IN O
N314D NNP O
/ NNP O
N314D NNP O
. . O

The DT O
characteristic JJ O
Duarte NNP O
isoform NN O
is VBZ O
also RB O
associated VBN O
with IN O
a DT O
variant NN O
called VBN O
the DT O
"""" NNP O
Los NNP O
Angeles NNP O
( ( O
LA NNP O
) ) O
phenotype NN O
, , O
"""" NNP O
which WDT O
has VBZ O
increased VBN O
GALT NNP O
enzyme JJ O
activity NN O
. . O

We PRP O
evaluated VBD O
GALT NNP O
enzyme JJ O
activity NN O
and CC O
screened VBD O
the DT O
GALT NNP O
genes NNS O
of IN O
145 CD O
patients NNS O
with IN O
one CD O
or CC O
more JJR O
N314D NNP O
- : O
containing NN O
alleles NNS O
. . O

We PRP O
found VBD O
seven CD O
with IN O
the DT O
LA NNP O
biochemical JJ O
phenotype NN O
, , O
and CC O
all DT O
had VBD O
a DT O
1721C CD O
- : O
- : O
> NN O
T NNP O
transition NN O
in IN O
exon JJ O
7 CD O
in IN O
cis NN O
with IN O
the DT O
N314D NNP O
missense NN O
mutation NN O
. . O

The DT O
1721C CD O
- : O
- : O
> NN O
T NNP O
transition NN O
is VBZ O
a DT O
neutral JJ O
polymorphism NN O
for IN O
leucine NN O
at IN O
amino NN O
acid NN O
218 CD O
( ( O
L218L NNP O
) ) O
. . O

In IN O
pedigree JJ O
analyses NNS O
, , O
this DT O
1721C CD O
- : O
- : O
> NN O
T NNP O
transition NN O
segregated VBD O
with IN O
the DT O
LA NNP O
phenotype NN O
of IN O
increased JJ O
GALT NNP O
activity NN O
in IN O
three CD O
different JJ O
biochemical JJ O
phenotypes NNS O
( ( O
LA NNP O
/ NNP O
N NNP O
, , O
LA NNP O
/ NNP O
G NNP O
, , O
and CC O
LA NNP O
/ NNP O
D NNP O
) ) O
. . O

To TO O
determine VB O
the DT O
mechanism NN O
for IN O
increased JJ O
activity NN O
of IN O
the DT O
LA NNP O
variant NN O
, , O
we PRP O
compared VBN O
GALT NNP O
mRNA NN O
, , O
protein NN O
abundance NN O
, , O
and CC O
enzyme VB O
thermal JJ O
stability NN O
in IN O
lymphoblast NN O
cell NN O
lines NNS O
of IN O
D NNP O
and CC O
LA NNP O
phenotypes NNS O
with IN O
comparable JJ O
genotypes NNS O
. . O

GALT NNP O
protein VBD O
abundance NN O
was VBD O
increased VBN O
in IN O
LA NNP O
compared VBN O
to TO O
D NNP O
alleles NNS O
, , O
but CC O
mRNA NN O
was VBD O
similar JJ O
among IN O
all DT O
genotypes NNS O
. . O

When WRB O
LA NNP O
/ NNP O
D NNP O
and CC O
D NNP O
/ NNP O
D NNP O
GALT NNP O
biochemical JJ O
phenotypes NNS O
were VBD O
compared VBN O
to TO O
N NNP O
/ NNP O
N NNP O
GALT NNP O
phenotypes NNS O
, , O
both DT O
had VBD O
50 CD O
% NN O
, , O
as IN O
compared VBN O
to TO O
21 CD O
% NN O
, , O
reduction NN O
in IN O
GALT NNP O
activity NN O
in IN O
the DT O
wild JJ O
type NN O
( ( O
N NNP O
/ NNP O
N NNP O
) ) O
after IN O
exposure NN O
at IN O
identical JJ O
initial JJ O
enzyme NN O
activity NN O
to TO O
50 CD O
degrees NNS O
C NNP O
for IN O
15 CD O
min NN O
. . O

We PRP O
conclude VBP O
that IN O
the DT O
codon NN O
change NN O
N314D NNP O
in IN O
cis NN O
with IN O
the DT O
base NN O
- : O
pair NN O
transition NN O
1721C CD O
- : O
- : O
> NN O
T NNP O
produces VBZ O
the DT O
LA NNP B-Disease
variant NN I-Disease
of IN I-Disease
galactosemia NN I-Disease
and CC O
that IN O
this DT O
nucleotide JJ O
change NN O
increases NNS O
GALT NNP O
activity NN O
by IN O
increasing VBG O
GALT NNP O
protein NN O
abundance NN O
without IN O
increasing VBG O
transcription NN O
or CC O
decreasing VBG O
thermal JJ O
lability NN O
. . O

A DT O
favorable JJ O
codon NN O
bias NN O
for IN O
the DT O
mutated JJ O
codon NN O
with IN O
consequently RB O
increased VBN O
translation NN O
rates NNS O
is VBZ O
postulated VBN O
as IN O
the DT O
mechanism NN O
. . O
. . O

The DT O
TSG101 NNP O
tumor NN B-Disease
susceptibility NN O
gene NN O
is VBZ O
located VBN O
in IN O
chromosome NN O
11 CD O
band NN O
p15 NN O
and CC O
is VBZ O
mutated VBN O
in IN O
human JJ O
breast NN B-Disease
cancer NN I-Disease
. . O

Recent JJ O
work NN O
has VBZ O
identified VBN O
a DT O
mouse NN O
gene NN O
( ( O
tsg101 JJ O
) ) O
whose WP$ O
inactivation NN O
in IN O
fibroblasts NNS O
results NNS O
in IN O
cellular JJ O
transformation NN O
and CC O
the DT O
ability NN O
to TO O
produce VB O
metastatic JJ B-Disease
tumors NNS I-Disease
in IN O
nude JJ O
mice NN O
. . O

Here RB O
, , O
we PRP O
report VBP O
that IN O
the DT O
human JJ O
homolog NN O
, , O
TSG101 NNP O
, , O
which WDT O
we PRP O
isolated VBD O
and CC O
mapped VBD O
to TO O
chromosome VB O
11 CD O
, , O
bands VBZ O
15 CD O
. . O

1 CD O
- : O
15 CD O
1 CD O
- : O
15 CD O
. . O

2 CD O
, , O
a DT O
region NN O
proposed VBN O
to TO O
contain VB O
tumor NN B-Disease
suppressor NN O
gene NN O
( ( O
s PRP O
) ) O
, , O
is VBZ O
mutated VBN O
at IN O
high JJ O
frequency NN O
in IN O
human JJ O
breast NN B-Disease
cancer NN I-Disease
. . O

In IN O
7 CD O
of IN O
15 CD O
uncultured JJ O
primary JJ O
human JJ O
breast NN B-Disease
carcinomas NN I-Disease
, , O
intragenic JJ O
deletions NNS O
were VBD O
shown VBN O
in IN O
TSG101 NNP O
genomic JJ O
DNA NNP O
and CC O
transcripts NNS O
by IN O
gel NN O
and CC O
sequence NN O
analysis NN O
, , O
and CC O
mutations NNS O
affecting VBG O
two CD O
TSG101 NNP O
alleles NNS O
were VBD O
identified VBN O
in IN O
four CD O
of IN O
these DT O
cancers NNS B-Disease
. . O

No DT O
TSG101 NNP O
defects NNS O
were VBD O
found VBN O
in IN O
matched JJ O
normal JJ O
breast NN O
tissue NN O
from IN O
the DT O
breast NN B-Disease
cancer NN I-Disease
patients NNS O
. . O

These DT O
findings NNS O
strongly RB O
implicate VBP O
TSG101 NNP O
mutations NNS O
in IN O
human JJ O
breast NN B-Disease
cancer NN I-Disease

Moderate NNP O
intergenerational JJ O
and CC O
somatic JJ O
instability NN O
of IN O
a DT O
55 CD O
- : O
CTG NN O
repeat NN O
in IN O
transgenic JJ O
mice NN O
. . O

Myotonic JJ B-Disease
dystrophy NN I-Disease
( ( O
DM NNP B-Disease
) ) O
is VBZ O
associated VBN O
with IN O
the DT O
expansion NN O
of IN O
a DT O
( ( O
CTG NNP O
) ) O
n FW O
trinucleotide JJ O
repeat NN O
in IN O
the DT O
3 CD O
untranslated JJ O
region NN O
( ( O
UTR NNP O
) ) O
of IN O
the DT O
DM NNP B-Disease
protein NN O
kinase NN O
gene NN O
( ( O
DMPK NNP O
) ) O
. . O

The DT O
( ( O
CTG NNP O
) ) O
n FW O
repeat NN O
is VBZ O
polymorphic JJ O
and CC O
varies NNS O
in IN O
size NN O
between IN O
5 CD O
and CC O
37 CD O
repeats NNS O
in IN O
unaffected JJ O
individuals NNS O
whereas VBP O
in IN O
affected JJ O
patients NNS O
there EX O
are VBP O
between IN O
50 CD O
and CC O
4 CD O
, , O
0 CD O
CTGs NNP O
. . O

The DT O
size NN O
of IN O
the DT O
( ( O
CTG NNP O
) ) O
n RB O
repeat NN O
, , O
which WDT O
increases VBZ O
through IN O
generations NNS O
, , O
generally RB O
correlates VBZ O
with IN O
clinical JJ O
severity NN O
and CC O
age NN O
of IN O
onset NN O
. . O

The DT O
instability NN O
of IN O
the DT O
CTG NNP O
repeat NN O
appears VBZ O
to TO O
depend VB O
on IN O
its PRP$ O
size NN O
as RB O
well RB O
as IN O
on IN O
the DT O
sex NN O
of IN O
the DT O
transmitting JJ O
parent NN O
. . O

Moreover RB O
, , O
mitotic JJ O
instability NN O
analysis NN O
of IN O
different JJ O
human JJ O
DM NNP B-Disease
tissues NN O
shows NNS O
length VBP O
mosaicism NN O
between IN O
different JJ O
cell NN O
lineages NNS O
. . O

The DT O
molecular JJ O
mechanisms NN O
of IN O
triplet NN O
instability NN O
remain VBP O
elusive JJ O
. . O

To TO O
investigate VB O
the DT O
role NN O
of IN O
genomic JJ O
sequences NNS O
in IN O
instability NN O
, , O
we PRP O
produced VBD O
transgenic JJ O
mice NN O
containing VBG O
a DT O
45 CD O
- : O
kb NN O
genomic JJ O
segment NN O
with IN O
a DT O
55 CD O
- : O
CTG NNP O
repeat NN O
cloned VBD O
from IN O
a DT O
mildly RB O
affected JJ O
patient NN O
. . O

In IN O
contrast NN O
to TO O
other JJ O
mouse NN O
models NNS O
containing VBG O
CAG NNP O
repeats NNS O
within IN O
cDNAs NN O
, , O
these DT O
mice NN O
showed VBD O
both DT O
intergenerational JJ O
and CC O
somatic JJ O
repeat NN O
instability NN O
. . O
. . O

Missense JJ O
mutations NNS O
in IN O
the DT O
Fas NNP O
gene NN O
resulting VBG O
in IN O
autoimmune JJ B-Disease
lymphoproliferative JJ I-Disease
syndrome NN I-Disease
: : O
a DT O
molecular JJ O
and CC O
immunological JJ O
analysis NN O
. . O

Programmed NNP O
cell NN O
death NN O
( ( O
or CC O
apoptosis NN O
) ) O
is VBZ O
a DT O
physiological JJ O
process NN O
essential JJ O
to TO O
the DT O
normal JJ O
development NN O
and CC O
homeostatic JJ O
maintenance NN O
of IN O
the DT O
immune NN O
system NN O
. . O

The DT O
Fas NNP O
/ NNP O
Apo NNP O
- : O
1 CD O
receptor NN O
plays VBZ O
a DT O
crucial JJ O
role NN O
in IN O
the DT O
regulation NN O
of IN O
apoptosis NN O
, , O
as IN O
demonstrated VBN O
by IN O
lymphoproliferation NN O
in IN O
MRL NNP O
- : O
lpr NN O
/ JJ O
lpr JJ O
mice NN O
and CC O
by IN O
the DT O
recently RB O
described VBN O
autoimmune JJ B-Disease
lymphoproliferative JJ I-Disease
syndrome NN I-Disease
( ( O
ALPS NNP B-Disease
) ) O
in IN O
humans NNS O
, , O
both DT O
of IN O
which WDT O
are VBP O
due JJ O
to TO O
mutations NNS O
in IN O
the DT O
Fas NNP O
gene NN O
. . O

We PRP O
describe VBP O
a DT O
novel JJ O
family NN O
with IN O
ALPS NNP B-Disease
in IN O
which WDT O
three CD O
affected VBD O
siblings NNS O
carry VBP O
two CD O
distinct JJ O
missense NN O
mutations NNS O
on IN O
both DT O
the DT O
Fas NNP O
gene NN O
alleles NNS O
and CC O
show VBP O
lack NN O
of IN O
Fas NNP O
- : O
induced JJ O
apoptosis NN O
. . O

The DT O
children NNS O
share NN O
common JJ O
clinical JJ O
features NNS O
including VBG O
splenomegaly NN B-Disease
and CC O
lymphadenopathy JJ B-Disease
, , O
but CC O
only RB O
one CD O
developed VBD O
severe JJ O
autoimmune JJ B-Disease
manifestations NNS I-Disease
. . O

In IN O
all DT O
three CD O
siblings NNS O
, , O
we PRP O
demonstrated VBD O
the DT O
presence NN O
of IN O
anergic JJ O
CD3 NNP O
+ NNP O
CD4 NNP O
- : O
CD8 NNP O
- : O
( ( O
double JJ O
negative JJ O
, , O
[ JJ O
DN NNP O
] NNP O
) ) O
T NNP O
cells NNS O
; : O
moreover RB O
, , O
a DT O
chronic JJ O
lymphocyte NN O
activation NN O
was VBD O
found VBN O
, , O
as IN O
demonstrated VBN O
by IN O
the DT O
presence NN O
of IN O
high JJ O
levels NNS O
of IN O
HLA NNP O
- : O
DR NNP O
expression NN O
on IN O
peripheral JJ O
CD3 NNP O
+ NNP O
cells NNS O
and CC O
by IN O
the DT O
presence NN O
of IN O
high JJ O
levels NNS O
of IN O
serum NN O
activation NN O
markers NNS O
such JJ O
as IN O
soluble JJ O
interleukin JJ O
- : O
2 CD O
receptor NN O
( ( O
slL JJ O
- : O
2R CD O
) ) O
and CC O
soluble JJ O
CD30 NNP O
( ( O
sCD30 NN O
) ) O
. . O
. . O

The DT O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
gene NN O
product NN O
, , O
a DT O
constitutively RB O
expressed VBN O
nuclear JJ O
protein NN O
that WDT O
is VBZ O
not RB O
up RP O
- : O
regulated VBN O
following VBG O
genome JJ O
damage NN O
. . O

The DT O
product NN O
of IN O
the DT O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
gene NN O
( ( O
ATM NNP O
) ) O
was VBD O
identified VBN O
by IN O
using VBG O
an DT O
antiserum NN O
developed VBD O
to TO O
a DT O
peptide NN O
corresponding VBG O
to TO O
the DT O
deduced VBN O
amino NN O
acid NN O
sequence NN O
. . O

The DT O
ATM NNP O
protein NN O
is VBZ O
a DT O
single JJ O
, , O
high JJ O
- : O
molecular JJ O
weight NN O
protein NN O
predominantly RB O
confined VBN O
to TO O
the DT O
nucleus NN O
of IN O
human JJ O
fibroblasts NNS O
, , O
but CC O
is VBZ O
present JJ O
in IN O
both DT O
nuclear JJ O
and CC O
microsomal JJ O
fractions NNS O
from IN O
human JJ O
lymphoblast NN O
cells NNS O
and CC O
peripheral JJ O
blood NN O
lymphocytes NNS O
. . O

ATM NNP O
protein NN O
levels NNS O
and CC O
localization NN O
remain VBP O
constant JJ O
throughout IN O
all DT O
stages NNS O
of IN O
the DT O
cell NN O
cycle NN O
. . O

Truncated VBN O
ATM NNP O
protein NN O
was VBD O
not RB O
detected VBN O
in IN O
lymphoblasts NNS O
from IN O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
patients NNS O
homozygous JJ O
for IN O
mutations NNS O
leading VBG O
to TO O
premature VB O
protein JJ O
termination NN O
. . O

Exposure NN O
of IN O
normal JJ O
human JJ O
cells NNS O
to TO O
gamma VB O
- : O
irradiation NN O
and CC O
the DT O
radiomimetic JJ O
drug NN O
neocarzinostatin NN O
had VBD O
no DT O
effect NN O
on IN O
ATM NNP O
protein NN O
levels NNS O
, , O
in IN O
contrast NN O
to TO O
a DT O
noted JJ O
rise NN O
in IN O
p53 NN O
levels NNS O
over IN O
the DT O
same JJ O
time NN O
interval NN O
. . O

These DT O
findings NNS O
are VBP O
consistent JJ O
with IN O
a DT O
role NN O
for IN O
the DT O
ATM NNP O
protein NN O
in IN O
ensuring VBG O
the DT O
fidelity NN O
of IN O
DNA NNP O
repair NN O
and CC O
cell NN O
cycle NN O
regulation NN O
following VBG O
genome JJ O
damage NN O
. . O
. . O

Type NNP O
III NNP O
collagen NN O
is VBZ O
crucial JJ O
for IN O
collagen NN O
I PRP O
fibrillogenesis VBP O
and CC O
for IN O
normal JJ O
cardiovascular JJ O
development NN O
. . O

Type NNP O
III NNP O
collagen NN O
is VBZ O
a DT O
fibrillar JJ O
forming NN O
collagen NN O
comprising VBG O
three CD O
alpha1 NN O
( ( O
III NNP O
) ) O
chains NNS O
and CC O
is VBZ O
expressed VBN O
in IN O
early JJ O
embryos NN O
and CC O
throughout IN O
embryogenesis NN O
. . O

In IN O
the DT O
adult NN O
, , O
type NN O
III NNP O
collagen NN O
is VBZ O
a DT O
major JJ O
component NN O
of IN O
the DT O
extracellular JJ O
matrix NN O
in IN O
a DT O
variety NN O
of IN O
internal JJ O
organs NNS O
and CC O
skin NN O
. . O

Mutations NNS O
in IN O
the DT O
COL3A1 NNP O
gene NN O
have VBP O
been VBN O
implicated VBN O
as IN O
a DT O
cause NN O
of IN O
type NN B-Disease
IV NNP I-Disease
Ehlers NNP I-Disease
- : I-Disease
Danlos NNP I-Disease
syndrome NN I-Disease
, , O
a DT O
disease NN O
leading VBG O
to TO O
aortic JJ B-Disease
rupture NN I-Disease
in IN O
early JJ O
adult NN O
life NN O
. . O

To TO O
directly RB O
study VB O
the DT O
role NN O
of IN O
Col3a1 NNP O
in IN O
development NN O
and CC O
disease NN O
, , O
we PRP O
have VBP O
inactivated VBN O
the DT O
Col3a1 NNP O
gene NN O
in IN O
embryonic JJ O
stem NN O
cells NNS O
by IN O
homologous JJ O
recombination NN O
. . O

The DT O
mutated JJ O
allele NN O
was VBD O
transmitted VBN O
through IN O
the DT O
mouse NN O
germ JJ O
line NN O
and CC O
homozygous JJ O
mutant NN O
animals NNS O
were VBD O
derived VBN O
from IN O
heterozygous JJ O
intercrosses NNS O
. . O

About RB O
10 CD O
% NN O
of IN O
the DT O
homozygous JJ O
mutant NN O
animals NNS O
survived VBD O
to TO O
adulthood VB O
but CC O
have VB O
a DT O
much JJ O
shorter JJR O
life NN O
span NNS O
compared VBN O
with IN O
wild JJ O
- : O
type NN O
mice NN O
. . O

The DT O
major JJ O
cause NN O
of IN O
death NN O
of IN O
mutant JJ O
mice NN O
was VBD O
rupture NN O
of IN O
the DT O
major JJ O
blood NN O
vessels NNS O
, , O
similar JJ O
to TO O
patients NNS O
with IN O
type JJ B-Disease
IV NNP I-Disease
Ehlers NNP I-Disease
- : I-Disease
Danlos NNP I-Disease
syndrome NN I-Disease
. . O

Ultrastructural JJ O
analysis NN O
of IN O
tissues NNS O
from IN O
mutant JJ O
mice NN O
revealed VBD O
that IN O
type NN O
III NNP O
collagen NN O
is VBZ O
essential JJ O
for IN O
normal JJ O
collagen NN O
I PRP O
fibrillogenesis VBP O
in IN O
the DT O
cardiovascular JJ O
system NN O
and CC O
other JJ O
organs NNS O
. . O
. . O

Nonsense NNP O
mutation NN O
in IN O
exon JJ O
3 CD O
of IN O
the DT O
proteolipid JJ O
protein NN O
gene NN O
( ( O
PLP NNP O
) ) O
in IN O
a DT O
family NN O
with IN O
an DT O
unusual JJ O
form NN O
of IN O
Pelizaeus NNP B-Disease
- : I-Disease
Merzbacher PRP$ I-Disease
disease NN I-Disease
. . O

We PRP O
report VBP O
a DT O
G NNP O
- : O
- : O
> VB O
A DT O
transition NN O
at IN O
nucleotide JJ O
431 CD O
of IN O
the DT O
proteolipid JJ O
protein NN O
gene NN O
( ( O
PLP NNP O
) ) O
results NNS O
in IN O
a DT O
nonsense JJ O
codon NN O
in IN O
a DT O
family NN O
with IN O
an DT O
unusual JJ O
form NN O
of IN O
Pelizaeus NNP B-Disease
- : I-Disease
Merzbacher PRP$ I-Disease
disease NN I-Disease
( ( O
PMD NNP B-Disease
) ) O
. . O

The DT O
mutation NN O
, , O
which WDT O
creates VBZ O
a DT O
second JJ O
AluI NNP O
restriction NN O
site NN O
, , O
results NNS O
in IN O
a DT O
nonsense JJ O
mutation NN O
in IN O
PLP NNP O
. . O

The DT O
clinical JJ O
picture NN O
resembles VBZ O
somewhat RB O
that IN O
of IN O
X NNP B-Disease
- : I-Disease
linked VBN I-Disease
spastic JJ I-Disease
paraplegia NN I-Disease
( ( O
SPG NNP B-Disease
) ) O
. . O

It PRP O
differs VBZ O
from IN O
this DT O
and CC O
both DT O
the DT O
classical JJ O
and CC O
connatal JJ O
forms NNS O
of IN O
PMD NNP B-Disease
in IN O
that DT O
it PRP O
is VBZ O
relatively RB O
mild JJ O
in IN O
form NN O
, , O
onset NN O
is VBZ O
delayed VBN O
beyond IN O
age NN O
2 CD O
years NNS O
, , O
nystagmus NN B-Disease
is VBZ O
absent JJ O
, , O
tremors NNS B-Disease
are VBP O
prominent JJ O
, , O
mental JJ B-Disease
retardation NN I-Disease
is VBZ O
not RB O
severe JJ O
, , O
some DT O
patients NNS O
show VBP O
dementia JJ B-Disease
or CC O
personality NN B-Disease
disorders NNS I-Disease
, , O
the DT O
disease NN O
is VBZ O
progressive JJ O
rather RB O
than IN O
static JJ O
in IN O
some DT O
, , O
and CC O
several JJ O
females NNS O
show VBP O
signs NNS O
of IN O
disease NN O
. . O

The DT O
nonsense JJ O
mutation NN O
, , O
which WDT O
is VBZ O
in IN O
exon JJ O
3B CD O
, , O
should MD O
block VB O
the DT O
synthesis NN O
of IN O
normal JJ O
PLP NNP O
but CC O
spare JJ O
DM20 NNP O
, , O
the DT O
isoform NN O
whose WP$ O
persistence NN O
has VBZ O
been VBN O
associated VBN O
with IN O
mild JJ O
forms NNS O
of IN O
PLP NNP B-Disease
- : I-Disease
associated JJ I-Disease
disease NN I-Disease
in IN O
both DT O
humans NNS O
and CC O
mice NN O
. . O
. . O

Common JJ O
BRCA1 NNP O
variants NNS O
and CC O
susceptibility NN O
to TO O
breast VB B-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
in IN O
the DT O
general JJ O
population NN O
. . O

Most JJS O
multiple JJ O
case NN O
families NNS O
of IN O
young JJ O
onset VBN O
breast NN B-Disease
cancer NN I-Disease
and CC O
ovarian JJ B-Disease
cancer NN I-Disease
are VBP O
thought VBN O
to TO O
be VB O
due JJ O
to TO O
highly RB O
penetrant JJ O
mutations NNS O
in IN O
the DT O
predisposing NN O
genes NNS O
BRCA1 NNP O
and CC O
BRCA2 NNP O
. . O

However RB O
, , O
these DT O
mutations NNS O
are VBP O
uncommon JJ O
in IN O
the DT O
population NN O
and CC O
they PRP O
probably RB O
account VBP O
for IN O
only RB O
a DT O
few JJ O
percent NN O
of IN O
all DT O
breast NN B-Disease
cancer NN I-Disease
incidence NN O
. . O

A DT O
much RB O
larger JJR O
fraction NN O
of IN O
breast NN B-Disease
cancer NN I-Disease
might MD O
, , O
in IN O
principle NN O
, , O
be VB O
due JJ O
to TO O
common JJ O
variants NNS O
which WDT O
confer VBP O
more JJR O
modest JJ O
individual JJ O
risks NNS O
. . O

There EX O
are VBP O
several JJ O
common JJ O
polymorphisms NNS O
in IN O
the DT O
BRCA1 NNP O
gene NN O
which WDT O
generate VBP O
amino NN O
acid JJ O
substitutions NNS O
. . O

We PRP O
have VBP O
examined VBN O
the DT O
frequency NN O
of IN O
four CD O
of IN O
these DT O
polymorphisms NNS O
Gln356Arg NNP O
, , O
Pro871Leu NNP O
, , O
Glu1038Gly NNP O
and CC O
Ser1613Gly NNP O
in IN O
large JJ O
series NN O
of IN O
breast NN B-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
cases NNS O
and CC O
matched JJ O
controls NNS O
. . O

Due JJ O
to TO O
strong JJ O
linkage NN O
disequilibrium NN O
, , O
these DT O
four CD O
sites NNS O
generate VBP O
only RB O
three CD O
haplotypes NNS O
with IN O
a DT O
frequency NN O
> $ O
1 CD O
. . O

3 CD O
% NN O
. . O

The DT O
most RBS O
common JJ O
haplotypes NNS O
, , O
defined VBN O
by IN O
the DT O
alleles NNS O
Gln356Pro871Glu1038Ser1613 NNP O
and CC O
Gln356Leu871Gly1038Gly1613 NNP O
, , O
have VBP O
frequencies NNS O
of IN O
0 CD O
. . O

57 CD O
and CC O
0 CD O
. . O

32 CD O
respectively RB O
, , O
and CC O
these DT O
frequencies NNS O
do VBP O
not RB O
differ VB O
significantly RB O
between IN O
patient JJ O
and CC O
control NN O
groups NNS O
. . O

Thus RB O
the DT O
most RBS O
common JJ O
polymorphisms NN O
of IN O
the DT O
BRCA1 NNP O
gene NN O
do VBP O
not RB O
make VB O
a DT O
significant JJ O
contribution NN O
to TO O
breast VB B-Disease
or CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
risk NN O
. . O

However RB O
, , O
our PRP$ O
data NNS O
suggest VBP O
that IN O
the DT O
Arg356 NNP O
allele NN O
may MD O
have VB O
a DT O
different JJ O
genotype NN O
distribution NN O
in IN O
breast NN B-Disease
cancer NN I-Disease
patients NNS O
from IN O
that DT O
in IN O
controls NNS O
( ( O
Arg356 NNP O
homozygotes NNS O
are VBP O
more RBR O
frequent JJ O
in IN O
the DT O
control NN O
groups NNS O
, , O
P NNP O
= VBZ O
0 CD O
. . O
1 CD O
) ) O
, , O
indicating VBG O
that IN O
it PRP O
may MD O
be VB O
protective JJ O
against IN O
breast NN B-Disease
cancer NN I-Disease
. . O

If IN O
this DT O
finding NN O
can MD O
be VB O
confirmed VBN O
, , O
it PRP O
may MD O
provide VB O
an DT O
insight NN O
into IN O
the DT O
structural JJ O
features NNS O
of IN O
the DT O
BRCA1 NNP O
protein NN O
that WDT O
are VBP O
important JJ O
for IN O
its PRP$ O
function NN O
. . O

Kniest NNP B-Disease
dysplasia NN I-Disease
: : O
Dr NNP O
. . O
W NNP O
. . O

Kniest NNP O
, , O
his PRP$ O
patient NN O
, , O
the DT O
molecular JJ O
defect NN O
. . O

Kniest NNP B-Disease
dysplasia NN I-Disease
is VBZ O
a DT O
severe JJ O
chondrodysplasia NN B-Disease
caused VBN O
by IN O
the DT O
defective JJ B-Disease
formation NN I-Disease
of IN I-Disease
type NN I-Disease
II NNP I-Disease
collagen NN I-Disease
. . O

We PRP O
report VBP O
about IN O
Dr NNP O
. . O
Kniest NNP O
, , O
who WP O
first RB O
described VBD O
the DT O
condition NN O
in IN O
1952 CD O
, , O
and CC O
his PRP$ O
patient NN O
, , O
who WP O
, , O
at IN O
the DT O
age NN O
of IN O
50 CD O
years NNS O
is VBZ O
severely RB B-Disease
handicapped VBN I-Disease
with IN O
short JJ B-Disease
stature NN I-Disease
, , O
restricted VBD B-Disease
joint JJ I-Disease
mobility NN I-Disease
, , O
and CC O
blindness NN B-Disease
but CC O
is VBZ O
mentally RB O
alert JJ O
and CC O
leads VBZ O
an DT O
active JJ O
life NN O
. . O

Molecular JJ O
analysis NN O
of IN O
the DT O
patients NNS O
DNA NNP O
showed VBD O
a DT O
single JJ O
base NN O
( ( O
G NNP O
) ) O
deletion NN O
involving VBG O
the DT O
GT NNP O
dinucleotide NN O
at IN O
the DT O
start NN O
of IN O
intron NN O
18 CD O
destroying VBG O
a DT O
splice JJ O
site NN O
of IN O
the DT O
COL2A1 NNP O
gene NN O
. . O

This DT O
is VBZ O
in IN O
accordance NN O
with IN O
molecular JJ O
findings NNS O
in IN O
other JJ O
patients NNS O
with IN O
Kniest NNP B-Disease
dysplasia NN I-Disease
and CC O
confirms NNS O
, , O
in IN O
the DT O
original JJ O
patient NN O
, , O
that IN O
the DT O
disorder NN O
is VBZ O
caused VBN O
by IN O
small JJ O
inframe NN O
deletions NNS O
often RB O
due JJ O
to TO O
exon VB O
skipping VBG O
as IN O
a DT O
result NN O
of IN O
COL2A1 NNP O
splice NN O
site NN O
mutations NNS O
. . O
. . O

Cloning NN O
of IN O
the DT O
homogentisate NN O
1 CD O
, , O
2 CD O
- : O
dioxygenase NN O
gene NN O
, , O
the DT O
key JJ O
enzyme NN O
of IN O
alkaptonuria NN B-Disease
in IN O
mouse NN O
. . O

We PRP O
determined VBD O
48 CD O
amino NN O
acid NN O
residues NNS O
from IN O
five CD O
peptides NNS O
from IN O
the DT O
homogeneous JJ O
monomer NN O
of IN O
homogentisate NN O
1 CD O
, , O
2 CD O
- : O
dioxygenase NN O
( ( O
HGO NNP O
; : O
E NNP O
. . O
C NNP O
. . O
1 CD O
. . O
13 CD O
. . O
11 CD O
. . O
15 CD O
) ) O
of IN O
mouse NN O
liver NN O
. . O

After IN O
digestion NN O
with IN O
trypsin NN O
, , O
peptides NNS O
were VBD O
separated VBN O
by IN O
reversed JJ O
phase NN O
chromatography NN O
and CC O
amino NN O
acid NN O
sequenced VBD O
. . O

The DT O
deduced JJ O
codon NN O
sequence NN O
of IN O
three CD O
peptides NNS O
was VBD O
used VBN O
to TO O
derive VB O
degenerated JJ O
oligomeres NNS O
. . O

By IN O
combining VBG O
these DT O
oligos NNS O
, , O
we PRP O
were VBD O
able JJ O
to TO O
amplify VB O
fragments NNS O
from IN O
100 CD O
to TO O
300 CD O
bases NNS O
( ( O
b NN O
) ) O
from IN O
mouse NN O
liver NN O
cDNA NN O
by IN O
polymerase NN O
chain NN O
reaction NN O
after IN O
reverse JJ O
transcription NN O
( ( O
RT NNP O
- : O
PCR NN O
) ) O
. . O

A DT O
fragment NN O
of IN O
200 CD O
b NN O
was VBD O
cloned VBN O
and CC O
used VBN O
as IN O
a DT O
probe NN O
to TO O
screen VB O
a DT O
mouse NN O
liver NN O
cDNA NN O
library NN O
. . O

One CD O
clone NN O
from IN O
this DT O
library NN O
contained VBD O
the DT O
complete JJ O
cDNA NN O
- : O
insert NN O
for IN O
HGO NNP O
as IN O
determined VBN O
by IN O
sequencing VBG O
. . O

The DT O
cDNA NN O
encodes VBZ O
for IN O
a DT O
protein NN O
of IN O
50 CD O
kDa NNS O
, , O
as IN O
predicted VBN O
. . O

The DT O
cDNA NN O
of IN O
mouse NN O
HGO NNP O
has VBZ O
an DT O
overall JJ O
identity NN O
of IN O
41 CD O
% NN O
to TO O
the DT O
corresponding JJ O
gene NN O
hmgA NN O
from IN O
Aspergillus NNP O
. . O

Sequence NN O
similarities NNS O
to TO O
human NNS O
expressed VBN O
sequence NN O
tags NN O
( ( O
EST NNP O
) ) O
clones NNS O
ranged VBD O
from IN O
70 CD O
% NN O
to TO O
20 CD O
% NN O
. . O

The DT O
positions NNS O
of IN O
122 CD O
conserved VBD O
amino NN O
acids NNS O
could MD O
be VB O
determined VBN O
by IN O
multiple JJ O
sequence NN O
alignment NN O
. . O

We PRP O
identified VBD O
one CD O
first JJ O
intron NN O
of IN O
928 CD O
b NN O
in IN O
the DT O
mouse NN O
gene NN O
. . O

The DT O
gene NN O
for IN O
HGO NNP O
seems VBZ O
to TO O
be VB O
expressed VBN O
in IN O
various JJ O
tissues NNS O
, , O
as IN O
shown VBN O
by IN O
RT NNP O
- : O
PCR NN O
on IN O
different JJ O
cDNAs NN O
. . O

FISH NN O
experiments NNS O
with IN O
the DT O
whole JJ O
murine NN O
cDNA NN O
as IN O
probe NN O
clearly RB O
revealed VBD O
signals NNS O
at IN O
the DT O
human JJ O
chromosomal JJ O
band NN O
3q13 CD O
. . O

3 LS O
- : O
q21 NN O
. . O

This DT O
corresponds VBZ O
well RB O
to TO O
the DT O
previous JJ O
assignment NN O
of IN O
the DT O
locus NN O
for IN O
the DT O
human JJ O
alkaptonuria NN B-Disease
gene NN O
( ( O
AKU NNP O
) ) O
to TO O
the DT O
same JJ O
chromosomal JJ O
region NN O
by IN O
multipoint NN O
linkage NN O
analysis NN O
. . O

We PRP O
therefore VBP O
conclude VBP O
that IN O
the DT O
HGO NNP O
cDNA NN O
encodes VBZ O
the DT O
gene NN O
responsible JJ O
for IN O
alkaptonuria NN B-Disease
. . O

PTEN NNP O
, , O
a DT O
putative JJ O
protein NN O
tyrosine NN O
phosphatase NN O
gene NN O
mutated VBN O
in IN O
human JJ O
brain NN B-Disease
, , I-Disease
breast NN I-Disease
, , I-Disease
and CC I-Disease
prostate NN I-Disease
cancer NN I-Disease
. . O

Mapping NN O
of IN O
homozygous JJ O
deletions NNS O
on IN O
human JJ O
chromosome NN O
10q23 CD O
has VBZ O
led VBN O
to TO O
the DT O
isolation NN O
of IN O
a DT O
candidate NN O
tumor NN B-Disease
suppressor NN O
gene NN O
, , O
PTEN NNP O
, , O
that WDT O
appears VBZ O
to TO O
be VB O
mutated VBN O
at IN O
considerable JJ O
frequency NN O
in IN O
human JJ O
cancers NNS B-Disease
. . O

In IN O
preliminary JJ O
screens NNS O
, , O
mutations NNS O
of IN O
PTEN NNP O
were VBD O
detected VBN O
in IN O
31 CD O
% NN O
( ( O
13 CD O
/ RB O
42 CD O
) ) O
of IN O
glioblastoma NN B-Disease
cell NN O
lines NNS O
and CC O
xenografts NNS O
, , O
100 CD O
% NN O
( ( O
4 CD O
/ RB O
4 CD O
) ) O
of IN O
prostate NN B-Disease
cancer NN I-Disease
cell NN O
lines NNS O
, , O
6 CD O
% NN O
( ( O
4 CD O
/ RB O
65 CD O
) ) O
of IN O
breast NN B-Disease
cancer NN I-Disease
cell NN O
lines NNS O
and CC O
xenografts NNS O
, , O
and CC O
17 CD O
% NN O
( ( O
3 CD O
/ RB O
18 CD O
) ) O
of IN O
primary JJ B-Disease
glioblastomas NN I-Disease
. . O

The DT O
predicted JJ O
PTEN NNP O
product NN O
has VBZ O
a DT O
protein NN O
tyrosine NN O
phosphatase NN O
domain NN O
and CC O
extensive JJ O
homology NN O
to TO O
tensin VB O
, , O
a DT O
protein NN O
that WDT O
interacts VBZ O
with IN O
actin JJ O
filaments NNS O
at IN O
focal JJ O
adhesions NNS O
. . O

These DT O
homologies NNS O
suggest VBP O
that IN O
PTEN NNP O
may MD O
suppress VB O
tumor NN B-Disease
cell NN O
growth NN O
by IN O
antagonizing VBG O
protein JJ O
tyrosine NN O
kinases NNS O
and CC O
may MD O
regulate VB O
tumor NN B-Disease
cell NN O
invasion NN O
and CC O
metastasis NN B-Disease
through IN O
interactions NNS O
at IN O
focal JJ O
adhesions NNS O
. . O
. . O

Heterogeneity NN O
in IN O
Schwartz NNP B-Disease
- : I-Disease
Jampel NNP I-Disease
chondrodystrophic JJ I-Disease
myotonia NN I-Disease
. . O

The DT O
Schwartz NNP B-Disease
- : I-Disease
Jampel NNP I-Disease
syndrome NN I-Disease
( ( O
SJS NNP B-Disease
; : O
chondrodystrophic JJ B-Disease
myotonia NN I-Disease
; : O
McK NNP O
255 CD O
, , O
800 CD O
) ) O
is VBZ O
a DT O
recessively RB B-Disease
inherited JJ I-Disease
condition NN I-Disease
defined VBN O
by IN O
myotonia NN B-Disease
, , O
short JJ B-Disease
stature NN I-Disease
, , O
and CC O
bone NN B-Disease
dysplasia NN I-Disease
. . O

Genetic JJ O
linkage NN O
between IN O
SJS NNP B-Disease
and CC O
chromosomal JJ O
region NN O
1q36 CD O
- : O
34 CD O
has VBZ O
been VBN O
observed VBN O
in IN O
several JJ O
families NNS O
, , O
but CC O
the DT O
gene NN O
has VBZ O
not RB O
yet RB O
been VBN O
identified VBN O
. . O

We PRP O
studied VBD O
the DT O
clinical JJ O
and CC O
radiological JJ O
features NNS O
in IN O
81 CD O
patients NNS O
from IN O
the DT O
literature NN O
and CC O
5 CD O
own JJ O
patients NNS O
trying VBG O
to TO O
identify VB O
distinct JJ O
subgroups NNS O
. . O

In IN O
addition NN O
, , O
we PRP O
tested VBD O
genetic JJ O
linkage NN O
to TO O
the DT O
SJS NNP B-Disease
locus NN O
on IN O
chromosome NN O
1 CD O
in IN O
one CD O
family NN O
with IN O
two CD O
affected JJ O
sibs NN O
. . O

We PRP O
found VBD O
that IN O
a DT O
group NN O
of IN O
patients NNS O
have VBP O
mild VBN O
skeletal JJ O
changes NNS O
which WDT O
may MD O
be VB O
secondary JJ O
consequences NNS O
of IN O
myotonia NN B-Disease
, , O
while IN O
another DT O
group NN O
of IN O
patients NNS O
appear VBP O
to TO O
have VB O
primary JJ O
bone NN B-Disease
dysplasia NN I-Disease
with IN O
myotonia NN B-Disease
. . O

Within IN O
this DT O
latter JJ O
group NN O
, , O
there EX O
are VBP O
differences NNS O
in IN O
age NN O
of IN O
manifestation NN O
, , O
clinical JJ O
course NN O
and CC O
pattern NN O
of IN O
bone NN O
changes NNS O
. . O

We PRP O
tentatively RB O
isolate VBP O
three CD O
different JJ O
types NNS O
of IN O
SJS NNP B-Disease
type NN I-Disease
1A CD I-Disease
, , O
usually RB O
recognized VBN O
in IN O
childhood NN O
, , O
with IN O
moderate JJ O
bone NN B-Disease
dysplasia NN I-Disease
, , O
corresponding VBG O
to TO O
the DT O
original JJ O
descriptions NNS O
of IN O
Schwartz NNP O
, , O
Jampel NNP O
and CC O
Aberfeld NNP O
; : O
type NN O
1B CD O
, , O
similar JJ O
to TO O
type VB O
1A CD O
but CC O
recognizable JJ O
at IN O
birth NN O
, , O
with IN O
more RBR O
pronounced JJ O
bone NN B-Disease
dysplasia NN I-Disease
resembling VBG O
Kniest NNP B-Disease
dysplasia NN I-Disease
; : O
and CC O
type VB O
2 CD O
, , O
manifest NN O
at IN O
birth NN O
, , O
with IN O
increased VBN O
mortality NN O
and CC O
bone NN B-Disease
dysplasia NN I-Disease
resembling VBG O
Pyle NNP B-Disease
disease NN I-Disease
. . O

Genetic JJ O
analysis NN O
of IN O
the DT O
family NN O
with IN O
two CD O
sibs NNS O
affected VBN O
by IN O
SJS NNP B-Disease
type NN I-Disease
2 CD I-Disease
showed VBD O
evidence NN O
against IN O
linkage NN O
to TO O
chromosome VB O
1p36 CD O
- : O
34 CD O
. . O

CONCLUSIONS NNP O
SJS NNP B-Disease
is VBZ O
clinically RB O
and CC O
radiologically RB O
heterogeneous JJ O
. . O

The DT O
causes NNS O
of IN O
heterogeneity NN O
are VBP O
not RB O
known VBN O
yet RB O
but CC O
are VBP O
likely JJ O
to TO O
include VB O
both DT O
different JJ O
mutations NNS O
at IN O
the DT O
SJS NNP B-Disease
locus NN O
on IN O
chromosome NN O
1 CD O
and CC O
the DT O
presence NN O
of IN O
a DT O
second JJ O
SJS NNP B-Disease
locus NN O
. . O

A DT O
tentative JJ O
clinico NN O
- : O
radiological JJ O
classification NN O
can MD O
be VB O
useful JJ O
for IN O
the DT O
characterization NN O
of IN O
patients NNS O
and CC O
the DT O
development NN O
of IN O
genotype NN O
- : O
phenotype NN O
correlations NNS O
. . O
. . O

A DT O
clinical JJ O
overview NN O
of IN O
WT1 NNP O
gene NN O
mutations NNS O
. . O

Mutations NNS O
in IN O
the DT O
WT1 NNP O
gene NN O
were VBD O
anticipated VBN O
to TO O
explain VB O
the DT O
genetic JJ O
basis NN O
of IN O
the DT O
childhood NN O
kidney NN B-Disease
cancer NN I-Disease
, , O
Wilms NNP B-Disease
tumour NN I-Disease
( ( O
WT NNP B-Disease
) ) O
. . O

Six CD O
years NNS O
on IN O
, , O
we PRP O
review VBP O
100 CD O
reports NNS O
of IN O
intragenic JJ O
WT1 NNP O
mutations NNS O
and CC O
examine VB O
the DT O
accompanying VBG O
clinical JJ O
phenotypes NNS O
. . O

While IN O
only RB O
5 CD O
% NN O
of IN O
sporadic JJ B-Disease
Wilms NNP I-Disease
tumours NNS I-Disease
have VBP O
intragenic JJ O
WT1 NNP O
mutations NNS O
, , O
> VBP O
90 CD O
% NN O
of IN O
patients NNS O
with IN O
the DT O
Denys NNP B-Disease
- : I-Disease
Drash NNP I-Disease
syndrome NN I-Disease
( ( O
renal JJ B-Disease
nephropathy NN I-Disease
, , O
gonadal JJ B-Disease
anomaly NN I-Disease
, , O
predisposition NN B-Disease
to TO I-Disease
WT NNP I-Disease
) ) O
carry VBP O
constitutional JJ O
intragenic JJ O
WT1 NNP O
mutations NNS O
. . O

WT1 NNP O
mutations NNS O
have VBP O
also RB O
been VBN O
reported VBN O
in IN O
juvenile NN B-Disease
granulosa NN I-Disease
cell NN I-Disease
tumour NN I-Disease
, , O
non SYM B-Disease
- : I-Disease
asbestos NN I-Disease
related JJ I-Disease
mesothelioma NN I-Disease
, , O
desmoplastic JJ B-Disease
small JJ I-Disease
round NN I-Disease
cell NN I-Disease
tumour NN I-Disease
and CC O
, , O
most RBS O
recently RB O
, , O
acute JJ B-Disease
myeloid NN I-Disease
leukemia NN I-Disease
. . O
. . O

A DT O
mutation NN O
in IN O
autosomal JJ B-Disease
dominant JJ I-Disease
myotonia NN I-Disease
congenita NN I-Disease
affects VBZ O
pore IN O
properties NNS O
of IN O
the DT O
muscle NN O
chloride NN O
channel NN O
. . O

Autosomal NNP B-Disease
dominant JJ I-Disease
myotonia NN I-Disease
congenita NN I-Disease
is VBZ O
an DT O
inherited JJ B-Disease
disorder NN I-Disease
of IN I-Disease
skeletal JJ I-Disease
muscle NN I-Disease
caused VBN O
by IN O
mutations NNS O
in IN O
a DT O
voltage NN O
- : O
gated VBN O
Cl NNP O
- : O
channel NN O
gene NN O
( ( O
CLCN1 NNP O
, , O
7q35 CD O
) ) O
. . O

Here RB O
, , O
we PRP O
report VBP O
that IN O
a DT O
mutation NN O
predicting VBG O
the DT O
substitution NN O
of IN O
Gly NNP O
230 CD O
by IN O
glutamic JJ O
acid NN O
( ( O
G230E NNP O
) ) O
between IN O
segments NNS O
D3 NNP O
and CC O
D4 NNP O
dramatically RB O
alters VBZ O
the DT O
pore NN O
properties NNS O
of IN O
a DT O
recombinant JJ O
human JJ O
muscle NN O
Cl NNP O
- : O
channel NN O
( ( O
hCIC JJ O
- : O
1 CD O
) ) O
expressed VBN O
in IN O
a DT O
mammalian JJ O
cell NN O
line NN O
( ( O
tsA201 NN O
) ) O
. . O

The DT O
G230E NNP O
mutation NN O
causes VBZ O
substantial JJ O
changes NNS O
in IN O
anion NN O
and CC O
cation NN O
selectivity NN O
as RB O
well RB O
as IN O
a DT O
fundamental JJ O
change NN O
in IN O
rectification NN O
of IN O
the DT O
current JJ O
- : O
voltage NN O
relationship NN O
. . O

Whereas NNP O
wild SYM O
- : O
type NN O
channels NNS O
are VBP O
characterized VBN O
by IN O
pronounced JJ O
inward JJ O
rectification NN O
and CC O
a DT O
Cl NNP O
> NNP O
thiocyanate NN O
> NNP O
Br NNP O
> NNP O
NO NNP O
( ( O
3 CD O
) ) O
> NN O
I PRP O
> VBP O
CH NNP O
( ( O
3 CD O
) ) O
SO NNP O
( ( O
3 CD O
) ) O
selectivity NN O
, , O
G230E NNP O
exhibits VBZ O
outward JJ O
rectification NN O
at IN O
positive JJ O
potentials NNS O
and CC O
a DT O
thiocyanate NN O
> NN O
NO NNP O
( ( O
3 CD O
) ) O
> NN O
I PRP O
> VBP O
Br NNP O
> NNP O
Cl NNP O
> NNP O
CH NNP O
( ( O
3 CD O
) ) O
SO NNP O
( ( O
3 CD O
) ) O
selectivity NN O
. . O

Furthermore RB O
, , O
the DT O
cation NN O
- : O
to TO O
- : O
anion NN O
permeability NN O
ratio NN O
of IN O
the DT O
mutant NN O
is VBZ O
much RB O
greater JJR O
than IN O
that DT O
of IN O
the DT O
wild JJ O
- : O
type NN O
channel NN O
. . O

Voltage NNP O
- : O
dependent NN O
blocks NNS O
by IN O
intracellular JJ O
and CC O
extracellular JJ O
iodide NN O
help NN O
to TO O
distinguish VB O
two CD O
distinct JJ O
ion NN O
binding VBG O
sites NNS O
within IN O
the DT O
hClC NN O
- : O
1 CD O
conduction NN O
pathway NN O
. . O

Both DT O
binding VBG O
sites NNS O
are VBP O
preserved VBN O
in IN O
the DT O
mutant NN O
but CC O
have VBP O
decreased VBN O
affinities NNS O
for IN O
iodide NN O
. . O

These DT O
findings NNS O
suggest VBP O
that IN O
Gly NNP O
230 CD O
is VBZ O
critical JJ O
for IN O
normal JJ O
ion NN O
conductance NN O
in IN O
hClC JJ O
- : O
1 CD O
and CC O
that IN O
this DT O
residue JJ O
resides NNS O
within IN O
the DT O
channel NN O
pore NN O
. . O
. . O

The DT O
incidence NN O
of IN O
PAX6 NNP O
mutation NN O
in IN O
patients NNS O
with IN O
simple JJ O
aniridia NN B-Disease
: : O
an DT O
evaluation NN O
of IN O
mutation NN O
detection NN O
in IN O
12 CD O
cases NNS O
. . O

Twelve NNP O
aniridia NN B-Disease
patients NNS O
, , O
five CD O
with IN O
a DT O
family NN O
history NN O
and CC O
seven CD O
presumed VBD O
to TO O
be VB O
sporadic JJ O
, , O
were VBD O
exhaustively RB O
screened VBN O
in IN O
order NN O
to TO O
test VB O
what WP O
proportion NN O
of IN O
people NNS O
with IN O
aniridia NN B-Disease
, , O
uncomplicated VBN O
by IN O
associated JJ O
anomalies NNS O
, , O
carry VBP O
mutations NNS O
in IN O
the DT O
human JJ O
PAX6 NNP O
gene NN O
. . O

Mutations NNS O
were VBD O
detected VBN O
in IN O
90 CD O
% NN O
of IN O
the DT O
cases NNS O
. . O

Three CD O
mutation NN O
detection NN O
techniques NNS O
were VBD O
used VBN O
to TO O
determine VB O
if IN O
one CD O
method NN O
was VBD O
superior JJ O
for IN O
this DT O
gene NN O
. . O

The DT O
protein NN O
truncation NN O
test NN O
( ( O
PTT NNP O
) ) O
was VBD O
used VBN O
on IN O
RT NNP O
- : O
PCR NN O
products NNS O
, , O
SSCP NNP O
on IN O
genomic JJ O
PCR NNP O
amplifications NNS O
, , O
and CC O
chemical JJ O
cleavage NN O
of IN O
mismatch NN O
on IN O
both DT O
RT NNP O
- : O
PCR NN O
and CC O
genomic JJ O
amplifications NNS O
. . O

For IN O
RT NNP O
- : O
PCR NN O
products NNS O
, , O
only RB O
the DT O
translated JJ O
portion NN O
of IN O
the DT O
gene NN O
was VBD O
screened VBN O
. . O

On IN O
genomic JJ O
products NNS O
exons NNS O
1 CD O
to TO O
13 CD O
( ( O
including VBG O
740 CD O
bp NN O
of IN O
the DT O
3 CD O
untranslated JJ O
sequence NN O
and CC O
all DT O
intron NN O
/ NNP O
exon NNP O
boundaries NNS O
) ) O
were VBD O
screened VBN O
, , O
as IN O
was VBD O
a DT O
neuroretina JJ O
specific JJ O
enhancer NN O
in IN O
intron NN O
4 CD O
. . O

Ten CD O
of IN O
the DT O
possible JJ O
12 CD O
mutations NNS O
in IN O
the DT O
five CD O
familial JJ O
cases NNS O
and CC O
five CD O
of IN O
the DT O
sporadic JJ O
patients NNS O
were VBD O
found VBN O
, , O
all DT O
of IN O
which WDT O
conformed VBD O
to TO O
a DT O
functional JJ O
outcome NN O
of IN O
haploinsufficiency NN O
. . O

Five CD O
were VBD O
splice NN O
site NN O
mutations NNS O
( ( O
one CD O
in IN O
the DT O
donor JJ O
site NN O
of IN O
intron NN O
4 CD O
, , O
two CD O
in IN O
the DT O
donor JJ O
site NN O
of IN O
intron NN O
6 CD O
, , O
one CD O
in IN O
each DT O
of IN O
the DT O
acceptor NN O
sites NNS O
of IN O
introns NNS O
8 CD O
and CC O
9 CD O
) ) O
and CC O
five CD O
were VBD O
nonsense JJ O
mutations NNS O
in IN O
exons NNS O
8 CD O
, , O
9 CD O
, , O
10 CD O
, , O
11 CD O
, , O
and CC O
12 CD O
. . O

SSCP NNP O
analysis NN O
of IN O
individually RB O
amplified JJ O
exons NNS O
, , O
with IN O
which WDT O
nine CD O
of IN O
the DT O
10 CD O
mutations NNS O
were VBD O
seen VBN O
, , O
was VBD O
the DT O
most RBS O
useful JJ O
detection NN O
method NN O
for IN O
PAX6 NNP O
. . O
. . O

Insulin NNP O
gene NN O
region NN O
contributes NNS O
to TO O
genetic JJ O
susceptibility NN O
to TO O
, , O
but CC O
may MD O
not RB O
to TO O
low JJ O
incidence NN O
of IN O
, , O
insulin FW B-Disease
- : I-Disease
dependent NN I-Disease
diabetes VBZ I-Disease
mellitus NNS I-Disease
in IN O
Japanese JJ O
. . O

In IN O
the DT O
Caucasian JJ O
population NN O
, , O
it PRP O
has VBZ O
been VBN O
demonstrated VBN O
that IN O
the DT O
insulin NN O
gene NN O
( ( O
INS NNP O
) ) O
region NN O
contains VBZ O
the DT O
insulin NN B-Disease
- : I-Disease
dependent NN I-Disease
diabetes VBZ I-Disease
mellitus JJ I-Disease
locus NN O
( ( O
IDDM2 NNP O
) ) O
. . O

In IN O
the DT O
Japanese JJ O
population NN O
, , O
however RB O
, , O
there EX O
has VBZ O
been VBN O
no DT O
report NN O
demonstrating VBG O
the DT O
contribution NN O
of IN O
IDDM2 NNP O
to TO O
the DT O
pathogenesis NN O
of IN O
IDDM NNP B-Disease
. . O

We PRP O
conducted VBD O
an DT O
association NN O
study NN O
of IN O
IDDM NNP B-Disease
in IN O
a DT O
large JJ O
number NN O
of IN O
Japanese JJ O
subjects NNS O
with IN O
multiple JJ O
polymorphisms NNS O
in IN O
INS NNP O
region NN O
. . O

We PRP O
found VBD O
a DT O
significant JJ O
association NN O
of IN O
the DT O
INS NNP O
region NN O
with IN O
IDDM NNP B-Disease
. . O

Alleles NNS O
positively RB O
associated VBN O
with IN O
IDDM NNP B-Disease
in IN O
INS NNP O
region NN O
were VBD O
the DT O
same JJ O
as IN O
those DT O
positively JJ O
- : O
associated VBN O
with IN O
IDDM NNP B-Disease
in IN O
Caucasian NNP O
population NN O
, , O
although IN O
positively RB O
- : O
associated VBN O
alleles NNS O
are VBP O
very RB O
common JJ O
( ( O
allele JJ O
frequencies NNS O
> VBP O
0 CD O
. . O
9 CD O
) ) O
in IN O
the DT O
Japanese JJ O
general JJ O
population NN O
. . O

These DT O
data NNS O
suggest VBP O
that IN O
IDDM2 NNP O
is VBZ O
involved VBN O
in IN O
the DT O
genetic JJ O
susceptibility NN O
to TO O
IDDM NNP B-Disease
in IN O
Japanese NNP O
. . O

The DT O
high JJ O
frequencies NNS O
of IN O
disease NN O
- : O
associated VBN O
alleles NNS O
in IN O
the DT O
general JJ O
population NN O
suggest VBP O
that IN O
IDDM2 NNP O
locus NN O
is VBZ O
not RB O
responsible JJ O
for IN O
the DT O
low JJ O
incidence NN O
of IN O
IDDM NNP B-Disease
in IN O
Japanese NNP O
. . O

The DT O
human JJ O
complement NN O
C9 NNP O
gene NN O
: : O
identification NN O
of IN O
two CD O
mutations NNS O
causing VBG O
deficiency NN O
and CC O
revision NN O
of IN O
the DT O
gene NN O
structure NN O
. . O

The DT O
ninth JJ O
component NN O
of IN O
human JJ O
complement NN O
( ( O
C9 NNP O
) ) O
is VBZ O
the DT O
last JJ O
of IN O
the DT O
terminal JJ O
complement NN O
components NNS O
creating VBG O
the DT O
membrane NN O
attack NN O
complex NN O
. . O

C9 NNP O
is VBZ O
a DT O
single JJ O
- : O
chain NN O
serum NN O
protein NN O
that WDT O
is VBZ O
encoded VBN O
by IN O
a DT O
gene NN O
located VBN O
on IN O
chromosome NN O
5p CD O
. . O

Deficiency NN B-Disease
of IN I-Disease
terminal JJ I-Disease
complement NN I-Disease
components NNS I-Disease
is VBZ O
generally RB O
associated VBN O
with IN O
recurrent NN O
neisseria NNS B-Disease
infections NNS I-Disease
. . O

We PRP O
studied VBD O
a DT O
previously RB O
described VBN O
Swiss JJ O
family NN O
with IN O
inherited JJ B-Disease
C9 NNP I-Disease
deficiency NN I-Disease
. . O

To TO O
identify VB O
the DT O
genetic JJ O
basis NN O
of IN O
C9 NNP B-Disease
deficiency NN I-Disease
, , O
we PRP O
developed VBD O
an DT O
approach NN O
using VBG O
exon JJ O
- : O
specific JJ O
PCR NNP O
and CC O
direct JJ O
DNA NNP O
sequencing NN O
. . O

As IN O
a DT O
cause NN O
of IN O
C9 NNP B-Disease
deficiency NN I-Disease
, , O
we PRP O
found VBD O
two CD O
different JJ O
point NN O
mutations NNS O
, , O
both DT O
generating VBG O
TGA NNP O
stop JJ O
codons NNS O
in IN O
the DT O
coding NN O
sequence NN O
. . O

One CD O
mutation NN O
, , O
a DT O
C NNP O
to TO O
A NNP O
exchange NN O
, , O
was VBD O
detected VBN O
in IN O
exon JJ O
2 CD O
at IN O
cDNA NN O
position NN O
166 CD O
, , O
the DT O
other JJ O
, , O
a DT O
C NNP O
to TO O
T NNP O
exchange NN O
, , O
was VBD O
located VBN O
in IN O
exon JJ O
4 CD O
( ( O
cDNA JJ O
position NN O
464 CD O
) ) O
. . O

In IN O
family NN O
studies NNS O
of IN O
three CD O
first JJ O
- : O
degree NN O
relatives NNS O
with IN O
heterozygous JJ O
C9 NNP B-Disease
deficiency NN I-Disease
, , O
we PRP O
demonstrated VBD O
that IN O
the DT O
two CD O
mutations NNS O
are VBP O
segregating VBG O
independently RB O
. . O

Therefore RB O
, , O
these DT O
mutations NNS O
are VBP O
sufficient JJ O
to TO O
explain VB O
the DT O
complete JJ O
deficiency NN O
of IN O
both CC O
the DT O
probands NNS O
studied VBN O
. . O

DNA NN O
sequencing NN O
of IN O
the DT O
exon JJ O
- : O
intron NN O
junctions NNS O
revealed VBD O
a DT O
number NN O
of IN O
revisions NNS O
regarding VBG O
the DT O
boundaries NNS O
between IN O
exons NNS O
4 CD O
, , O
5 CD O
, , O
and CC O
6 CD O
as RB O
well RB O
as IN O
between IN O
exons NNS O
10 CD O
and CC O
11 CD O
. . O

No DT O
additional JJ O
introns NNS O
were VBD O
detected VBN O
in IN O
exons NNS O
6 CD O
and CC O
10 CD O
. . O

Furthermore RB O
, , O
DNA NNP O
marker NN O
studies NNS O
were VBD O
conducted VBN O
using VBG O
known VBN O
polymorphisms NNS O
of IN O
the DT O
C6 NNP O
, , O
C7 NNP O
, , O
and CC O
C9 NNP O
genes NNS O
, , O
confirming VBG O
the DT O
linkage NN O
of IN O
the DT O
observed JJ O
C9 NNP O
mutations NNS O
with IN O
defined JJ O
haplotypes NNS O
. . O
. . O

BRCA1 NNP O
mutations NNS O
in IN O
women NNS O
attending VBG O
clinics NNS O
that WDT O
evaluate VBP O
the DT O
risk NN O
of IN O
breast NN B-Disease
cancer NN I-Disease
. . O

BACKGROUND NNP O
To TO O
define VB O
the DT O
incidence NN O
of IN O
BRCA1 NNP O
mutations NNS O
among IN O
patients NNS O
seen VBN O
in IN O
clinics NNS O
that WDT O
evaluate VBP O
the DT O
risk NN O
of IN O
breast NN B-Disease
cancer NN I-Disease
, , O
we PRP O
analyzed VBD O
DNA NNP O
samples NNS O
from IN O
women NNS O
seen VBN O
in IN O
this DT O
setting NN O
and CC O
constructed VBN O
probability NN O
tables NNS O
to TO O
provide VB O
estimates NNS O
of IN O
the DT O
likelihood NN O
of IN O
finding VBG O
a DT O
BRCA1 NNP O
mutation NN O
in IN O
individual JJ O
families NNS O
. . O

METHODS NNP O
Clinical NNP O
information NN O
, , O
family NN O
histories NNS O
, , O
and CC O
blood NN O
for IN O
DNA NN O
analysis NN O
were VBD O
obtained VBN O
from IN O
263 CD O
women NNS O
with IN O
breast NN B-Disease
cancer NN I-Disease
. . O

Conformation NNP O
- : O
sensitive JJ O
gel NN O
electrophoresis NN O
and CC O
DNA NNP O
sequencing NN O
were VBD O
used VBN O
to TO O
identify VB O
BRCA1 NNP O
mutations NNS O
. . O

RESULTS NNP O
BRCA1 NNP O
mutations NNS O
were VBD O
identified VBN O
in IN O
16 CD O
percent NN O
of IN O
women NNS O
with IN O
a DT O
family NN O
history NN O
of IN O
breast NN B-Disease
cancer NN I-Disease
. . O

Only RB O
7 CD O
percent NN O
of IN O
women NNS O
from IN O
families NNS O
with IN O
a DT O
history NN O
of IN O
breast NN B-Disease
cancer NN I-Disease
but CC O
not RB O
ovarian JJ B-Disease
cancer NN I-Disease
had VBD O
BRCA1 NNP O
mutations NNS O
. . O

The DT O
rates NNS O
were VBD O
higher JJR O
among IN O
women NNS O
from IN O
families NNS O
with IN O
a DT O
history NN O
of IN O
both DT O
breast NN B-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
. . O

Among IN O
family NN O
members NNS O
, , O
an DT O
average JJ O
age NN O
of IN O
less JJR O
than IN O
55 CD O
years NNS O
at IN O
the DT O
diagnosis NN O
of IN O
breast NN B-Disease
cancer NN I-Disease
, , O
the DT O
presence NN O
of IN O
ovarian JJ B-Disease
cancer NN I-Disease
, , O
the DT O
presence NN O
of IN O
breast NN B-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
in IN O
the DT O
same JJ O
woman NN O
, , O
and CC O
Ashkenazi NNP O
Jewish NNP O
ancestry NN O
were VBD O
all DT O
associated VBN O
with IN O
an DT O
increased VBN O
risk NN O
of IN O
detecting VBG O
a DT O
BRCA1 NNP O
mutation NN O
. . O

No DT O
association NN O
was VBD O
found VBN O
between IN O
the DT O
presence NN O
of IN O
bilateral JJ O
breast NN B-Disease
cancer NN I-Disease
or CC O
the DT O
number NN O
of IN O
breast NN B-Disease
cancers NNS I-Disease
in IN O
a DT O
family NN O
and CC O
the DT O
detection NN O
of IN O
a DT O
BRCA1 NNP O
mutation NN O
, , O
or CC O
between IN O
the DT O
position NN O
of IN O
the DT O
mutation NN O
in IN O
the DT O
BRCA1 NNP O
gene NN O
and CC O
the DT O
presence NN O
of IN O
ovarian JJ B-Disease
cancer NN I-Disease
in IN O
a DT O
family NN O
. . O

CONCLUSIONS NNP O
Among IN O
women NNS O
with IN O
breast NN B-Disease
cancer NN I-Disease
and CC O
a DT O
family NN O
history NN O
of IN O
the DT O
disease NN O
, , O
the DT O
percentage NN O
with IN O
BRCA1 NNP O
coding VBG O
- : O
region NN O
mutations NNS O
is VBZ O
less JJR O
than IN O
the DT O
45 CD O
percent NN O
predicted VBN O
by IN O
genetic JJ O
- : O
linkage NN O
analysis NN O
. . O

These DT O
results NNS O
suggest VBP O
that IN O
even RB O
in IN O
a DT O
referral JJ O
clinic NN O
specializing VBG O
in IN O
screening VBG O
women NNS O
from IN O
high JJ O
- : O
risk NN O
families NNS O
, , O
the DT O
majority NN O
of IN O
tests NNS O
for IN O
BRCA1 NNP O
mutations NNS O
will MD O
be VB O
negative JJ O
and CC O
therefore RB O
uninformative JJ O
. . O
. . O

Mutations NNS O
in IN O
the DT O
arginine NN O
- : O
rich JJ O
protein NN O
gene NN O
( ( O
ARP NNP O
) ) O
in IN O
pancreatic JJ B-Disease
cancer NN I-Disease
. . O

The DT O
ARP NNP O
gene NN O
encodes VBZ O
a DT O
highly RB O
conserved VBN O
arginine NN O
- : O
rich JJ O
protein NN O
from IN O
chromosomal JJ O
band NN O
3p21 CD O
. . O

1 CD O
1 CD O
. . O

At IN O
the DT O
cytogenetic JJ O
level NN O
this DT O
region NN O
is VBZ O
frequently RB O
deleted VBN O
in IN O
a DT O
variety NN O
of IN O
different JJ O
solid JJ B-Disease
tumors NNS I-Disease
, , O
although IN O
not RB O
in IN O
pancreatic JJ B-Disease
cancer NN I-Disease
. . O

We PRP O
have VBP O
reported VBN O
the DT O
presence NN O
of IN O
a DT O
specific JJ O
mutation NN O
( ( O
ATG50 NNP O
- : O
- : O
> NN O
AGG NNP O
) ) O
or CC O
deletion NN O
of IN O
codon JJ O
50 CD O
of IN O
the DT O
ARP NNP O
gene NN O
in IN O
different JJ O
tumor NN B-Disease
types NNS I-Disease
( ( O
Shridhar NNP O
et RB O
al RB O
. . O
, , O
1996 CD O
, , O
1996a CD O
) ) O
. . O

In IN O
the DT O
present JJ O
study NN O
, , O
we PRP O
have VBP O
observed VBN O
mutations NNS O
involving VBG O
codon NN O
50 CD O
in IN O
11 CD O
of IN O
37 CD O
pancreatic JJ B-Disease
tumors NNS I-Disease
. . O

The DT O
frequency NN O
of IN O
codon NN O
50 CD O
mutation NN O
is VBZ O
roughly RB O
the DT O
same JJ O
in IN O
pancreatic JJ B-Disease
tumors NNS I-Disease
as IN O
in IN O
the DT O
other JJ O
types NNS O
of IN O
tumors NNS B-Disease
previously RB O
examined VBN O
. . O

In IN O
addition NN O
, , O
we PRP O
have VBP O
detected VBN O
mutations NNS O
at IN O
codon NN O
51 CD O
in IN O
multiple JJ O
PCR NNP O
subclones NNS O
in IN O
two CD O
other JJ O
pancreatic JJ B-Disease
tumors NNS I-Disease
. . O

Mutations NNS O
in IN O
the DT O
ARP NNP O
gene NN O
are VBP O
thus RB O
commonly RB O
observed VBN O
in IN O
pancreatic JJ B-Disease
cancer NN I-Disease
, , O
as RB O
well RB O
as IN O
many JJ O
other JJ O
cancers NNS B-Disease
. . O

Difficulties NNS O
in IN O
the DT O
ascertainment NN O
of IN O
C9 NNP B-Disease
deficiency NN I-Disease
: : O
lessons NNS O
to TO O
be VB O
drawn VBN O
from IN O
a DT O
compound NN O
heterozygote NN O
C9 NNP B-Disease
- : I-Disease
deficient NN I-Disease
subject NN O
. . O

A DT O
group NN O
of IN O
patients NNS O
with IN O
long JJ O
- : O
surviving VBG O
mismatched VBN O
kidney NN O
allografts NNS O
were VBD O
investigated VBN O
for IN O
complement NN O
function NN O
using VBG O
haemolytic JJ O
assays NNS O
in IN O
agarose JJ O
gels NNS O
. . O

One CD O
patient NN O
was VBD O
found VBN O
to TO O
have VB O
no DT O
alternative JJ O
pathway NN O
activity NN O
but CC O
a DT O
low JJ O
normal JJ O
classical JJ O
pathway NN O
. . O

Surprisingly RB O
, , O
investigation NN O
revealed VBD O
that IN O
the DT O
patients NNS O
complement NN O
was VBD O
normal JJ O
for IN O
all DT O
components NNS O
except IN O
C9 NNP O
, , O
which WDT O
was VBD O
functionally RB O
absent JJ O
. . O

The DT O
patient NN O
was VBD O
shown VBN O
to TO O
be VB O
heterozygous JJ O
for IN O
DNA NN O
markers NNS O
in IN O
the DT O
C6 NNP O
, , O
C7 NNP O
and CC O
C9 NNP O
region NN O
of IN O
chromosome NN O
5 CD O
and CC O
therefore RB O
appears VBZ O
to TO O
be VB O
a DT O
compound NN O
heterozygote NN O
for IN O
two CD O
uncharacterized JJ O
C9 NNP B-Disease
deficiency NN I-Disease
genes NNS O
. . O

Serological JJ O
analysis NN O
by IN O
ELISA NNP O
revealed VBD O
that IN O
he PRP O
has VBZ O
trace NN O
concentrations NNS O
of IN O
a DT O
non JJ O
- : O
functional JJ O
C9 NNP O
molecule NN O
. . O

Western JJ O
blot NN O
analysis NN O
was VBD O
not RB O
sufficiently RB O
sensitive JJ O
to TO O
permit VB O
detection NN O
of IN O
this DT O
molecule NN O
. . O

We PRP O
hypothesize VBP O
that IN O
the DT O
patient NN O
is VBZ O
heterozygous JJ O
for IN O
a DT O
complete JJ B-Disease
deficiency NN I-Disease
of IN I-Disease
C9 NNP I-Disease
and CC O
for IN O
a DT O
gene NN O
directing VBG O
hyposynthesis NN O
of IN O
a DT O
defective JJ O
C9 NNP O
. . O

We PRP O
also RB O
suggest VBP O
that IN O
C9 NNP B-Disease
deficiency NN I-Disease
may MD O
be VB O
more JJR O
common JJ O
among IN O
Caucasians NNPS O
than IN O
has VBZ O
been VBN O
reported VBN O
. . O
. . O

Screening VBG O
for IN O
ESR NNP O
mutations NNS O
in IN O
breast NN B-Disease
and CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
patients NNS O
. . O

In IN O
the DT O
present JJ O
study NN O
, , O
leukocyte JJ O
DNA NN O
from IN O
143 CD O
patients NNS O
with IN O
familial JJ O
clustering NN O
of IN O
breast NN B-Disease
and CC I-Disease
/ NN I-Disease
or CC I-Disease
ovarian JJ I-Disease
cancer NN I-Disease
and CC O
tumour VB B-Disease
DNA NN O
from IN O
96 CD O
breast NN B-Disease
carcinomas NN I-Disease
were VBD O
screened VBN O
for IN O
base NN O
mutations NNS O
in IN O
the DT O
estrogen NN O
receptor NN O
gene NN O
( ( O
ESR NNP O
) ) O
. . O

Three CD O
patients NNS O
with IN O
a DT O
family NN O
history NN O
of IN O
cancer NN B-Disease
were VBD O
carrying VBG O
a DT O
Gly160Cys NNP O
germline NN O
substitution NN O
. . O

This DT O
alteration NN O
was VBD O
also RB O
detected VBN O
in IN O
eight CD O
( ( O
four CD O
females NNS O
and CC O
four CD O
males NNS O
) ) O
of IN O
729 CD O
controls NNS O
( ( O
366 CD O
female NN O
, , O
363 CD O
males NNS O
) ) O
, , O
indicating VBG O
that IN O
the DT O
substitution NN O
probably RB O
represents VBZ O
a DT O
polymorphism NN O
. . O

However RB O
, , O
in IN O
the DT O
229 CD O
female NN O
controls NNS O
in IN O
whom WP O
family NN O
history NN O
of IN O
cancer NN B-Disease
was VBD O
known VBN O
, , O
one CD O
of IN O
two CD O
who WP O
had VBD O
a DT O
sister NN O
with IN O
breast NN B-Disease
cancer NN I-Disease
was VBD O
carrying VBG O
the DT O
variant JJ O
allele NN O
. . O

Hence NNP O
, , O
a DT O
possible JJ O
clinical JJ O
significance NN O
of IN O
the DT O
glycine NN O
into IN O
cysteine NN O
cannot NN O
be VB O
completely RB O
ruled VBN O
out RP O
and CC O
should MD O
be VB O
further RB O
investigated VBN O
. . O

Somatic JJ O
mutations NNS O
were VBD O
not RB O
detected VBN O
in IN O
any DT O
of IN O
the DT O
tumours NNS B-Disease
studied VBN O
, , O
and CC O
the DT O
present JJ O
data NNS O
do VBP O
not RB O
provide VB O
support NN O
for IN O
somatic JJ O
ESR NNP O
base NN O
mutations NNS O
as IN O
an DT O
important JJ O
mechanism NN O
for IN O
hormonal JJ O
therapy NN O
resistance NN O
in IN O
estrogen NN B-Disease
receptor NN I-Disease
- : I-Disease
positive JJ I-Disease
breast NN I-Disease
carcinomas NN I-Disease
. . O
. . O

Molecular JJ O
bases NNS O
of IN O
C7 NNP B-Disease
deficiency NN I-Disease
: : O
three CD O
different JJ O
defects NNS O
. . O

The DT O
molecular JJ O
basis NN O
of IN O
C7 NNP B-Disease
deficiency NN I-Disease
has VBZ O
been VBN O
investigated VBN O
in IN O
two CD O
Irish JJ O
families NNS O
and CC O
a DT O
number NN O
of IN O
Israeli NNP O
families NNS O
of IN O
Moroccan NNP O
Sephardic NNP O
Jewish NNP O
origin NN O
. . O

Exon NNP O
PCR NNP O
and CC O
sequencing VBG O
revealed VBD O
a DT O
heterozygous JJ O
point NN O
mutation NN O
at IN O
the DT O
3 CD O
splice NN O
acceptor NN O
site NN O
of IN O
intron NN O
1 CD O
in IN O
one CD O
Irish JJ O
family NN O
. . O

In IN O
the DT O
other JJ O
Irish JJ O
family NN O
, , O
exons NNS O
7 CD O
and CC O
8 CD O
failed VBD O
to TO O
amplify VB O
and CC O
they PRP O
were VBD O
shown VBN O
to TO O
be VB O
deleted VBN O
. . O

Marker NNP O
haplotype NN O
studies NNS O
of IN O
the DT O
C6 NNP O
and CC O
C7 NNP O
gene NN O
region NN O
and CC O
Southern NNP O
blots NNS O
show VBP O
that IN O
the DT O
Irish NNP O
family NN O
with IN O
the DT O
splice NN O
defect NN O
also RB O
segregate NN O
for IN O
the DT O
deletion NN O
, , O
which WDT O
is VBZ O
not RB O
easily RB O
detected VBN O
in IN O
heterozygotes NNS O
. . O

The DT O
Israeli NNP O
C7 NNP B-Disease
- : I-Disease
deficient NN I-Disease
cases NNS O
all DT O
share NN O
a DT O
C7 NNP O
haplotype NN O
and CC O
are VBP O
homozygous JJ O
for IN O
a DT O
mis JJ O
- : O
sense NN O
mutation NN O
in IN O
exon JJ O
9 CD O
. . O

However RB O
, , O
one CD O
individual NN O
is VBZ O
heterozygous JJ O
for IN O
markers NNS O
at IN O
adjacent JJ O
C6 NNP O
loci NN O
, , O
showing VBG O
that IN O
there EX O
has VBZ O
been VBN O
an DT O
intergenic JJ O
recombination NN O
and CC O
suggesting VBG O
that IN O
the DT O
deficiency NN O
mutation NN O
is VBZ O
of IN O
appreciable JJ O
antiquity NN O
. . O
. . O

Molecular JJ O
heterogeneity NN O
of IN O
classical JJ B-Disease
and CC I-Disease
Duarte NNP I-Disease
galactosemia NN I-Disease
: : O
mutation NN O
analysis NN O
by IN O
denaturing VBG O
gradient JJ O
gel JJ O
electrophoresis NN O
. . O

Classical JJ B-Disease
galactosemia NN I-Disease
is VBZ O
caused VBN O
by IN O
one CD O
common JJ O
missense NN O
mutation NN O
( ( O
Q188R NNP O
) ) O
and CC O
by IN O
several JJ O
rare JJ O
mutations NNS O
in IN O
the DT O
galactose JJ O
- : O
1 CD O
- : O
phosphate NN O
uridyltransferase NN O
( ( O
GALT NNP O
) ) O
gene NN O
. . O

The DT O
most RBS O
common JJ O
variant NN O
of IN O
GALT NNP O
, , O
the DT O
Duarte NNP O
variant NN O
, , O
occurs VBZ O
as IN O
two CD O
types NNS O
, , O
Duarte NNP O
- : O
1 CD O
( ( O
D NNP O
- : O
1 CD O
) ) O
and CC O
Duarte NNP O
- : O
2 CD O
( ( O
D NNP O
- : O
2 CD O
) ) O
, , O
both DT O
of IN O
which WDT O
carry VBP O
the DT O
sequence NN O
change NN O
N314D NNP O
. . O

D NNP O
- : O
1 CD O
increases NNS O
, , O
whereas NNS O
D NNP O
- : O
2 CD O
decreases NNS O
GALT NNP O
activity NN O
. . O

To TO O
study VB O
the DT O
molecular JJ O
genetics NNS O
of IN O
classical JJ B-Disease
and CC I-Disease
Duarte NNP I-Disease
galactosemia NN I-Disease
, , O
we PRP O
analyzed VBD O
the DT O
GALT NNP O
mutations NNS O
in IN O
30 CD O
families NNS O
with IN O
classical JJ B-Disease
galactosemia NN I-Disease
, , O
in IN O
10 CD O
families NNS O
with IN O
the DT O
D NNP O
- : O
2 CD O
variant NN O
and CC O
in IN O
3 CD O
individuals NNS O
carrying VBG O
the DT O
D NNP O
- : O
1 CD O
allele NN O
by IN O
denaturing VBG O
gradient JJ O
gel NN O
electrophoresis NN O
( ( O
DGGE NNP O
) ) O
. . O

DGGE NNP O
detected VBD O
59 CD O
of IN O
the DT O
60 CD O
classical JJ O
galactosemia NN B-Disease
alleles NNS O
. . O

Q188R NNP O
accounted VBD O
for IN O
60 CD O
% NN O
, , O
K285N NNP O
accounted VBD O
for IN O
28 CD O
% NN O
of IN O
these DT O
alleles NNS O
. . O

Eight CD O
novel JJ O
candidate NN O
galactosemia NN B-Disease
mutations NNS O
were VBD O
found VBN O
. . O

On IN O
all DT O
D NNP O
- : O
2 CD O
alleles NNS O
N314D NNP O
occurred VBD O
in IN O
cis NN O
with IN O
two CD O
intronic JJ O
sequence NN O
changes NNS O
, , O
on IN O
the DT O
D NNP O
- : O
1 CD O
alleles NNS O
in IN O
cis NN O
with IN O
a DT O
neutral JJ O
mutation NN O
in IN O
exon JJ O
7 CD O
. . O

We PRP O
conclude VBP O
that IN O
the DT O
mutations NNS O
causing VBG O
galactosemia NN B-Disease
are VBP O
highly RB O
heterogeneous JJ O
and CC O
that DT O
K285N NNP O
is VBZ O
a DT O
second JJ O
common JJ O
galactosemia NN B-Disease
mutation NN O
in IN O
our PRP$ O
population NN O
. . O
. . O

Isolation NN O
of IN O
full JJ O
- : O
length NN O
ATM NNP O
cDNA NN O
and CC O
correction NN O
of IN O
the DT O
ataxia JJ B-Disease
- : I-Disease
telangiectasia NN I-Disease
cellular JJ O
phenotype NN O
. . O

A DT O
gene NN O
mutated VBN O
in IN O
the DT O
human JJ O
genetic JJ B-Disease
disorder NN I-Disease
ataxia NN B-Disease
- : I-Disease
telangiectasia NN I-Disease
( ( O
A DT B-Disease
- : I-Disease
T NN I-Disease
) ) O
, , O
ATM NNP O
, , O
was VBD O
recently RB O
identified VBN O
by IN O
positional JJ O
cloning NN O
. . O

ATM NNP O
is VBZ O
a DT O
member NN O
of IN O
the DT O
phosphatidylinositol NN O
- : O
3 CD O
- : O
kinase NN O
superfamily RB O
, , O
some DT O
of IN O
which WDT O
are VBP O
protein JJ O
kinases NNS O
and CC O
appear VBP O
to TO O
have VB O
important JJ O
roles NNS O
in IN O
cell NN O
cycle NN O
control NN O
and CC O
radiation NN O
signal JJ O
transduction NN O
. . O

We PRP O
describe VBP O
herein RB O
, , O
to TO O
our PRP$ O
knowledge NN O
, , O
for IN O
the DT O
first JJ O
time NN O
, , O
the DT O
cloning NN O
of IN O
a DT O
full JJ O
- : O
length NN O
cDNA NN O
for IN O
ATM NNP O
and CC O
correction NN O
of IN O
multiple JJ O
aspects NNS O
of IN O
the DT O
radio NN O
- : O
sensitive JJ O
phenotype NN O
of IN O
A NNP B-Disease
- : I-Disease
T NN I-Disease
cells NNS O
by IN O
transfection NN O
with IN O
this DT O
cDNA NN O
. . O

Overexpression NN O
of IN O
ATM NNP O
cDNA NN O
in IN O
A NNP B-Disease
- : I-Disease
T NNP I-Disease
cells NNS O
enhanced VBD O
the DT O
survival NN O
of IN O
these DT O
cells NNS O
in IN O
response NN O
to TO O
radiation NN O
exposure NN O
, , O
decreased VBN O
radiation NN O
- : O
induced JJ O
chromosome NN O
aberrations NNS O
, , O
reduced VBD O
radio NN O
- : O
resistant JJ O
DNA NNP O
synthesis NN O
, , O
and CC O
partially RB O
corrected VBN O
defective JJ O
cell NN O
cycle NN O
checkpoints NNS O
and CC O
induction NN O
of IN O
stress NN O
- : O
activated VBN O
protein JJ O
kinase NN O
. . O

This DT O
correction NN O
of IN O
the DT O
defects NNS O
in IN O
A NNP B-Disease
- : I-Disease
T NNP I-Disease
cells NNS O
provides VBZ O
further JJ O
evidence NN O
of IN O
the DT O
multiplicity NN O
of IN O
effector NN O
functions NNS O
of IN O
the DT O
ATM NNP O
protein NN O
and CC O
suggests VBZ O
possible JJ O
approaches NNS O
to TO O
gene NN O
therapy NN O
. . O
. . O

Fusion NNP O
genes NNS O
resulting VBG O
from IN O
alternative JJ O
chromosomal JJ O
translocations NNS O
are VBP O
overexpressed VBN O
by IN O
gene NN O
- : O
specific JJ O
mechanisms NNS O
in IN O
alveolar JJ B-Disease
rhabdomyosarcoma NN I-Disease
. . O

Chromosomal JJ O
translocations NNS O
identified VBN O
in IN O
hematopoietic JJ B-Disease
and CC I-Disease
solid JJ I-Disease
tumors NNS I-Disease
result VBP O
in IN O
deregulated JJ O
expression NN O
of IN O
protooncogenes NNS O
or CC O
creation NN O
of IN O
chimeric JJ O
proteins NNS O
with IN O
tumorigenic JJ O
potential NN O
. . O

In IN O
the DT O
pediatric JJ O
solid JJ B-Disease
tumor NN I-Disease
alveolar JJ B-Disease
rhabdomyosarcoma NN I-Disease
, , O
a DT O
consistent JJ O
t NN O
( ( O
2 CD O
; : O
13 CD O
) ) O
( ( O
q35 NN O
; : O
q14 CC O
) ) O
or CC O
variant JJ O
t NN O
( ( O
1 CD O
; : O
13 CD O
) ) O
( ( O
p36 NN O
; : O
q14 CC O
) ) O
translocation NN O
generates VBZ O
PAX3 NNP O
- : O
FKHR NN O
or CC O
PAX7 NNP O
- : O
FKHR NNP O
fusion NN O
proteins NNS O
, , O
respectively RB O
. . O

In IN O
this DT O
report NN O
, , O
we PRP O
demonstrate VBP O
that IN O
in IN O
addition NN O
to TO O
functional JJ O
alterations NNS O
these DT O
translocations NNS O
are VBP O
associated VBN O
with IN O
fusion NN O
product NN O
overexpression NN O
. . O

Furthermore RB O
, , O
PAX3 NNP O
- : O
FKHR NN O
and CC O
PAX7 NNP O
- : O
FKHR NNP O
overexpression NN O
occurs NNS O
by IN O
distinct JJ O
mechanisms NNS O
. . O

Transcription NN O
of IN O
PAX3 NNP O
- : O
FKHR NNP O
is VBZ O
increased VBN O
relative JJ O
to TO O
wild VB O
- : O
type NN O
PAX3 NNP O
by IN O
a DT O
copy NN O
number NN O
- : O
independent JJ O
process NN O
. . O

In IN O
contrast NN O
, , O
PAX7 NNP O
- : O
FKHR NNP O
overexpression NN O
results NNS O
from IN O
fusion JJ O
gene NN O
amplification NN O
. . O

Thus RB O
, , O
gene NN O
- : O
specific JJ O
mechanisms NNS O
were VBD O
selected VBN O
to TO O
overexpress VB O
PAX3 NNP O
- : O
FKHR NN O
and CC O
PAX7 NNP O
- : O
FKHR NN O
in IN O
alveolar JJ B-Disease
rhabdomyosarcoma NN I-Disease
, , O
presumably RB O
due JJ O
to TO O
differences NNS O
in IN O
regulation NN O
between IN O
the DT O
wild JJ O
- : O
type NN O
loci NN O
. . O

We PRP O
postulate VBP O
that IN O
these DT O
overexpression NN O
mechanisms NNS O
ensure VB O
a DT O
critical JJ O
level NN O
of IN O
gene NN O
product NN O
for IN O
the DT O
oncogenic JJ O
effects NNS O
of IN O
these DT O
fusions NNS O
. . O
. . O

atm NN O
and CC O
p53 NN O
cooperate NN O
in IN O
apoptosis NN O
and CC O
suppression NN O
of IN O
tumorigenesis NN O
, , O
but CC O
not RB O
in IN O
resistance NN O
to TO O
acute VB B-Disease
radiation NN I-Disease
toxicity NN I-Disease
. . O

Mutations NNS O
in IN O
atm NN O
and CC O
p53 NN O
cause VBP O
the DT O
human JJ O
cancer NN B-Disease
- : I-Disease
associated VBN I-Disease
diseases NNS I-Disease
ataxia VBP B-Disease
- : I-Disease
telangiectasia NN I-Disease
and CC O
Li NNP B-Disease
- : I-Disease
Fraumeni NNP I-Disease
syndrome NN I-Disease
, , O
respectively RB O
. . O

The DT O
two CD O
genes NNS O
are VBP O
believed VBN O
to TO O
interact VB O
in IN O
a DT O
number NN O
of IN O
pathways NNS O
, , O
including VBG O
regulation NN O
of IN O
DNA NNP O
damage NN O
- : O
induced VBN O
cell NN O
- : O
cycle NN O
checkpoints NNS O
, , O
apoptosis NN O
and CC O
radiation NN O
sensitivity NN O
, , O
and CC O
cellular JJ O
proliferation NN O
. . O

Atm NNP O
- : O
null JJ O
mice NN O
, , O
as RB O
well RB O
as IN O
those DT O
null JJ O
for IN O
p53 NN O
, , O
develop VB O
mainly RB O
T NNP B-Disease
- : I-Disease
cell NN I-Disease
lymphomas NN I-Disease
, , O
supporting VBG O
the DT O
view NN O
that IN O
these DT O
genes NNS O
have VBP O
similar JJ O
roles NNS O
in IN O
thymocyte NN O
development NN O
. . O

To TO O
study VB O
the DT O
interactions NNS O
of IN O
these DT O
two CD O
genes NNS O
on IN O
an DT O
organismal JJ O
level NN O
, , O
we PRP O
bred VBD O
mice RB O
heterozygous JJ O
for IN O
null JJ O
alleles NNS O
of IN O
both DT O
atm NNS O
and CC O
p53 NN O
to TO O
produce VB O
all DT O
genotypic NN O
combinations NNS O
. . O

Mice NNP O
doubly RB O
null RB O
for IN O
atm NN O
and CC O
p53 NN O
exhibited VBD O
a DT O
dramatic JJ O
acceleration NN O
of IN O
tumour JJ B-Disease
formation NN O
relative NN O
to TO O
singly RB O
null JJ O
mice NN O
, , O
indicating VBG O
that IN O
both DT O
genes NNS O
collaborate VBP O
in IN O
a DT O
significant JJ O
manner NN O
to TO O
prevent VB O
tumorigenesis NN O
. . O

With IN O
respect NN O
to TO O
their PRP$ O
roles NNS O
in IN O
apoptosis NN O
, , O
loss NN O
of IN O
atm NN O
rendered VBN O
thymocytes VBZ O
only RB O
partly RB O
resistant JJ O
to TO O
irradiation VB O
- : O
induced JJ O
apoptosis NN O
, , O
whereas JJ O
additional JJ O
loss NN O
of IN O
p53 NN O
engendered VBD O
complete JJ O
resistance NN O
. . O

This DT O
implies VBZ O
that IN O
the DT O
irradiation NN O
- : O
induced JJ O
atm NN O
and CC O
p53 NN O
apoptotic JJ O
pathways NNS O
are VBP O
not RB O
completely RB O
congruent JJ O
. . O

Finally RB O
- : O
and CC O
in IN O
contrast NN O
to TO O
prior VB O
predictions NNS O
- : O
atm NN O
and CC O
p53 NN O
do VBP O
not RB O
appear VB O
to TO O
interact VB O
in IN O
acute JJ B-Disease
radiation NN I-Disease
toxicity NN I-Disease
, , O
suggesting VBG O
a DT O
separate JJ O
atm NN O
effector NN O
pathway NN O
for IN O
this DT O
DNA NNP O
damage NN O
response NN O
and CC O
having VBG O
implications NNS O
for IN O
the DT O
prognosis NN O
and CC O
treatment NN O
of IN O
human JJ O
tumours NNS B-Disease
. . O
. . O

Trinucleotide NNP O
repeat NN O
expansion NN O
at IN O
the DT O
myotonic JJ B-Disease
dystrophy NN I-Disease
locus NN O
reduces VBZ O
expression NN O
of IN O
DMAHP NNP O
. . O

Myotonic NNP B-Disease
dystrophy NN I-Disease
, , O
or CC O
dystrophia NN B-Disease
myotonica NN I-Disease
( ( O
DM NNP B-Disease
) ) O
, , O
is VBZ O
an DT O
autosomal JJ B-Disease
dominant JJ I-Disease
multisystem NN I-Disease
disorder NN I-Disease
caused VBN O
by IN O
the DT O
expansion NN O
of IN O
a DT O
CTG NNP O
trinucleotide NN O
repeat NN O
in IN O
the DT O
3 CD O
untranslated JJ O
region NN O
of IN O
the DT O
DMPK NNP O
protein NN O
kinase VBD O
gene NN O
on IN O
chromosome NN O
19q13 CD O
. . O

3 CD O
( ( O
refs VB O
1 CD O
- : O
3 CD O
) ) O
. . O

Although IN O
the DT O
DM NNP B-Disease
mutation NN O
was VBD O
identified VBN O
more JJR O
than IN O
five CD O
years NNS O
ago RB O
, , O
the DT O
pathogenic JJ O
mechanisms NN O
underlying VBG O
this DT O
most RBS O
prevalent JJ O
form NN O
of IN O
hereditary JJ O
adult NN O
neuromuscular JJ B-Disease
disease NN I-Disease
remain VBP O
elusive JJ O
. . O

Previous JJ O
work NN O
from IN O
our PRP$ O
laboratory NN O
demonstrated VBD O
that IN O
a DT O
DNase NNP O
l NN O
- : O
hypersensitive JJ O
site NN O
located VBN O
adjacent JJ O
to TO O
the DT O
repeats NNS O
on IN O
the DT O
wild JJ O
- : O
type NN O
allele NN O
is VBZ O
eliminated VBN O
by IN O
repeat NN O
expansion NN O
, , O
indicating VBG O
that IN O
large JJ O
CTG NNP O
- : O
repeat NN O
arrays NNS O
may MD O
be VB O
associated VBN O
with IN O
a DT O
local JJ O
chromatin NN O
environment NN O
that WDT O
represses VBZ O
gene NN O
expression NN O
. . O

Here RB O
we PRP O
report VBP O
that IN O
the DT O
hypersensitive JJ O
site NN O
contains VBZ O
an DT O
enhancer NN O
element NN O
that WDT O
regulates VBZ O
transcription NN O
of IN O
the DT O
adjacent JJ O
DMAHP NNP O
homeobox NN O
gene NN O
. . O

Analysis NN O
of IN O
DMAHP NNP O
expression NN O
in IN O
the DT O
cells NNS O
of IN O
DM NNP B-Disease
patients NNS O
with IN O
loss NN O
of IN O
the DT O
hypersensitive JJ O
site NN O
revealed VBD O
a DT O
two CD O
- : O
to TO O
fourfold VB O
reduction NN O
in IN O
steady JJ O
- : O
state NN O
DMAHP NNP O
transcript NN O
levels NNS O
relative VBP O
to TO O
wild VB O
- : O
type NN O
controls NNS O
. . O

Allele NNP O
- : O
specific JJ O
analysis NN O
of IN O
DMAHP NNP O
expression NN O
showed VBD O
that IN O
steady JJ O
- : O
state NN O
transcript NN O
levels NNS O
from IN O
the DT O
expanded VBN O
allele NN O
were VBD O
greatly RB O
reduced VBN O
in IN O
comparison NN O
to TO O
those DT O
from IN O
the DT O
wild JJ O
- : O
type NN O
allele NN O
. . O

Together RB O
, , O
these DT O
results NNS O
demonstrate VBP O
that IN O
CTG NNP O
- : O
repeat NN O
expansions NNS O
can MD O
suppress VB O
local JJ O
gene NN O
expression NN O
and CC O
implicate NN O
DMAHP NNP O
in IN O
DM NNP B-Disease
pathogenesis NN O
. . O

Constitutively RB O
methylated VBN O
CpG NNP O
dinucleotides NNS O
as IN O
mutation NN O
hot JJ O
spots NNS O
in IN O
the DT O
retinoblastoma NN B-Disease
gene NN O
( ( O
RB1 NNP O
) ) O
. . O

A DT O
wide JJ O
spectrum NN O
of IN O
mutations NNS O
, , O
ranging VBG O
from IN O
point NN O
mutations NNS O
to TO O
large JJ O
deletions NNS O
, , O
have VBP O
been VBN O
described VBN O
in IN O
the DT O
retinoblastoma NN B-Disease
gene NN O
( ( O
RB1 NNP O
) ) O
. . O

Mutations NNS O
have VBP O
been VBN O
found VBN O
throughout IN O
the DT O
gene NN O
; : O
however RB O
, , O
these DT O
genetic JJ O
alterations NNS O
do VBP O
not RB O
appear VB O
to TO O
be VB O
homogeneously RB O
distributed VBN O
. . O

In IN O
particular JJ O
, , O
a DT O
significant JJ O
proportion NN O
of IN O
disease NN O
- : O
causing NN O
mutations NNS O
results NNS O
in IN O
the DT O
premature JJ O
termination NN O
of IN O
protein JJ O
synthesis NN O
, , O
and CC O
the DT O
majority NN O
of IN O
these DT O
mutations NNS O
occur VBP O
as IN O
C NNP O
- : O
- : O
> NN O
T NNP O
transitions NNS O
at IN O
CpG NNP O
dinucleotides NNS O
( ( O
CpGs NNP O
) ) O
. . O

Such JJ O
recurrent NN O
CpG NNP O
mutations NNS O
, , O
including VBG O
those DT O
found VBN O
in IN O
RB1 NNP O
, , O
are VBP O
likely JJ O
the DT O
result NN O
of IN O
the DT O
deamination NN O
of IN O
5 CD O
- : O
methylcytosine NN O
within IN O
these DT O
CpGs NNP O
. . O

In IN O
the DT O
present JJ O
study NN O
, , O
we PRP O
used VBD O
the DT O
sodiumbisulfite JJ O
conversion NN O
method NN O
to TO O
detect VB O
cytosine JJ O
methylation NN O
in IN O
representative JJ O
exons NNS O
of IN O
RB1 NNP O
. . O

We PRP O
analyzed VBD O
DNA NN O
from IN O
a DT O
variety NN O
of IN O
tissues NNS O
and CC O
specifically RB O
targeted VBD O
CGA NNP O
codons NNS O
in IN O
RB1 NNP O
, , O
where WRB O
recurrent JJ O
premature NN O
termination NN O
mutations NNS O
have VBP O
been VBN O
reported VBN O
. . O

We PRP O
found VBD O
that IN O
DNA NNP O
methylation NN O
within IN O
RB1 NNP O
exons NNS O
8 CD O
, , O
14 CD O
, , O
25 CD O
, , O
and CC O
27 CD O
appeared VBD O
to TO O
be VB O
restricted VBN O
to TO O
CpGs NNP O
, , O
including VBG O
six CD O
CGA NNP O
codons NNS O
. . O

Other JJ O
codons NNS O
containing VBG O
methylated VBN O
cytosines NNS O
have VBP O
not RB O
been VBN O
reported VBN O
to TO O
be VB O
mutated VBN O
. . O

Therefore RB O
, , O
disease VB O
- : O
causing NN O
mutations NNS O
at IN O
CpGs NNP O
in IN O
RB1 NNP O
appear VBP O
to TO O
be VB O
determined VBN O
by IN O
several JJ O
factors NNS O
, , O
including VBG O
the DT O
constitutive JJ O
presence NN O
of IN O
DNA NNP O
methylation NN O
at IN O
cytosines NNS O
within IN O
CpGs NNP O
, , O
the DT O
specific JJ O
codon NN O
within IN O
which WDT O
the DT O
methylated JJ O
cytosine NN O
is VBZ O
located VBN O
, , O
and CC O
the DT O
particular JJ O
region NN O
of IN O
the DT O
gene NN O
within IN O
which WDT O
that IN O
codon NN O
resides NNS O
. . O
. . O

The DT O
von NN B-Disease
Hippel NNP I-Disease
- : I-Disease
Lindau NNP I-Disease
tumor NN I-Disease
suppressor NN O
gene NN O
product NN O
interacts NNS O
with IN O
Sp1 NNP O
to TO O
repress VB O
vascular JJ O
endothelial JJ O
growth NN O
factor NN O
promoter NN O
activity NN O
. . O

The DT O
von NN B-Disease
Hippel NNP I-Disease
- : I-Disease
Lindau NNP I-Disease
tumor NN I-Disease
suppressor NN O
gene NN O
( ( O
VHL NNP O
) ) O
has VBZ O
a DT O
critical JJ O
role NN O
in IN O
the DT O
pathogenesis NN O
of IN O
clear JJ B-Disease
- : I-Disease
cell NN I-Disease
renal JJ I-Disease
cell NN I-Disease
carcinoma NN I-Disease
( ( O
RCC NNP B-Disease
) ) O
, , O
as IN O
VHL NNP O
mutations NNS O
have VBP O
been VBN O
found VBN O
in IN O
both DT O
von NNP B-Disease
Hippel NNP I-Disease
- : I-Disease
Lindau NNP I-Disease
disease NN I-Disease
- : I-Disease
associated VBN I-Disease
and CC I-Disease
sporadic JJ I-Disease
RCCs NNP I-Disease
. . O

Recent JJ O
studies NNS O
suggest VBP O
that IN O
vascular JJ O
endothelial JJ O
growth NN O
factor NN O
( ( O
VEGF NNP O
) ) O
mRNA NN O
is VBZ O
upregulated VBN O
in IN O
RCC NNP B-Disease
- : I-Disease
and CC I-Disease
von VB I-Disease
Hippel NNP I-Disease
- : I-Disease
Lindau NNP I-Disease
disease NN I-Disease
- : I-Disease
associated VBN I-Disease
tumors NNS I-Disease
. . O

We PRP O
have VBP O
therefore RB O
assessed VBN O
the DT O
effect NN O
of IN O
the DT O
VHL NNP O
gene NN O
product NN O
on IN O
VEGF NNP O
expression NN O
. . O

VEGF NNP O
promoter NN O
- : O
luciferase NN O
constructs NNS O
were VBD O
transiently RB O
cotransfected VBN O
with IN O
a DT O
wild JJ O
- : O
type NN O
VHL NNP O
( ( O
wt SYM O
- : O
VHL NN O
) ) O
vector NN O
in IN O
several JJ O
cell NN O
lines NNS O
, , O
including VBG O
293 CD O
embryonic JJ O
kidney NN O
and CC O
RCC NNP B-Disease
cell NN O
lines NNS O
. . O

wt SYM O
- : O
VHL NNP O
protein NN O
inhibited VBD O
VEGF NNP O
promoter NN O
activity NN O
in IN O
a DT O
dose JJ O
- : O
dependent NN O
manner NN O
up IN O
to TO O
5 CD O
- : O
to TO O
10 CD O
- : O
fold NN O
. . O

Deletion NN O
analysis NN O
defined VBD O
a DT O
144 CD O
- : O
bp JJ O
region NN O
of IN O
the DT O
VEGF NNP O
promoter NN O
necessary JJ O
for IN O
VHL NNP O
repression NN O
. . O

This DT O
VHL NNP O
- : O
responsive JJ O
element NN O
is VBZ O
GC NNP O
rich JJ O
and CC O
specifically RB O
binds VBZ O
the DT O
transcription NN O
factor NN O
Sp1 NNP O
in IN O
crude JJ O
nuclear JJ O
extracts NNS O
. . O

In IN O
Drosophila NNP O
cells NNS O
, , O
cotransfected VBD O
VHL NNP O
represses NNS O
Sp1 NNP O
- : O
mediated VBN O
activation NN O
but CC O
not RB O
basal JJ O
activity NN O
of IN O
the DT O
VEGF NNP O
promoter NN O
. . O

We PRP O
next RB O
demonstrated VBD O
in IN O
coimmunoprecipitates NNS O
that IN O
VHL NNP O
and CC O
Sp1 NNP O
were VBD O
part NN O
of IN O
the DT O
same JJ O
complex NN O
and CC O
, , O
by IN O
using VBG O
a DT O
glutathione NN O
- : O
S NNP O
- : O
transferase NN O
- : O
VHL NNP O
fusion NN O
protein NN O
and CC O
purified JJ O
Sp1 NNP O
, , O
that IN O
VHL NNP O
and CC O
Sp1 NNP O
directly RB O
interact VBP O
. . O

Furthermore RB O
, , O
endogenous JJ O
VEGF NNP O
mRNA NN O
levels NNS O
were VBD O
suppressed VBN O
in IN O
permanent JJ O
RCC NNP B-Disease
cell NN O
lines NNS O
expressing VBG O
wt SYM O
- : O
VHL NN O
, , O
and CC O
nuclear JJ O
run NN O
- : O
on IN O
studies NNS O
indicated VBD O
that IN O
VHL NNP O
regulation NN O
of IN O
VEGF NNP O
occurs VBZ O
at IN O
least JJS O
partly RB O
at IN O
the DT O
transcriptional JJ O
level NN O
. . O

These DT O
observations NNS O
support VBP O
a DT O
new JJ O
mechanism NN O
for IN O
VHL NNP O
- : O
mediated VBD O
transcriptional JJ O
repression NN O
via IN O
a DT O
direct JJ O
inhibitory NN O
action NN O
on IN O
Sp1 NNP O
and CC O
suggest VBP O
that IN O
loss NN O
of IN O
Sp1 NNP O
inhibition NN O
may MD O
be VB O
important JJ O
in IN O
the DT O
pathogenesis NN O
of IN O
von NN B-Disease
Hippel NNP I-Disease
- : I-Disease
Lindau NNP I-Disease
disease NN I-Disease
and CC O
RCC NNP B-Disease
. . O
. . O

Adult NNP B-Disease
onset MD I-Disease
globoid VB I-Disease
cell NN I-Disease
leukodystrophy NN I-Disease
( ( O
Krabbe NNP B-Disease
disease NN I-Disease
) ) O
: : O
analysis NN O
of IN O
galactosylceramidase NN O
cDNA NN O
from IN O
four CD O
Japanese JJ O
patients NNS O
. . O

We PRP O
examined VBD O
galactosylceramidase NN O
( ( O
GALC NNP O
) ) O
cDNA NN O
in IN O
four CD O
Japanese JJ O
patients NNS O
with IN O
adult JJ B-Disease
onset VBN I-Disease
globoid NN I-Disease
cell NN I-Disease
leukodystrophy NN I-Disease
( ( O
Krabbe NNP B-Disease
disease NN I-Disease
; : O
AO NNP B-Disease
- : I-Disease
GLD NN I-Disease
) ) O
by IN O
polymerase NN O
chain NN O
reaction NN O
/ NNP O
single JJ O
- : O
strand NN O
conformation NN O
polymorphism NN O
( ( O
PCR NNP O
- : O
SSCP NN O
) ) O
analysis NN O
, , O
subsequent JJ O
sequence NN O
determination NN O
, , O
and CC O
restriction NN O
enzyme FW O
digestion NN O
of IN O
PCR NNP O
products NNS O
, , O
initial JJ O
symptoms NNS O
were VBD O
the DT O
onset NN O
of IN O
slowly RB O
progressive JJ O
spastic JJ B-Disease
paraplegia NN I-Disease
from IN O
the DT O
middle NN O
of IN O
the DT O
second JJ O
decade NN O
, , O
and CC O
all DT O
patients NNS O
had VBD O
diminished VBN B-Disease
GALC NNP I-Disease
activity NN I-Disease
in IN O
their PRP$ O
leukocytes NNS O
. . O

We PRP O
identified VBD O
three CD O
missense NN O
mutations NNS O
( ( O
I66M NNP O
, , O
G270D NNP O
, , O
L618S NNP O
) ) O
and CC O
one CD O
exon NN O
- : O
6 CD O
skipping NN O
( ( O
535 CD O
- : O
573del CD O
) ) O
. . O

Two CD O
of IN O
the DT O
patients NNS O
had VBD O
only RB O
the DT O
I66M NNP O
mutant NN O
mRNA NN O
, , O
and CC O
one CD O
only RB O
the DT O
G27OD NNP O
mutant NN O
mRNA NN O
. . O

The DT O
fourth JJ O
patient NN O
carried VBD O
a DT O
compound NN O
heterozygous JJ O
mutation NN O
of IN O
535 CD O
- : O
573del CD O
and CC O
L618S NNP O
. . O

To TO O
determine VB O
the DT O
enzymatic JJ O
activities NNS O
produced VBN O
by IN O
these DT O
mutations NNS O
, , O
we PRP O
constructed VBD O
mutated VBN O
GALC NNP O
cDNAs NN O
and CC O
expressed VBD O
them PRP O
in IN O
COS NNP O
- : O
1 CD O
cells NNS O
. . O

Three CD O
mutations NNS O
, , O
viz NN O
. . O
, , O
G270D NNP O
, , O
L618S NNP O
, , O
and CC O
exon SYM O
- : O
6 CD O
skipping NN O
( ( O
535 CD O
- : O
573del CD O
) ) O
, , O
produced VBD O
diminished JJ B-Disease
GALC NNP I-Disease
activity NN I-Disease
as IN O
expected VBN O
. . O

The DT O
I66M NNP O
mutation NN O
in IN O
the DT O
wild JJ O
- : O
type NN O
GALC NNP O
cDNA NN O
( ( O
I289 NNP O
) ) O
had VBD O
normal JJ O
activity NN O
, , O
but CC O
when WRB O
this DT O
mutation NN O
and CC O
the DT O
V289 NNP O
polymorphism NN O
were VBD O
introduced VBN O
into IN O
the DT O
same JJ O
allele NN O
, , O
it PRP O
had VBD O
decreased VBN O
activity NN O
. . O

Thus RB O
, , O
the DT O
combination NN O
of IN O
a DT O
unique JJ O
mutation NN O
and CC O
polymorphism NN O
causes NNS O
conformational JJ O
change NN O
in IN O
the DT O
GALC NNP O
enzyme NN O
, , O
resulting VBG O
in IN O
low JJ O
enzymatic JJ O
activity NN O
. . O

AO NNP B-Disease
- : I-Disease
GLD NNP I-Disease
mutations NNS O
, , O
including VBG O
those DT O
found VBN O
here RB O
, , O
are VBP O
located VBN O
in IN O
the DT O
N NNP O
- : O
terminus NN O
( ( O
I66M NNP O
, , O
G270D NNP O
, , O
535 CD O
- : O
573del CD O
) ) O
or CC O
C NNP O
- : O
terminus NN O
( ( O
L618S NNP O
) ) O
of IN O
the DT O
GALC NNP O
enzyme NN O
, , O
whereas IN O
the DT O
reported JJ O
mutations NNS O
in IN O
the DT O
infantile JJ O
form NN O
( ( O
IF NNP B-Disease
- : I-Disease
GLD NN I-Disease
) ) O
are VBP O
in IN O
the DT O
central JJ O
domain NN O
. . O

This DT O
difference NN O
in IN O
mutation NN O
sites NNS O
may MD O
affect VB O
the DT O
clinical JJ O
features NNS O
of IN O
GLD NNP B-Disease
. . O
